Integrative Oncology

A Comprehensive Academic Synthesis of Mechanisms,

Guidelines, Evidence, and Clinical Translation

(2022–2026)

An Academic Book Chapter

Yoon Hang "John" Kim, MD, MPH, FAAMA

Practice of Yoon Hang Kim, MD

www.directintegrativecare.com

San Antonio, Texas

May 2026

Copyright and Disclosures

© 2026 by the author. This chapter is intended for academic and educational use. The material may be reproduced for non-commercial educational purposes with appropriate attribution.

Disclosure of conflicts of interest: The author has no financial relationships with pharmaceutical manufacturers, supplement companies, or device manufacturers whose products are discussed in this chapter. The author maintains a clinical integrative medicine practice that includes oncology consultation; no payments have been received from any commercial interest for the content of this chapter.

Medical disclaimer: This chapter is intended for educational purposes and as an academic synthesis of contemporary integrative oncology literature. It does not constitute individual medical advice and is not a substitute for personalized clinical evaluation by a qualified oncologist or integrative medicine physician. Patients with cancer should make all treatment decisions in partnership with their oncology team, and complementary or integrative interventions should be coordinated with that team to ensure safety and avoid pharmacologic interactions.

Funding: No external funding was received for the preparation of this chapter.

About the Author

Yoon Hang "John" Kim, MD, MPH, FAAMA, is a board-certified preventive medicine physician and integrative medicine specialist whose clinical and academic work has spanned acupuncture, mind–body medicine, functional medicine, and integrative oncology consultation for more than two decades. He is a Fellow of the American Academy of Medical Acupuncture and has held faculty appointments at multiple academic medical centers. His current clinical practice (Practice of Yoon Hang Kim, MD; www.directintegrativecare.com) focuses on the application of evidence-informed complementary therapies in cancer, autoimmune disease, and chronic illness, with a particular emphasis on translating mechanism-based research into accessible patient care. He has written extensively on integrative oncology topics, including pharmacologic ascorbate, modified citrus pectin, medicinal mushrooms, and the orthomolecular approach to cancer.

Abstract

Background. Integrative oncology has matured from a patient-driven movement into a guideline-supported clinical discipline. Between 2022 and 2025, the Society for Integrative Oncology (SIO) and the American Society of Clinical Oncology (ASCO) jointly issued guidelines on pain management, anxiety and depression, and cancer-related fatigue, and ASCO independently issued a guideline on cannabis and cannabinoids in adults with cancer. The same period has produced practice-changing randomized trials in adjunctive cancer care.

Objective. This chapter synthesizes contemporary integrative oncology literature with reference to the most recent guidelines, randomized phase 2 and 3 trials, mechanistic advances, and clinical implementation considerations. It is structured to distinguish explicitly among tiers of evidence, so that practice-changing randomized data are never conflated with case-series or mechanistic literature.

Structure. The chapter is organized into four parts. Part I covers guideline-concordant standard of care, including the SIO-ASCO guideline framework, mind–body medicine, oncology acupuncture, exercise oncology, and digital integrative medicine. Part II covers emerging therapies with phase 2 randomized or strong mechanistic evidence: pharmacologic ascorbate, fasting-mimicking diets, psilocybin-assisted psychotherapy, mistletoe in immune checkpoint combinations, and locoregional hyperthermia. Part III covers investigational, metabolic, and repurposed frameworks: the mitochondrial–stem cell connection, the glutathione paradox, modified citrus pectin, medicinal mushrooms, and drug repurposing. Part IV addresses cross-cutting topics: the gut microbiome and immunotherapy response, chronotherapy, disease-specific applications, special populations, health disparities, end-of-life care, and a clinical implementation framework.

Conclusion. Integrative oncology in 2026 occupies a substantially different position than it did even five years ago. The discipline now possesses authoritative practice guidelines, phase 3 randomized survival evidence for structured exercise in colon cancer, phase 2 randomized evidence in selected disease settings, and a credible footprint within institutional cancer care. The strongest integrative oncology practice anchors on conventional oncologic standards, coordinates closely with the oncology team, and brings mechanism-based complementary interventions to the whole-person care of patients living with cancer.

Keywords: integrative oncology, mind–body medicine, mindfulness-based interventions, oncology acupuncture, exercise oncology, pharmacologic ascorbate, fasting-mimicking diet, psilocybin, modified citrus pectin, medicinal mushrooms, hyperthermia, mistletoe, cannabis, gut microbiome, chronotherapy, drug repurposing, digital health, health disparities, palliative care.

Learning Objectives

After completing this chapter, the reader will be able to:

1. Articulate the formal definition of integrative oncology and the role of the SIO-ASCO joint guidelines in establishing evidence-graded standards for symptom management.
2. Distinguish among three tiers of evidence—guideline-concordant standard of care, phase 2/strong mechanistic, and investigational/metabolic—and assign specific interventions to the appropriate tier.
3. Summarize the design and primary findings of the CHALLENGE trial and explain why structured exercise now constitutes level 1 evidence for reducing recurrence and mortality in stage II–III colon cancer.
4. Describe the pharmacokinetic rationale for intravenous (versus oral) ascorbate in oncology and the mechanism by which pharmacologic ascorbate selectively damages cancer cells.
5. Identify the principal mechanisms of fasting-mimicking diets in enhancing chemotherapy efficacy and protecting normal tissues (differential stress resistance).
6. Describe the foundational 2016 trials of psilocybin-assisted psychotherapy in cancer-related existential distress and the role of the mystical-type experience in therapeutic outcome.
7. Recognize the immunogenic cell death mechanism underlying mistletoe extracts and interpret the registry-based survival signal in NSCLC patients receiving PD-1/PD-L1 inhibitors plus Viscum album.
8. Outline the role of the gut microbiome in modulating response to immune checkpoint inhibitors and articulate the current best-practice recommendations regarding dietary fiber, probiotics, and fecal microbiota transplantation.
9. Identify the principal drug–nutrient and drug–herb interactions of concern in integrative oncology practice, including St. John's Wort, curcumin, EGCG, fish oil, and high-dose antioxidant cocktails during cytotoxic therapy.
10. Apply the five-part clinical implementation framework to specific patient scenarios, distinguishing among curative-intent, palliative-intent, and survivorship contexts.
11. Discuss the demographic disparities in integrative oncology access and clinical trial representation and identify structural solutions.

List of Abbreviations

Editorial Note: A Tiered-Evidence Approach

A perennial criticism of integrative oncology writing is that it places evidence of profoundly unequal weight in adjacent sections, leaving readers to infer—incorrectly—that a phase 3 randomized trial and an investigational case series occupy the same epistemic terrain. To prevent that conflation, this chapter is explicitly organized into three tiers of evidence:

• Part I: Guideline-Concordant Standard of Care (Sections 1–6) — modalities supported by SIO-ASCO joint guidelines, phase 3 randomized evidence, or both.
• Part II: Emerging Therapies with Phase 2 / Strong Mechanistic Evidence (Sections 7–11) — interventions supported by randomized phase 2 trials, large registries, or substantive translational evidence, but not yet practice-changing.
• Part III: Investigational, Metabolic, and Repurposed Frameworks (Sections 12–16) — biologically plausible frameworks supported predominantly by mechanistic, preclinical, retrospective, or case-series data.
• Part IV: Cross-Cutting Considerations (Sections 17–24) — gut microbiome, chronotherapy, disease-specific summaries, special populations, end-of-life care, disparities, and clinical implementation.

Each section opens with an explicit evidence-tier header so that the reader is never asked to infer equivalence where none exists.

Part I

Guideline-Concordant Standard of Care

Modalities supported by SIO-ASCO joint guidelines,

phase 3 randomized evidence, or both.

1. The Guideline Landscape: SIO-ASCO Joint Frameworks

Evidence tier: Practice guidelines synthesizing systematic reviews and randomized trials.

Integrative oncology has been formally defined by Witt and colleagues (2017) as "a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments." Its core premise is that complementary therapies augment, rather than replace, surgery, radiation, cytotoxic chemotherapy, targeted agents, and immunotherapy. Between 2022 and 2025, four landmark practice guidelines have established the operational infrastructure of contemporary integrative oncology practice.

1.1 Pain Management (2022)

The Mao et al. (2022) SIO-ASCO joint guideline on integrative medicine for cancer pain management reviewed 227 studies and produced graded recommendations. The strongest recommendations support acupuncture in aromatase inhibitor-associated joint pain (moderate strength); acupuncture, reflexology, or acupressure for general cancer or musculoskeletal pain; hypnosis for procedural pain; and massage during palliative care. Yoga is recommended for pain related to musculoskeletal symptoms, breast cancer treatment, and aromatase inhibitor-related arthralgias.

1.2 Anxiety and Depression (2023)

The Carlson et al. (2023) SIO-ASCO joint guideline on integrative oncology care of anxiety and depression drew on 110 studies including 30 systematic reviews and 80 randomized controlled trials, encompassing more than 400 individual trials in aggregate. Mindfulness-based interventions received the strongest recommendations for both anxiety and depression in patients on active treatment and post-treatment. Specific graded recommendations include mindfulness-based interventions, yoga, relaxation, music therapy, reflexology, and aromatherapy (via inhalation) for anxiety during active treatment; mindfulness-based interventions, yoga, acupuncture, tai chi/qigong, and reflexology for post-treatment anxiety; and mindfulness-based interventions, yoga, and music therapy for depressive symptoms in selected settings.

1.3 Cancer-Related Fatigue (2024)

The Bower et al. (2024) ASCO-SIO guideline update on cancer-related fatigue reviewed 113 randomized controlled trials published between 2013 and 2023. Strong recommendations with moderate-quality evidence support exercise, cognitive behavioral therapy (with or without hypnosis), mindfulness-based programs, and tai chi/qigong during active treatment. American ginseng received a conditional recommendation. The guideline elevates behavioral and integrative interventions to first-line treatment status for cancer-related fatigue—a striking development given that fatigue affects 30–60% of patients during active treatment and 20–30% of long-term survivors. A companion clinical insights paper (Mustian et al., 2024) operationalizes the recommendations for the practicing oncologist.

1.4 Cannabis and Cannabinoids (2024)

The Braun et al. (2024) ASCO guideline on cannabis and cannabinoids in adults with cancer reviewed 366 publications including 13 systematic reviews and 5 additional primary studies. The highest-quality evidence supports synthetic cannabinoids (dronabinol and nabilone) for refractory chemotherapy-induced nausea and vomiting (CINV) added to guideline-concordant antiemetic regimens. The guideline recommends against cannabis or cannabinoids as cancer-directed treatment outside of clinical trials. Low-quality or insufficient evidence exists for most other indications including pain, sleep, and quality of life. Common adverse effects include somnolence, dizziness, xerostomia, cognitive impairment, and—at higher doses or in vulnerable individuals—psychiatric symptoms (Nierengarten, 2024).

1.5 Implications and Convergence

The convergence of these four guidelines establishes the operational infrastructure of contemporary integrative oncology. They provide oncologists, integrative physicians, and patients with evidence-graded options across the symptom domains that most affect quality of life, and they normalize the integration of complementary therapies within conventional cancer care. CME-supported training modules now accompany each guideline, and the Society for Integrative Oncology maintains a publicly accessible repository at integrativeonc.org.

2. Mind–Body Medicine: From Mechanism to Mainstream

Evidence tier: Multiple randomized trials, meta-analyses, and SIO-ASCO guideline recommendations.

Mind–body medicine in oncology has matured into the most rigorously evidenced domain of integrative cancer care, with mechanisms now characterized at neurobiological, immunological, and psychometric levels.

2.1 Mindfulness-Based Interventions

Mindfulness-Based Stress Reduction (MBSR), developed by Kabat-Zinn in 1979, and its cancer-adapted version Mindfulness-Based Cancer Recovery (MBCR), developed by Carlson and Speca in the early 2000s, represent the most robustly evidenced mind–body modalities in oncology. The 2023 SIO-ASCO joint guideline (Carlson et al., 2023) assigned mindfulness-based interventions the highest tier of recommendation across both anxiety and depression in cancer.

A 2025 three-level meta-analysis of 11 reports including 991 breast cancer patients examined the effect of mindfulness-based meditation on immune function, finding a small but statistically significant effect on immune biomarkers (Hedges' g = 0.100, p = .026). Specifically, the analysis suggested that mindfulness may modestly reduce systemic inflammation, increase immune cell counts and activity, and potentially promote telomere length—although effect heterogeneity across biomarker categories warrants cautious interpretation (Zhang et al., 2025).

2.2 The MATCH Trial

The Mindfulness and Tai Chi for Cancer Health (MATCH) trial, published by Carlson et al. (2025) in the Journal of Clinical Oncology, is the largest preference-based comparative effectiveness trial in integrative oncology to date. Conducted at the Tom Baker Cancer Centre in Calgary and the Princess Margaret Cancer Centre in Toronto, the trial enrolled 587 distressed cancer survivors between 2017 and 2020. The preference-based design is particularly important: participants who expressed a preference (64% of enrollees) received their chosen intervention—57% chose MBCR and 43% chose tai chi/qigong (TCQ)—while those without preference (36%) were randomly assigned. All participants were then randomized 2:1 to immediate intervention or waitlist control.

Both MBCR and TCQ significantly improved Total Mood Disturbance on the Profile of Mood States compared with waitlist control. Whether participants chose their program or were randomly assigned did not modify outcomes—a critical finding for pragmatic clinical implementation. MBCR produced the greatest improvements in tension and anger; TCQ produced the greatest reductions in depression and anger. Moderator analyses revealed that women responded more strongly to MBCR, whereas younger participants and those with advanced cancer stages responded more strongly to TCQ. The trial therefore establishes both interventions as clinically meaningful options and supports patient choice without compromising effectiveness.

2.3 Yoga, Tai Chi, and Qigong

A 2025 systematic umbrella review of 16 meta-analyses encompassing 134 randomized controlled trials and 9,469 breast cancer patients found convincing evidence for yoga in reducing depression (Hedges' G = −0.77, 95% CI [−0.93, −0.61]), with yoga, tai chi, and qigong each supported by at least weak-to-moderate evidence across fatigue, quality of life, anxiety, and sleep outcomes. A separate 2025 network meta-analysis comparing health qigong and yoga for breast cancer patients found tai chi chuan to be the most effective modality for fatigue and quality of life. The ASCO-SIO 2024 fatigue guideline conditionally recommends tai chi/qigong for post-treatment fatigue (low-quality evidence) and assigns a strong recommendation for yoga during active treatment (Bower et al., 2024).

2.4 Music Therapy, Expressive Arts, Hypnosis, and Relaxation

Music therapy received formal recommendation in the 2023 SIO-ASCO guideline for reducing anxiety and depression during active cancer treatment (Carlson et al., 2023). It is also explicitly recommended in the 2017 SIO breast cancer guideline (Greenlee et al., 2017) and the 2018 ASCO endorsement (Lyman et al., 2018) for mood disturbance and anxiety reduction—one of the few interventions appearing across multiple SIO-ASCO guidelines with consistent endorsement.

Implementation encompasses two distinct delivery modalities. Active music therapy involves patient performance or improvisation with a credentialed music therapist (MT-BC credential from the Certification Board for Music Therapists), typically using instruments selected for accessibility and emotional expression rather than musical skill. Receptive music therapy involves structured patient listening, often with therapist guidance and processing of emotional response. Both modalities have randomized-trial support. The Cassileth, Vickers, and Magill (2003) Cancer trial of music therapy for mood disturbance during autologous stem cell transplantation hospitalization demonstrated significant reductions in mood disturbance, anxiety, and nausea—a foundational study in oncology music therapy.

Beyond music therapy specifically, the expressive arts therapies—art therapy, dance/movement therapy, writing therapy, and drama therapy—share a common theoretical framework: that non-verbal or symbolic expression of cancer-related experience can access emotional, existential, and physical content that verbal processing alone cannot reach. The evidence base for each is smaller than for music therapy, but the underlying clinical logic is sound. Art therapy with credentialed providers (ATR-BC credential from the Art Therapy Credentials Board) has emerging evidence for anxiety, depression, body image, and quality of life in cancer populations. Writing therapy, including expressive writing protocols developed by Pennebaker and adapted for oncology, has emerging evidence for psychological adjustment. Dance/movement therapy has small-trial evidence for mood, body image, and quality of life in breast cancer survivors specifically.

Hypnosis has emerging Stage 3 evidence specifically for procedural pain (large core breast biopsies, tumor embolization, radiofrequency ablation), hot flashes in breast cancer survivors (Elkins et al.), and CINV. CBT with or without hypnosis is among the strongest recommendations in the 2024 fatigue guideline (Bower et al., 2024), and hypnosis-assisted relaxation is recommended for anxiety management during active treatment. The clinical positioning of music therapy and the expressive arts within integrative oncology is increasingly established—not as adjunctive amusement but as evidence-based therapeutic modalities delivered by credentialed providers, with specific symptom-domain recommendations and a growing body of randomized-trial support.

2.5 Meaning-Centered Psychotherapy and the Exceptional Cancer Patient

Beyond symptom-focused interventions, a persistently relevant tradition in psycho-oncology emphasizes meaning, agency, and transcendence as core dimensions of the cancer experience. Four prominent works converge on a recognizable description of patients who outperform statistical expectation: Siegel's Love, Medicine and Miracles (1986), Frankl's Man's Search for Meaning (1946/2006), Turner's Radical Remission (2014) and Radical Hope (Turner & White, 2020), and McLelland's How to Starve Cancer Without Starving Yourself (2018). Eight themes recur across these works: active agency rather than passive patienthood; strong reasons for living; radical lifestyle reset, particularly dietary; spiritual or transcendent orientation; emotional release; community and social support; intuition paired with information; and hope as chosen orientation.

Meaning-Centered Group Psychotherapy, developed at Memorial Sloan Kettering Cancer Center by Breitbart and colleagues, has demonstrated reductions in depression, hopelessness, and existential distress in patients with advanced cancer (Breitbart et al., 2015). Adapted logotherapy and meaning-centered interventions have shown similar benefits in women with breast and gynecologic cancers. A 2024 evaluation of the Radical Remission Multimodal Intervention demonstrated improvements in quality of life among participants (Barnett et al., 2024).

The empirical question of whether psychosocial intervention also extends survival remains unresolved. Spiegel et al.'s (1989) original Lancet finding—that supportive-expressive group therapy was associated with approximately 18 months longer median survival in women with metastatic breast cancer—was among the most influential observations of mid-twentieth-century psycho-oncology and shaped two decades of clinical practice. The finding has not consistently replicated: Goodwin et al. (2001) in the New England Journal of Medicine reported no survival benefit in a larger multicenter replication, and Spiegel et al.'s own 2007 replication trial in Cancer also did not confirm a survival benefit, though improvements in mood, pain, and distress were robust across studies. To his credit, Spiegel did not suppress the negative replication; he published it. The honest position in 2026 is that psychosocial interventions reliably improve quality of life and may improve survival in some populations and settings, but the survival signal is not as well-established as the quality-of-life signal.

An illuminating epidemiological parallel is the Roseto effect, originally described by Stout, Wolf, and colleagues (Stout et al., 1964, JAMA) in the small Italian-American community of Roseto, Pennsylvania. From 1955 to 1965, age-adjusted myocardial infarction mortality in Roseto was approximately half that of the immediately adjacent town of Bangor, despite equivalent prevalence of conventional risk factors (smoking, diet, hypertension, obesity). The proposed explanation was social cohesion: three-generation households, dense intergenerational community structures, civic engagement, and shared cultural norms that produced what the investigators interpreted as a community-level psychosocial protective effect on cardiovascular disease. As Roseto became more "Americanized" through the 1960s and 1970s—with erosion of multi-generational households, loss of community cohesion, and rising material individualism—the mortality advantage progressively disappeared. By the 50-year follow-up (Egolf, Lasker, Wolf, & Potvin, 1992, American Journal of Public Health), Roseto's myocardial infarction mortality had risen to match Bangor's.

The Roseto literature has been re-examined critically; methodological limitations of the original observations have been noted, and the diet-versus-social-cohesion attribution remains contested. But the parallel to the Spiegel question is conceptually instructive: both literatures generated compelling early observations that social and psychological factors might exert measurable effects on hard outcomes (cardiovascular mortality in Roseto, cancer survival in Spiegel 1989); both encountered replication challenges that complicate but do not refute the underlying hypothesis; and both leave the field with the reasonable conclusion that psychosocial and community factors plausibly influence biological outcomes through neuroendocrine, immune, and behavioral pathways, even if the magnitude and consistency of effect on hard endpoints is more modest than the original observations suggested. The integrative oncology contribution is not to overstate the survival case for psychosocial intervention—the post-replication evidence does not support that—but to preserve the recognition that human connection, community, and meaning are part of the biology of disease and recovery, and to deliver those interventions with rigor.

2.6 The Radical Remission Project: Bayesian Reasoning About Exceptional Survivors

Among contemporary works on the experience of patients who outperform statistical expectation, Kelly A. Turner's Radical Remission: Surviving Cancer Against All Odds (2014) and Radical Hope (Turner & White, 2020) occupy a distinctive position. Turner—who holds a PhD in oncology research from the University of California, Berkeley—undertook ten years of qualitative research interviewing more than 1,500 patients who experienced what she termed "radical remission": medically documented cancer reversal in circumstances where conventional prognosis predicted death. Her methodology drew on grounded-theory qualitative research, with cases verified through medical record review where possible. Across these cases, ten factors recurred: radically changing diet, taking control of health, following intuition, using herbs and supplements, releasing suppressed emotions, increasing positive emotions, embracing social support, deepening spiritual connection, having strong reasons for living, and engaging exercise or movement (added in subsequent editions). The 2024 evaluation of the Radical Remission Multimodal Intervention (Barnett et al., 2024) demonstrated improvements in quality of life among participants in a structured program operationalizing these factors.

The Methodological Critique—And Why It Does Not Fully Apply

Turner's work would not qualify as a randomized controlled trial, and a strict frequentist appraisal correctly notes that case series of self-selected survivors cannot prove that any specific intervention caused remission. This critique is accurate as far as it goes. But applied uncritically, it misses something important about the epistemic situation. The cases Turner studied are not patients with curable cancers who simply did well; they are patients with documented metastatic, refractory, or treatment-resistant disease in whom conventional medicine predicted death—and who instead achieved durable remission. In Bayesian language, the prior probability of such an event in genuinely terminal disease is extremely low. When the prior probability of an outcome is low, even modest-quality observational evidence updates the posterior probability substantially. The Bayesian calculation does not require that Turner's cases prove causation; it requires only that we ask whether her observations should shift our credence about which factors plausibly accompany the rare event of cancer reversal in advanced disease. The honest answer is yes, modestly, and in directions consistent with biological plausibility—dietary reset alters metabolic and microbiome substrate; emotional release and meaning-making engage neuroendocrine and immune pathways with mechanistic literature; social connection has the Spiegel and Roseto-related biological correlates discussed above; and active patient agency is associated with better adherence to evidence-based treatment in a substantial separate literature.

Why Bayesian Framing Matters Here

Frequentist statistical inference is the appropriate framework for trial-level evidence of average treatment effects in defined populations; it is the foundation of regulatory drug approval and SIO-ASCO guideline development. But the experience of exceptional survivors is not a treatment-effect question; it is a question about rare events that frequentist methods are poorly designed to characterize. Bayesian inference, by contrast, asks how observations should update prior beliefs. For a patient with documented stage IV pancreatic cancer who has been told they have six months to live, the question is not "what is the average effect of dietary change across all pancreatic cancer patients" (a frequentist question with a discouraging answer); the question is "given documented cases of exceptional survival, with consistent features described across hundreds of independent reports, how should I update my prior about which factors are worth attending to in my own situation?" That is a legitimate Bayesian question, and Turner's work is one of the few systematic data sources available to inform it. Her ten themes are not validated causal mechanisms, but they are credible candidate hypotheses about the lifestyle and psychosocial substrate of rare-event recovery in advanced cancer, and they substantially overlap with the themes independently identified by Siegel (1986), Frankl (1946/2006), and McLelland (2018) working in different traditions—a convergence that itself has Bayesian weight.

Clinical Integration

The defensible clinical posture toward Turner's work is neither dismissal nor over-claiming. It is not appropriate to tell patients that following the ten Radical Remission factors will cure their cancer; the evidence does not support that, and the substitution-harm literature (Section 47.3) demonstrates how such framing produces measurable mortality when patients skip evidence-based therapy. It is appropriate to recognize that the qualitative pattern Turner documents—across patients in different countries, with different cancers, working with different traditions—represents real observational data about the lifestyle and psychosocial features that accompany exceptional survival in genuinely advanced disease. Integrating these factors as supportive adjuncts to evidence-based oncologic care is reasonable, low-risk, often clinically beneficial along quality-of-life dimensions, and consistent with the integrative oncology framework throughout this chapter. Patients experiencing advanced cancer benefit from a clinician who can hold both the evidence-based standard of care and the broader human experience of exceptional survival in the same conversation, without conflating the two and without dismissing either.

The Radical Remission Project itself functions as something approaching a longitudinal patient registry, with ongoing case accrual and a 2024 published evaluation of its structured intervention (Barnett et al., 2024) that demonstrated quality-of-life improvements without claiming survival effects. This is, in fact, the right way to study exceptional-survivor patterns: structured prospective documentation, qualitative analysis paired with quantitative quality-of-life measurement, and intellectual honesty about what observational data can and cannot establish. The work occupies a legitimate place in integrative oncology, properly framed.

2.7 Massage Therapy

Massage therapy has accumulated some of the most robust randomized-trial and guideline-level evidence in supportive oncology. The 2022 SIO-ASCO Integrative Medicine for Pain Management guideline (Mao et al., 2022) provides a moderate-strength recommendation for massage therapy to manage pain in patients undergoing palliative or hospice care, based on intermediate-level evidence and a favorable benefit-to-risk ratio. The pivotal randomized controlled trial supporting this recommendation enrolled 380 patients with advanced cancer and demonstrated clinically significant reductions in moderate to severe pain. The 2017 SIO breast cancer guideline (Greenlee et al., 2017) and the 2018 ASCO endorsement (Lyman et al., 2018) additionally recommend massage for depression and mood disorders in breast cancer survivors.

Beyond pain and mood, the Cassileth and Vickers (2004) prospective outcome study of more than 1,200 cancer patients at Memorial Sloan Kettering—the foundational large observational study of oncology massage—documented significant immediate reductions in pain, fatigue, anxiety, nausea, and depression following individual sessions, with effects persisting for hours after treatment. Izgu et al. (2019) reported a randomized assessor-blinded trial of classical massage in breast cancer patients receiving paclitaxel, demonstrating reduced incidence and severity of chemotherapy-induced peripheral neuropathy with massage compared with control.

Implementation considerations include the use of credentialed providers—Licensed Massage Therapists (LMT) with oncology massage training, certified through programs such as Oncology Massage Education Associates or the Society for Oncology Massage. Pressure, positioning, and site avoidance are modified for thrombocytopenia, lymphedema risk, bone metastases, recent surgical sites, and active radiation fields; the historical injunction against any massage in cancer patients has been replaced by an evidence-based framework of adaptive technique. Contraindications relevant to specific clinical contexts include deep vein thrombosis (avoid affected extremity), severe thrombocytopenia (gentle modalities only), suspected abdominal obstruction (alternate sites), and active infection at planned treatment sites. With appropriate training and clinical coordination, massage therapy is among the safest and most effective integrative interventions in oncology.

2.8 Spirituality, Pastoral Care, and the Religious Dimension

Spirituality and religious practice occupy a distinct clinical domain from psychological intervention and meaning-centered psychotherapy, though they overlap substantially. Survey data consistently document that the majority of cancer patients identify spiritual or religious dimensions as important to their cancer experience, particularly in advanced disease and end-of-life contexts. The clinical implications include attention to spiritual distress as a domain of patient experience requiring assessment and response, integration of chaplaincy and pastoral care services, respect for diverse religious and spiritual traditions including those without formal religious affiliation, and recognition of the role of spiritual community in patient and family adaptation.

The work of Christina Puchalski and colleagues at the George Washington Institute for Spirituality and Health has provided structured frameworks for spiritual assessment in clinical care, including the FICA tool (Faith and belief, Importance, Community, Address in care) and the SPIRIT framework. These provide brief, validated approaches to identifying patients for whom spiritual concerns are clinically relevant and to whom referral to chaplaincy or pastoral care is appropriate. The Joint Commission and major palliative care guidelines require spiritual assessment as part of comprehensive care; integrative oncology programs should ensure this assessment is occurring and that findings are acted upon.

Board-Certified Chaplains (BCC credential from the Board of Chaplaincy Certification, Inc., affiliated with the Association of Professional Chaplains) provide clinically integrated spiritual care across denominational and non-denominational contexts. Modern hospital chaplaincy is multifaith, professionally credentialed, and clinically integrated; it is distinct from religious ministry in the community and operates within healthcare ethics, confidentiality, and team-based care frameworks. The cancer center chaplain is a resource for patients and families experiencing spiritual distress, existential questions, fear of death and dying, religious tradition-specific concerns, ethical dilemmas at end of life, and ritual and ceremony needs around treatment milestones, recurrence, transition to hospice, and death.

The evidence base for spiritual interventions in cancer outcomes is appropriately characterized as observational and supportive rather than mechanistic or causal. Spiritual well-being correlates with quality of life across multiple cancer populations; spiritual distress correlates with depression, anxiety, and worse symptom management. Religious community participation correlates with better health outcomes in observational data, with mechanisms including social support, behavioral factors, and meaning-making. Whether spiritual practice itself influences disease outcomes through biological pathways is an open question that should be approached with the same Bayesian framing applied to the Spiegel and Radical Remission literatures (Sections 2.5, 2.6): observational data suggests the question is legitimate even when randomized evidence is unavailable. Clinically, the integrative oncology contribution is to ensure spiritual assessment and pastoral care access are routine elements of comprehensive cancer care, to support patients across the diversity of religious and spiritual traditions, and to recognize the spiritual dimension as a distinct domain of clinical attention rather than a subordinate aspect of psychological care.

3. Oncology Acupuncture: A Credentialed Discipline

Evidence tier: Multiple randomized sham-controlled trials, real-world cohorts, SIO-ASCO recommendations, and a substantive clinical research program led by Dr. Weidong Lu at Dana-Farber Cancer Institute.

Acupuncture has one of the broadest clinical evidence bases in integrative oncology. The 2022 SIO-ASCO pain guideline lists acupuncture among its strongest recommendations for cancer-related pain (Mao et al., 2022); the 2023 anxiety/depression guideline recommends acupuncture for post-treatment anxiety (Carlson et al., 2023). Its safety profile is favorable even in immunocompromised patients when administered by appropriately trained practitioners.

3.1 Dr. Weidong Lu and the Dana-Farber Research Program

Dr. Weidong Lu, MB, MPH, PhD, at the Leonard P. Zakim Center for Integrative Therapies of Dana-Farber Cancer Institute and Harvard Medical School, has been a pivotal figure in transforming acupuncture from an "alternative" practice into a credentialed oncology discipline. His clinical research program has focused on three high-impact symptom domains and on the safety standards required for needling patients with cytopenias and other cancer-related vulnerabilities.

Chemotherapy-Induced Leukopenia and Neutropenia

Lu et al. (2007) published an exploratory meta-analysis of randomized controlled trials examining acupuncture for chemotherapy-induced leukopenia and neutropenia, synthesizing both English- and Chinese-language literature and establishing methodological standards for the field. Lu, Matulonis, et al. (2009) subsequently conducted a pilot randomized sham-controlled clinical trial in patients with gynecologic malignancies receiving myelosuppressive chemotherapy. The incidence of grade 2–4 leukopenia was significantly lower in the active acupuncture arm than the sham arm (30% vs. 90%; p = .02), with clinically relevant trends toward higher leukocyte and neutrophil nadirs after adjustment for baseline differences. The trial established the feasibility, safety, and preliminary myeloprotective signal of acupuncture during cytotoxic chemotherapy. The companion quality-of-life substudy demonstrated improvements on validated psychometric scales (Lu, Matulonis, et al., 2012).

Radiation-Induced Dysphagia and Xerostomia

Dysphagia occurs in up to 50% of patients receiving concurrent chemoradiation for advanced head and neck cancer (HNC) and is among the most quality-of-life-impairing late toxicities of curative-intent treatment. Lu, Posner, et al. (2010) published a case series of 10 HNC patients with radiation-induced dysphagia and xerostomia treated with acupuncture at Dana-Farber, with the dual aim of characterizing safety and identifying signal. The subsequent Lu et al. (2012) protocol paper outlined the rationale and design for a randomized sham-controlled trial supported by an NIH/NCCAM K01 award. The Lu, Wayne, et al. (2016) pilot randomized sham-controlled trial in 42 HNC patients undergoing curative-intent chemoradiation, published in The Oncologist, demonstrated that the trial design was feasible and safe. Dysphagia-related quality of life improved with both verum and sham acupuncture; a definitive trial powered for efficacy is warranted and remains an active research priority.

Professionalization and Safety Standards

Lu, Doherty-Gilman, and Rosenthal's (2010) review in Current Treatment Options in Oncology, titled Recent Advances in Oncology Acupuncture and Safety Considerations in Practice, established formal safety guidelines for needling patients with thrombocytopenia, neutropenia, lymphedema risk, central venous catheters, and bone metastases. The framework has shaped credentialing standards for oncology acupuncturists worldwide and is widely cited in subsequent SIO-ASCO and institutional protocols. The Society for Integrative Oncology has built on this work to establish the now-standard practice of group acupuncture in outpatient oncology settings, which substantially improves access while maintaining safety.

3.2 Real-World Evidence: The Lasheen Cohort

A landmark real-world study published by Lasheen et al. (2026) in Supportive Care in Cancer retrospectively analyzed 2,239 consecutive cancer patients receiving group Traditional Chinese acupuncture at Atrium Health Levine Cancer Institute between 2015 and 2022. The cohort was 83% female with a mean age of 57 years; 57% had breast cancer as the primary diagnosis. Common symptoms at intake included pain (61%), sleep disturbance (50%), fatigue (45%), hot flashes (42%), anxiety (40%), and neuropathy (40%); 68% reported two or more concurrent symptoms with median baseline severity of 5–6 on a 0–10 numeric rating scale.

By the second acupuncture session, all studied symptoms had improved statistically; by the third session, all improvements were both statistically and clinically significant. Specifically, 66% of patients experienced improvement in hot flashes, 62% in anxiety, 56% in fatigue, 55% in insomnia, 55% in neuropathy, and 50% in pain by session two. Benefits were consistent across age groups and sexes, although males were systematically underreferred—a finding that mirrors broader patterns in integrative oncology access. Multiple sessions were associated with sustained benefit, underscoring the importance of adherence protocols in clinical programming.

3.3 Acupuncture in Radiation Oncology

A 2025 review in Current Oncology Reports documented acupuncture's efficacy for chronic radiation-induced xerostomia in head and neck cancer survivors and identified an evidence-based role for calendula-based topicals for radiation dermatitis (Vehlow et al., 2025). The 2024 ASCO-SIO fatigue guideline conditionally recommends acupressure for post-treatment fatigue (Bower et al., 2024). Active phase 3 trials at multiple academic centers are evaluating acupuncture for chemotherapy-induced peripheral neuropathy, with results pending.

4. Exercise Oncology: The CHALLENGE Trial Era

Evidence tier: Phase 3 randomized controlled trial with survival endpoint; NEJM editorial calling for systemic integration into oncology practice.

4.1 The CHALLENGE Trial

Exercise has now accumulated stronger survival-level evidence than any other integrative oncology intervention. The CHALLENGE trial (Canadian Cancer Trials Group CO.21), published by Courneya et al. (2025) in the New England Journal of Medicine in June 2025, is the first phase 3 randomized trial to demonstrate that structured exercise improves cancer-specific outcomes. Eligible participants were 889 patients with high-risk stage II or stage III colon cancer who had completed adjuvant chemotherapy within the previous 60–180 days, reported less than 150 minutes per week of moderate-to-vigorous physical activity at baseline, and demonstrated adequate physical function for the protocol. They were randomized 1:1 to a 3-year structured exercise program (targeting ≥10 MET-hours per week of recreational aerobic exercise, equivalent to brisk walking 3–4 times per week for 45–60 minutes) or to a health education control.

At a median follow-up of 7.9 years, the structured exercise group experienced a 28% reduction in the risk of disease recurrence, new primary cancer, or death (hazard ratio 0.72; 5-year disease-free survival 80.3% vs. 73.9%) and a 37% reduction in overall mortality (hazard ratio 0.63; 8-year overall survival 90.3% vs. 83.2%—an absolute improvement of 7.1 percentage points). The benefits were consistent across age, sex, and disease subgroups, and were independent of weight loss, indicating a direct biological effect of physical activity itself rather than a body-composition mediator. The accompanying NEJM editorial by Irwin (2025) framed the magnitude of benefit as comparable to that of approved oncologic therapies and called for the systemic integration of exercise into oncology care, including dedicated infrastructure, funding, and clinical trial networks.

4.2 Mechanisms and Dose-Response

The biological mechanisms underlying exercise-associated survival benefit are incompletely characterized but appear to include reductions in systemic inflammation, modulation of insulin/IGF-1 signaling, alterations in adipokine profiles, improved immune surveillance, and direct effects on tumor metabolism. A dose-response analysis in colon cancer survivors documented graded reductions in high-sensitivity C-reactive protein, interleukin-6, and soluble TNF-α receptor 2 with increasing aerobic exercise dose (Brown et al., 2024). A 2025 JAMA Network Open meta-analysis confirmed reductions in depression, anxiety, and improvements in health-related quality of life with exercise therapy in older adults with cancer (Liu et al., 2025), supporting feasibility across a broad age range.

4.3 Clinical Recommendations

ASCO and SIO jointly recommend at least 150 minutes of moderate or 75 minutes of vigorous aerobic activity weekly, plus 2–3 weekly strength training sessions targeting major muscle groups (Ligibel et al., 2022). The CHALLENGE trial provides level 1 evidence for structured exercise as a recurrence-reduction strategy in colon cancer and establishes a foundational template for ongoing trials in other malignancies, including phase 3 evaluations in breast and prostate cancer. Implementation considerations include screening for cardiac and orthopedic safety, individualized program design, supervised initiation for previously sedentary patients, and integration with the oncology team. Behavioral support and group-based programming have been associated with improved adherence in the CHALLENGE protocol and subsequent implementation studies.

5. Digital Integrative Medicine: The IM@Home Trial

Evidence tier: Single-center randomized trial with strong patient-centered and economic endpoints; multicenter replication pending.

The Integrative Medicine at Home (IM@Home) trial, published by Mao et al. (2025) in npj Digital Medicine in January 2025, represents the most clinically significant recent advance in scalable integrative oncology delivery. The 12-week randomized controlled trial enrolled 200 patients with solid tumors experiencing fatigue during active cancer treatment at Memorial Sloan Kettering Cancer Center. Participants were randomized to a live digital program combining group-based exercise and mindfulness sessions versus enhanced usual care. The patient population was heterogeneous: 73 with breast cancer, 49 with thoracic cancer, 43 with gynecologic cancer, 25 with head and neck cancer, and 10 with melanoma; mean age 59.9 years; 91% female; 78% White.

The primary outcome—fatigue severity on the Brief Fatigue Inventory—decreased by a mean of 1.99 points in the IM@Home arm versus 1.51 points in the control arm (p = .04). Secondary outcomes were uniformly positive: reductions in symptom distress (p = .003), anxiety (p = .03), and depression (p = .02). Most strikingly, acute healthcare utilization was substantially lower in the intervention group:

• Emergency department visits: rate ratio 0.49 (p = .04)
• Hospitalizations: 4% vs. 12.9% (p = .03)
• Mean hospital length of stay: 4.25 vs. 10 days (p < .001)

The dramatic reduction in acute healthcare utilization—fewer emergency department visits, fewer hospitalizations, and a 5.75-day reduction in mean length of stay—represents a compelling economic argument for digital integrative medicine reimbursement. A qualitative companion analysis identified flexible, accessible, group-based programming, real-time guidance, tailored content, and community support as the principal patient-valued features.

Phase 3 multicenter confirmation, payer coverage frameworks, and equity-of-access infrastructure remain critical next steps for widespread scalability. The IM@Home trial also illustrates a broader trend in oncology care: the convergence of evidence-based supportive interventions with digital delivery platforms that can dramatically expand reach while reducing barriers of time, transportation, and proximity.

6. Foundational Supplements with Guideline Support

Evidence tier: Established clinical recommendations from NCCN, SIO, ASCO, and ESPEN frameworks.

Several foundational supplements occupy a place in guideline-concordant supportive care for oncology patients. The clinical priority is identifying and correcting documented deficiencies and supporting nutritional adequacy during treatment, rather than reflexive supplementation.

6.1 Vitamin D

Vitamin D deficiency affects more than 50% of newly diagnosed cancer patients. NCCN survivorship guidelines recommend screening and supplementation for at-risk patients, particularly those receiving androgen or estrogen deprivation therapy or living with bone metastases. Optimal serum 25-hydroxyvitamin D levels are 30–50 ng/mL; vitamin D₃ (cholecalciferol) is preferred over D₂ (ergocalciferol) and should be taken with fat-containing food for optimal absorption. Typical replacement doses range from 1,000–5,000 IU daily depending on baseline level and body mass index.

6.2 Vitamin B12 and Folate

Vitamin B12 deficiency affects up to 48% of patients with cancer, particularly those with gastrointestinal disease, older adults, and patients on proton pump inhibitors or metformin. Replacement options include oral, sublingual, or intramuscular forms depending on the degree of malabsorption. Folate deficiency—commonly attributable to poor diet, alcohol use, chemotherapy, or oral contraceptives—is corrected with 1 mg folic acid daily. Both deficiencies are essential, correctable, and frequently overlooked in routine oncology care.

6.3 Omega-3 Fatty Acids

ESPEN clinical nutrition guidelines recommend considering omega-3 fatty acid supplementation in weight-losing or malnourished cancer patients undergoing chemotherapy, with the goal of maintaining lean body mass and appetite. Doses of 1–3 g daily combined eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) are typical. High-dose fish oil carries antiplatelet properties and requires caution in patients on anticoagulants or before surgical procedures.

6.4 Magnesium

Magnesium is clinically important in oncology populations on tyrosine kinase inhibitors (sunitinib, cabozantinib) and platinum-based regimens, where renal wasting and gastrointestinal losses are common. Serum magnesium is a poor indicator of total body stores; clinical signs (cramping, fatigue, arrhythmia) and symptom-guided supplementation are reasonable. Magnesium glycinate or citrate at 200–400 mg daily is generally well tolerated.

6.5 American Ginseng

American ginseng (Panax quinquefolius) received a conditional recommendation in the 2024 ASCO-SIO fatigue guideline for patients on active cancer treatment, with low-quality but consistent evidence supporting an antifatigue effect (Bower et al., 2024). Typical doses are 1,000–2,000 mg daily of standardized extract. Caution is warranted with concurrent anticoagulants and with hormone-sensitive malignancies, where Panax ginseng (the Asian species) carries a theoretical estrogenic concern; American ginseng has not shown clear estrogenic activity.

6.6 Zinc and Selenium: A Cautionary Note

Zinc deficiency should be corrected at 2–3 times the recommended daily allowance, but chronic intake exceeding 75 mg daily has been associated with increased risk of aggressive prostate cancer in observational studies. Selenium at the recommended 55 µg daily is essential, but excess intake—particularly in men with specific genetic variants—may raise risk of prostate cancer and type 2 diabetes. Supplementation of zinc and selenium should target documented deficiencies, not blanket supplementation.

6.7 What This Section Does Not Cover

This foundational supplement section is deliberately limited to interventions with mature, low-risk, deficiency-correction or guideline-recommended evidence. Higher-tier mechanistic and investigational interventions—pharmacologic ascorbate, fasting-mimicking diets, modified citrus pectin, medicinal mushrooms, and the metabolic frameworks—are addressed in Parts II and III where their evidence and risk profile can be discussed with appropriate epistemic standards.

Part II

Emerging Therapies with Phase 2

or Strong Mechanistic Evidence

Interventions supported by randomized phase 2 trials, large registries,

or substantive translational evidence, but not yet practice-changing.

7. Pharmacologic Ascorbate: From Pauling to the University of Iowa

Evidence tier: Multiple randomized phase 2 trials in selected cancers; mature pharmacokinetic and mechanistic foundation; phase 3 confirmation pending.

7.1 Historical Trajectory

Few therapies in oncology have endured a more turbulent path than high-dose intravenous vitamin C. Ewan Cameron, a surgeon working at Vale of Leven Hospital in Scotland, reported in 1976 and again in 1978 with Linus Pauling that terminal cancer patients receiving 10 g of ascorbate intravenously followed by oral maintenance survived approximately four times longer than matched historical controls. The two Mayo Clinic randomized placebo-controlled trials that followed (Creagan et al., 1979; Moertel et al., 1985) found no benefit from vitamin C. The medical community concluded that Pauling had erred, and the hypothesis was largely abandoned for two decades.

The pivotal pharmacokinetic insight that rehabilitated intravenous ascorbate came from Padayatty, Levine, and colleagues at the National Institutes of Health in 2004. They demonstrated that maximally tolerated oral doses produce plasma ascorbate concentrations of approximately 220 µmol/L, whereas intravenous administration of 50 g produces peak plasma concentrations approaching 13,400 µmol/L—a 60-fold differential. The Mayo Clinic studies, by using only the oral route, had been testing a pharmacologically different intervention than Cameron and Pauling. This pharmacokinetic gulf is the foundation of all subsequent work in pharmacologic ascorbate.

7.2 Mechanisms of Anti-Cancer Activity

Four distinct, potentially synergistic mechanisms account for the anti-cancer activity of pharmacologic ascorbate.

First, at millimolar plasma concentrations achievable only intravenously, ascorbate paradoxically functions as a pro-oxidant via iron- and copper-catalyzed electron transfer to molecular oxygen, generating extracellular hydrogen peroxide that selectively damages cancer cells with reduced antioxidant defenses (Chen et al., 2005, 2007, 2008). Catalase abrogates this cytotoxicity, confirming hydrogen peroxide as the effector species. Cancer cells, with their characteristically elevated baseline reactive oxygen species and frequently impaired peroxide detoxification, are more vulnerable than normal cells to this insult.

Second, ascorbate is an essential cofactor for ten-eleven translocation (TET) dioxygenases, which catalyze active DNA demethylation (Blaschke et al., 2013). In hematologic malignancies harboring TET2 loss-of-function mutations—approximately 10–30% of acute myeloid leukemia and myelodysplastic syndrome—pharmacologic ascorbate can partially restore TET activity (Agathocleous et al., 2017; Cimmino et al., 2017). A case report by Das et al. (2019) documented clinical remission in TET2-mutant AML after ascorbate treatment.

Third, ascorbate is a cofactor for prolyl hydroxylases that mark hypoxia-inducible factor 1-alpha for proteasomal degradation, with downstream anti-angiogenic effects (Mikirova et al., 2008).

Fourth, Yun and colleagues (2015) demonstrated in Science that high-dose vitamin C selectively kills KRAS- and BRAF-mutant colorectal cancer cells through GAPDH inhibition. This mechanism is particularly relevant to the approximately 40% of colorectal cancers harboring KRAS mutations.

7.3 The University of Iowa Trials

The most significant recent clinical evidence comes from the University of Iowa group led by Joseph Cullen and Bryan Allen. Bodeker et al. (2024), publishing in Redox Biology, reported a randomized phase 2 trial in 34 patients with metastatic pancreatic adenocarcinoma randomized to gemcitabine plus nab-paclitaxel with or without intravenous ascorbate (75 g three times weekly). Median overall survival was 16 months in the ascorbate arm versus 8 months in the control arm—a doubling of survival in a disease where median survival with standard therapy is approximately 8–11 months. Progression-free survival extended from 3.9 to 6.2 months. The trial was stopped early for benefit. Intravenous ascorbate did not add measurable toxicity; patients in the ascorbate arm tolerated chemotherapy better and received higher cumulative chemotherapy doses.

A parallel University of Iowa phase 2 trial in glioblastoma (Allen et al., 2024) reported a five-month overall survival advantage with intravenous ascorbate added to standard chemoradiation, with the dual observation that ascorbate appeared to protect normal tissue from radiation-induced damage—a mechanistically distinct effect from its tumoricidal action and consistent with the differential antioxidant biology of normal versus malignant cells. A separate randomized trial in metastatic castration-resistant prostate cancer found no significant survival improvement with intravenous ascorbate added to docetaxel, underscoring the importance of disease-specific patient selection. Phase 3 confirmation in pancreatic cancer remains the priority next step.

7.4 The Riordan Protocol and Clinical Implementation

The Riordan IVC Protocol provides the most widely implemented clinical framework, developed over four decades at the Riordan Clinic in Wichita, Kansas (Mikirova et al., 2013; Riordan et al., 2005). Key elements include mandatory pre-screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency, baseline renal function and iron status assessment, and dose titration from 15 g to 75–100 g per infusion based on post-infusion plasma ascorbate targets of 20–23 mmol/L. Two to three weekly infusions are typical, with treatment continuing until tumor stabilization or until further infusions are no longer clinically appropriate. Padayatty et al. (2010), in a survey of approximately 10,000 intravenous ascorbate administrations by complementary medicine practitioners, documented that serious adverse events are rare when the protocol is followed.

7.5 Safety Considerations

The principal absolute contraindication is G6PD deficiency, in which oxidative hemolysis can be severe or fatal (Marik, 2019). Other relevant cautions include significantly reduced renal function (risk of oxalate nephropathy), iron overload states (amplified Fenton chemistry), and fluid-sensitive cardiac conditions. False-positive glucometer readings via the electrochemical method are common for several hours post-infusion (Padayatty et al., 2010); patients on insulin therapy should use a glucose-oxidase or hexokinase-based meter or finger-stick measurement at a clinical laboratory in the immediate post-infusion window.

8. Fasting and Fasting-Mimicking Diets

Evidence tier: Randomized phase 2 trials demonstrating safety, tumor-response signal, and survival association when combined with chemotherapy.

8.1 Mechanistic Foundation: Differential Stress Resistance

Valter Longo's group at the University of Southern California has developed and validated the concept of differential stress resistance (DSR): healthy cells respond to short-term nutrient deprivation by entering a protective, dormant metabolic state, whereas cancer cells—driven by oncogene-mediated proliferative signaling—fail to adapt and become more vulnerable to cytotoxic chemotherapy. Across preclinical models, fasting and fasting-mimicking diets (FMDs) protect normal tissues from chemotherapy toxicity while simultaneously sensitizing tumors to a wide range of cytotoxic and targeted agents (Longo & Mattson, 2014).

Mechanistically, FMD reduces circulating insulin-like growth factor 1 (IGF-1), glucose, and amino acid availability; activates AMP-activated protein kinase; suppresses mTORC1 and PI3K/AKT signaling; promotes autophagy in normal cells; and enhances cytotoxic stress on cells with oncogenic signaling that bypasses normal nutrient-sensing checkpoints. Caffa et al. (2020), publishing in Nature, demonstrated that FMD synergizes with hormone therapy (tamoxifen, fulvestrant) in hormone receptor-positive breast cancer models. Di Tano et al. (2020), in Nature Communications, demonstrated synergistic anti-cancer effects of FMD combined with pharmacologic vitamin C against KRAS-mutated cancers—a particularly compelling mechanistic convergence between two integrative interventions.

8.2 The DIRECT Trial

The randomized phase 2 DIRECT trial (de Groot et al., 2020), published in Nature Communications, randomized 131 patients with HER2-negative stage II/III breast cancer (BMI > 18 kg/m², no diabetes) to a 3-day FMD around each cycle of neoadjuvant chemotherapy versus regular diet. The FMD consisted of a low-calorie, low-protein, low-carbohydrate plant-based regimen of approximately 1,100 kcal on day 1 and 700 kcal on days 2 and 3.

A radiologically complete or partial response occurred more often in patients using the FMD (odds ratio 3.168, p = .039). The per-protocol analysis revealed that the Miller and Payne 4/5 pathological response—indicating 90–100% tumor cell loss—was significantly more likely with FMD (odds ratio 4.109, p = .016). FMD also significantly curtailed chemotherapy-induced DNA damage in T-lymphocytes, suggesting a normal-tissue-protective effect operating in parallel with the tumor-sensitizing effect. The companion quality-of-life analysis (Lugtenberg et al., 2021) demonstrated favorable patient-reported outcomes despite the dietary intervention.

8.3 NCT03340935 and Triple-Negative Breast Cancer

The Italian NCT03340935 trial, led by Vernieri and colleagues at Istituto Nazionale Tumori in Milan, evaluated FMD across multiple disease settings. Ligorio et al. (2024), in the International Journal of Cancer, reported that adding FMD to first-line carboplatin-based chemotherapy was associated with significantly better overall survival in advanced triple-negative breast cancer patients—a malignancy with historically poor metastatic-setting outcomes. Exceptional tumor responses to FMD combined with standard anticancer therapies have been documented in case-level analyses (Ligorio et al., 2022). A 2024 Iranian randomized controlled trial (Bahrami et al., 2024), publishing in Frontiers in Nutrition, confirmed feasibility and reduced toxicity signals in breast cancer patients on neoadjuvant chemotherapy.

8.4 Clinical Implementation

FMD is typically delivered as a 5-day low-calorie, low-protein, low-carbohydrate regimen implemented around chemotherapy cycles. Commercial pre-packaged versions (notably ProLon) have been used in clinical trials; equivalent dietitian-supervised regimens can be constructed from whole foods. Contraindications include type 1 diabetes, type 2 diabetes on insulin or sulfonylureas, BMI below 18.5 kg/m², active eating disorder, significant cachexia, pregnancy or lactation, and a small set of metabolic conditions. Implementation should be supervised by a clinician familiar with the protocol and coordinated with the oncology team.

The current evidence supports FMD as a phase 2-validated investigational adjunct, particularly in breast cancer; phase 3 confirmation is ongoing. The intervention is biologically rational, well tolerated when appropriately patient-selected, and inexpensive—a combination that argues for further rigorous trials.

9. Psilocybin-Assisted Therapy for Cancer-Related Existential Distress

Evidence tier: Two foundational 2016 randomized double-blind trials; active phase 2b/3 multicenter confirmation (NCT05398484); FDA Breakthrough Therapy designation.

9.1 The 2016 Foundational Trials

In December 2016, the Journal of Psychopharmacology published two parallel randomized double-blind trials of psilocybin-assisted psychotherapy in cancer patients with anxiety, depression, and existential distress. The trials, conducted at Johns Hopkins University and New York University, established the contemporary scientific foundation for psychedelic-assisted therapy in oncology.

Griffiths et al. (2016) randomized 51 cancer patients with life-threatening diagnoses and clinically significant symptoms of depression and/or anxiety to a high dose (22 or 30 mg per 70 kg) versus a placebo-like low dose (1 or 3 mg per 70 kg) of psilocybin, administered in counterbalanced crossover sequence with 5 weeks between sessions and a 6-month follow-up. High-dose psilocybin produced large and clinically significant decreases in clinician- and self-rated measures of depressed mood and anxiety, with increases in quality of life, life meaning, and optimism. At 6-month follow-up, approximately 80% of participants continued to show clinically significant decreases in depressed mood and anxiety. The intensity of the mystical-type experience during the session significantly predicted long-term therapeutic outcome.

Ross et al. (2016) randomized 29 patients with cancer-related anxiety or depression to single-dose psilocybin or active placebo (niacin) in a crossover design with embedded psychotherapy. Psilocybin produced rapid, substantial, and sustained reductions in cancer-related psychiatric distress and existential anxiety, with decreased cancer-related demoralization and hopelessness, increased spiritual wellbeing and quality of life, and improved attitudes toward death. The effects were maintained at 6.5-month follow-up, with approximately 60–80% of participants meeting criteria for clinically significant antidepressant or anxiolytic response.

9.2 Mechanism and the Mystical Experience

The therapeutic effect of psilocybin in this population appears to be mediated, at least in part, by the mystical-type experience induced during the session—a temporally bounded altered state of consciousness characterized by sense of unity, transcendence of time and space, ineffability, noetic insight, and profound positive mood. Mediation analyses across both trials demonstrated that the intensity of this experience predicted enduring therapeutic outcome, independent of overall drug effect intensity. The mystical experience bridges the neurobiological dimension (5-HT2A receptor agonism, default mode network modulation, increased cross-network neural connectivity, downstream BDNF and neuroplasticity effects) with the existential and spiritual dimensions of cancer care that are otherwise difficult to address pharmacologically (Malone et al., 2018).

Psilocybin was granted FDA Breakthrough Therapy designation for treatment-resistant depression in 2018 and again for major depressive disorder in 2019, based partly on the foundational cancer trials and partly on subsequent work in depression. Cancer-related distress remains an active area of investigation.

9.3 Phase 2b/3 Confirmation

NYU Langone Health is currently conducting NCT05398484, a phase 2b/3 randomized double-blind placebo-controlled multicenter study of psilocybin-assisted psychotherapy on psychiatric and existential distress in advanced cancer. The trial uses a 25 mg psilocybin capsule versus 100 mg niacin active placebo, with structured preparation and integration psychotherapy. Results are expected to inform a New Drug Application and, if positive, potential FDA approval for the indication.

9.4 Clinical Implementation

Psilocybin-assisted therapy is not yet broadly available outside investigational settings in the United States. Where state-level decriminalization or licensed therapeutic frameworks exist (notably Oregon's Measure 109 and Colorado's Proposition 122 implementation), trained clinicians may offer the intervention with formal screening, preparation sessions, supervised dosing, and integration psychotherapy. Contraindications include personal or family history of psychotic spectrum disorders, uncontrolled cardiovascular disease, and concurrent use of medications that significantly alter serotonergic signaling (notably MAOIs, lithium, and—on a case-by-case basis—SSRIs). The intervention requires substantial clinician training and a therapeutic infrastructure (supervised dosing space, two trained therapists per session, integration follow-up); it is not a pharmacologic intervention that can be delivered in a brief office visit.

10. Mistletoe and Immune Checkpoint Blockade

Evidence tier: Mature European clinical use; phase 1 FDA safety trial complete; multiple registry analyses suggesting benefit in NSCLC with checkpoint inhibitors; randomized phase 3 confirmation pending.

10.1 Background and Mechanistic Advances 2020–2025

Mistletoe therapy is the most widely used complementary cancer therapy in Central Europe, with several centuries of empirical use and integration into the German healthcare system as an approved adjunct cancer therapy. Wagner and colleagues (2025) synthesized transformative scientific advances from 2020–2025 in Current Issues in Molecular Biology. Three mechanistic findings are particularly important.

First, mistletoe extracts trigger immunogenic cell death (ICD) through endoplasmic reticulum stress, with calreticulin exposure on 18–51% of cancer cells and 7-fold increases in ATP release. This is a paradigm-shifting mechanism that places mistletoe alongside oxaliplatin and a handful of other agents capable of producing genuine immunogenic, rather than merely cytotoxic, tumor cell death.

Second, mistletoe extracts reprogram tumor-associated macrophages from immunosuppressive M2 to pro-inflammatory M1 phenotypes. Three-dimensional culture models demonstrate increased pro-inflammatory IL-6 (+15.8%) and decreased immunosuppressive IL-10 (−26.4%) in macrophages exposed to mistletoe.

Third, mistletoe extracts activate γδ T-cells via butyrophilin 3A signaling, enhancing innate-adaptive immune crosstalk and direct anti-tumor cytotoxicity.

10.2 Combination with Checkpoint Inhibitors in NSCLC

Building on these immunological mechanisms, real-world clinical evidence has demonstrated remarkable signals when mistletoe is combined with PD-1/PD-L1 checkpoint inhibitors. Thronicke et al. (2024), publishing in Pharmaceuticals, analyzed 415 patients with advanced or metastatic non-small-cell lung cancer in the German Network Oncology registry, applying ESMO Guidance for Reporting Real-World Evidence (ESMO-GROW) criteria. Adding abnobaViscum (Viscum album extract) to PD-1/PD-L1 inhibitor therapy doubled median overall survival from 6.8 to 13.8 months (p = .005), with 3-year survival rising from 8.0% to 16.5%. Biomarker-selected subgroups experienced up to a 91% reduction in mortality risk.

The registry methodology and selection biases warrant appropriate caution: patients well enough to attend mistletoe injections may differ from those who are not, and observational comparisons cannot exclude confounding by performance status, motivation, and concurrent supportive care. The directional signal across multiple independent analyses is, however, consistent, biologically plausible, and increasingly difficult to dismiss as artifact.

10.3 Phase 1 Intravenous Safety Trial

Paller and colleagues at Johns Hopkins (2023) conducted the first-in-human phase 1 dose-escalation study of intravenous Viscum album extract in patients with advanced cancer, publishing in Cancer Research Communications. The trial established safety of intravenous administration at 600 mg three times weekly, with manageable adverse effects (mild fever, fatigue, injection-site reactions). The trial provided the regulatory foundation for further U.S. clinical development.

10.4 Clinical Position and Implementation

Mistletoe is approved and reimbursed as adjunct cancer therapy in Germany and several other European countries. In North America, intravenous mistletoe is FDA-cleared on an investigational basis. Subcutaneous preparations (Iscador, Helixor, Abnoba, Iscucin) are widely used in European integrative oncology practice with dose individualization based on the patient's reaction pattern. The signal in NSCLC plus checkpoint inhibitor therapy is among the strongest combination-therapy signals in integrative oncology, but the registry-based evidence is observational. Phase 3 randomized confirmation remains a priority.

For U.S. clinicians, mistletoe is most appropriately positioned as a research-grade intervention available through clinical trials and select integrative oncology centers. Patients pursuing the therapy should do so with full disclosure of evidence limitations, coordination with their oncologist, and careful monitoring of injection-site reactions and systemic adverse effects.

11. Locoregional Hyperthermia in Pancreatic and Other Cancers

Evidence tier: Multiple retrospective cohorts with consistent directional signal; systematic review supportive; randomized phase 3 evidence not yet available.

11.1 Principles

Therapeutic hyperthermia in oncology refers to the deliberate heating of tumor tissue to approximately 39–43.5 °C using radiofrequency, microwave, or ultrasound energy, most commonly as an adjunct to chemotherapy or radiotherapy. Three biological mechanisms support its rationale: (a) improved tumor perfusion and chemotherapy drug delivery; (b) increased tumor oxygenation and radiosensitization, with direct enhancement of radiation-induced DNA damage; and (c) inhibition of DNA damage repair and induction of immunogenic cell death (National Cancer Institute, n.d.; van der Horst et al., 2018). Heat shock protein release and exposure of tumor antigens following thermal injury can prime adaptive immune responses, adding an immunological dimension to the conventional cytotoxic rationale.

11.2 Evidence in Pancreatic Cancer

The most-cited contemporary evidence in pancreatic cancer comes from Italian retrospective observational studies of modulated electro-hyperthermia (mEHT)—a 13.56 MHz capacitive radiofrequency technique that targets the malignant cell membrane and the tumor extracellular matrix. Fiorentini et al. (2023), publishing in the World Journal of Clinical Oncology, reported a multicenter retrospective comparison of 217 stage III–IV pancreatic cancer patients in which median overall survival was approximately 20 months with chemotherapy plus mEHT versus 9 months with chemotherapy alone, with partial response rates of 45% versus 24%. An earlier 158-patient analysis from the same group reported similar magnitudes (Fiorentini et al., 2021), and a 106-patient palliative cohort reported approximately 18 versus 11 months median overall survival (Fiorentini et al., 2019). A systematic review of 14 hyperthermia trials in pancreatic cancer (van der Horst et al., 2018) found median overall survival ranging from approximately 6 to 18.6 months with hyperthermia plus chemotherapy or chemoradiation.

11.3 Critical Appraisal

The Italian mEHT cohorts share investigators, methodology, and patient populations, and they are retrospective. Selection bias is substantial: a patient well enough to travel to a hyperthermia center for thrice-weekly sessions is, by definition, a different patient than one who is not. The signal is consistent and biologically plausible, but it has not yet reached the level of randomized controlled evidence that would change practice guidelines. The National Cancer Institute continues to classify hyperthermia as investigational. NCCN, ASCO, and ESMO guidelines for metastatic pancreatic cancer continue to prioritize systemic regimens (FOLFIRINOX or gemcitabine/nab-paclitaxel), with hyperthermia positioned as adjunctive or research.

11.4 Clinical Decision-Making in Pancreatic Cancer

For patients with metastatic pancreatic cancer and liver involvement considering hyperthermia, four principles apply. First, anchor on evidence-based systemic therapy at a center experienced in pancreatic oncology. Second, be transparent about the retrospective and selection-biased nature of the supporting evidence. Third, weigh the financial, logistical, and energy costs of thrice-weekly hyperthermia sessions against the realistic probability of meaningful response. Fourth, when pursued, do so at an experienced center, ideally within a clinical trial, with clear stopping criteria and integration with the rest of the supportive care plan.

11.5 Hyperthermia in Other Malignancies

Beyond pancreatic cancer, hyperthermia has been studied in soft-tissue sarcoma, cervical cancer, locally advanced rectal cancer, recurrent breast cancer, glioblastoma, and superficial head and neck malignancies. The cervical cancer evidence is among the strongest, with a Dutch randomized trial demonstrating that radiotherapy plus hyperthermia improved local control and overall survival compared with radiotherapy alone in locally advanced disease (Datta et al., 2016 systematic review and earlier van der Zee et al. trial). The cervical cancer experience supports the general principle that hyperthermia is most useful when deliverable to tumors accessible to localized heating, where the biological rationale is concrete and the addition to standard therapy is feasible.

Part III

Investigational, Metabolic,

and Repurposed Frameworks

Biologically plausible frameworks supported predominantly by

mechanistic, preclinical, retrospective, or case-series data.

12. The Mitochondrial–Stem Cell Connection and the Metabolic Theory

Evidence tier: Theoretical framework with substantive mechanistic and preclinical support; no validating randomized trials of the integrated protocol.

12.1 From the Somatic Mutation Hypothesis to Metabolic Reprogramming

For most of the twentieth century, cancer was conceptualized primarily as a disease of accumulated DNA mutations driving uncontrolled proliferation. This somatic mutation theory has produced extraordinary therapeutic advances, particularly in targeted therapy and immune checkpoint blockade. It has, however, struggled to explain three persistent clinical realities: the recurrence of disease after apparently curative therapy, the resilience of metastatic spread, and the functional immortality of a small subset of tumor cells (Seyfried & Shelton, 2010).

Otto Warburg's 1956 observation that cancer cells preferentially ferment glucose to lactate even in the presence of oxygen was, for decades, treated as a peripheral curiosity. Modern molecular oncology has rehabilitated this observation, demonstrating that tumor cells reprogram their metabolism toward aerobic glycolysis and glutaminolysis to support rapid biomass accumulation and to maintain redox balance (Dang, 2012; Vander Heiden et al., 2009). The reframing of cancer as both a genetic and a metabolic disease provides the theoretical foundation for the metabolic interventions discussed throughout this chapter.

12.2 The MSCC Framework

A 2024 hybrid orthomolecular protocol published in the Journal of Orthomolecular Medicine by Baghli, Makis, Marik, and colleagues proposed the Mitochondrial–Stem Cell Connection (MSCC) theory of cancer. The framework rests on three interlinked claims: (a) chronic mitochondrial dysfunction in tissue stem cells, rather than random nuclear DNA mutation, is the initiating event in carcinogenesis; (b) failure of oxidative phosphorylation forces affected stem cells into a fermentative metabolic state, producing cancer stem cells (CSCs); and (c) CSCs—not bulk tumor cells—are the principal drivers of metastasis, treatment resistance, and recurrence.

The clinical importance of cancer stem cells has been independently established in a substantial peer-reviewed literature dating back to Bonnet and Dick's (1997) foundational work in acute myeloid leukemia. CSCs are characterized by self-renewal capacity, intrinsic resistance to conventional cytotoxic agents, and a critical role in metastatic colonization (Batlle & Clevers, 2017).

12.3 The Press–Pulse Protocol

The MSCC framework operationalizes a press–pulse therapeutic logic: sustained metabolic stress (the "press") combined with intermittent high-impact pro-oxidant interventions (the "pulse") (Seyfried et al., 2017). The seven-step protocol proposed by Baghli et al. (2024) includes glucose restriction (ketogenic diet, intermittent fasting, metformin); glutamine targeting (epigallocatechin gallate, glutaminase inhibitors); restoration of oxidative phosphorylation (coenzyme Q10, alpha-lipoic acid, B vitamins, dichloroacetate); pro-oxidant therapy (intravenous vitamin C, artemisinin, hyperbaric oxygen); direct CSC targeting (doxycycline, azithromycin, berberine, curcumin); anti-angiogenic support (curcumin, resveratrol, EGCG); and lifestyle-based metabolic optimization.

12.4 Critical Appraisal

The MSCC protocol is not a randomized-trial-validated therapeutic regimen. Its evidence base derives from in vitro models, animal studies, and small clinical series. Several agents within the protocol—dichloroacetate, 6-diazo-5-oxo-L-norleucine, mitochondria-targeted antibiotics—carry meaningful toxicity and remain investigational. The strongest elements of the framework, however, align with mainstream oncologic thinking: metformin in obesity-related cancers (Pascale et al., 2021); exercise and weight management for survival outcomes (Schmid & Leitzmann, 2014); and cancer stem cell-directed therapy as a frontier of translational oncology (Lamb et al., 2015).

The intellectual value of the MSCC framework lies not in any specific protocol component but in its insistence that cancer is simultaneously a genetic and a metabolic disease, and that the metabolic dimension is clinically modifiable through dietary, pharmaceutical, and lifestyle interventions. The framework should not be presented to patients as a curative protocol, but its individual components may be reasonable adjuncts when integrated with standard care.

13. The Glutathione Paradox

Evidence tier: Mature mechanistic literature; mixed randomized trial data for CIPN prevention; recent paradigm shifts in tumor metabolism and metastasis biology.

13.1 Normal Physiology

Glutathione (γ-glutamyl-cysteinyl-glycine; GSH) is the most abundant non-protein thiol in mammalian tissues, present at millimolar intracellular concentrations. It serves as the principal cellular antioxidant via glutathione peroxidase, conjugates xenobiotics through glutathione-S-transferases, maintains redox homeostasis, and regulates ferroptosis—an iron-dependent form of programmed cell death increasingly recognized as a tumor-suppressive mechanism (Traverso et al., 2013; Kennedy et al., 2020).

13.2 The Cancer Paradox

The clinical relationship between glutathione and cancer is double-edged. In healthy tissues, glutathione defends against the oxidative insults that drive carcinogenesis. Once a malignancy is established, however, tumor cells frequently upregulate glutathione synthesis as a survival strategy, with elevated tumor GSH consistently associated with progression, chemoresistance, and worse prognosis across breast, ovarian, hepatic, and pancreatic cancers (Marini et al., 2023; Park & Jeong, 2024).

Three lines of recent evidence have substantially reshaped clinical thinking. First, Piskounova et al. (2015), in Nature, demonstrated that oxidative stress in circulating tumor cells limits metastatic colonization—and that chronic antioxidant treatment in murine models increased melanoma metastasis. Second, Yeh et al. (2025), in Cancer Discovery, showed that mitochondrial glutathione import via SLC25A39 is specifically required for breast cancer colonization of the lung, operating through integrated stress response signaling. Third, Hecht et al. (2026), in Nature, reported that breast tumors actively catabolize extracellular glutathione via γ-glutamyltransferase to harvest cysteine for tumor growth.

13.3 Glutathione and Chemotherapy Resistance

Many of the most effective cytotoxic agents—platinum compounds, alkylators, and certain anthracyclines—act in part through oxidative damage or reactive electrophilic intermediates that glutathione directly inactivates. The chemosensitization rationale for buthionine sulfoximine and similar glutathione-depleting agents reflects this biology. Supplementing glutathione during active cytotoxic therapy therefore carries a theoretical risk of antagonizing chemotherapy efficacy, although the magnitude of this risk in clinical practice remains uncertain.

13.4 Chemotherapy-Induced Peripheral Neuropathy

The most credible clinical application of intravenous glutathione is in the prevention of cisplatin- and oxaliplatin-induced peripheral neuropathy. Italian randomized trials (Cascinu et al., 1995, 2002) demonstrated neuroprotective benefit without apparent loss of antitumor efficacy. The phase 3 NCCTG/Alliance N08CA trial (Leal et al., 2014), however, found no protection against paclitaxel/carboplatin neuropathy. The Cochrane review (Albers et al., 2014) and ASCO guideline update (Loprinzi et al., 2020) do not endorse glutathione for routine CIPN prevention.

13.5 Clinical Framework

In contemporary integrative oncology, glutathione warrants individualized rather than reflexive use. The most defensible application is for established or emerging platinum-induced neuropathy under coordinated oncologic supervision. Routine high-dose oral or intravenous glutathione during active cytotoxic treatment is best avoided. N-acetylcysteine, a glutathione precursor, has been shown in murine KRAS-driven lung cancer to accelerate progression (Sayin et al., 2014), supporting a cautious posture during active malignancy. Foods naturally rich in glutathione precursors (sulfur-containing vegetables, lean protein) are appropriate components of a healthy diet and do not raise the same concerns as supplemental dosing.

14. Modified Citrus Pectin and Galectin-3 Modulation

Evidence tier: Substantive mechanistic and preclinical evidence; emerging clinical signal; randomized phase 3 confirmation not yet available.

14.1 Galectin-3 as an Immune Checkpoint

Galectin-3 (Gal-3) is a β-galactoside-binding lectin with a single carbohydrate-recognition domain and an N-terminal oligomerization region. At chronically elevated levels, Gal-3 builds extracellular lattices that prolong inflammatory receptor signaling, cluster glycoproteins on immune cells, and distort the activating signals that T-cells, natural killer cells, and macrophages depend upon (Liu & Stowell, 2023; Sciacchitano et al., 2018). Contemporary literature increasingly frames Gal-3 as a bona fide immune checkpoint, particularly in solid tumors and musculoskeletal malignancies (Nakajima et al., 2021).

14.2 Mechanisms of Gal-3-Driven Tumor Promotion

Tumors exploit Gal-3 through multiple overlapping pathways. Gal-3 binds T-cell receptor glycans, muffling activation and driving cytotoxic T-cell apoptosis (Guha et al., 2013). It interferes with NK-cell cytotoxicity, promotes M2-polarized tumor-associated macrophages secreting IL-10, TGF-β, and vascular growth factors, and physically enables circulating tumor cell aggregation, endothelial adhesion, and metastatic colonization (Dong et al., 2018; Díaz-Álvarez & Ortega, 2017).

14.3 Modified Citrus Pectin as a Targeted Inhibitor

Native citrus pectin is too large and branched to cross the intestinal barrier. The clinically studied modified citrus pectin (MCP) is processed under controlled pH, temperature, and enzymatic conditions to yield short, low-esterified, galactan-rich fragments of defined molecular weight that are absorbed systemically (Eliaz & Raz, 2019). Once absorbed, the galactan side chains bind competitively to the carbohydrate-recognition domain of Gal-3, occupying the site otherwise used to engage cell-surface glycoproteins.

14.4 Clinical Evidence in Cancer

In murine models of melanoma, breast, colon, and prostate cancer, oral MCP has repeatedly reduced metastatic burden by inhibiting tumor-cell adhesion, aggregation, anchorage-independent growth, and angiogenesis (Nangia-Makker et al., 2002; Glinsky & Raz, 2009). Ramachandran et al. (2011) demonstrated direct activation of T-helper, cytotoxic T-, B-, and NK-cells in vitro, with NK-mediated cytotoxicity against K562 chronic myeloid leukemia cells. Preclinical and early translational data also support MCP as a sensitizer to chemotherapy and radiation (Vityala, 2024).

Beyond oncology, MCP has been studied as a chelator of toxic heavy metals (lead, cadmium, arsenic) with significant urinary excretion increases documented in clinical work (Eliaz et al., 2007). Its anti-fibrotic effects extend to cardiac, renal, and hepatic disease (Bouffette et al., 2023). Serum Gal-3 testing—originally FDA-cleared for heart failure prognostication—provides a tractable biomarker for tracking systemic inflammatory and fibrotic burden in oncology patients.

14.5 Clinical Integration

MCP is most defensibly positioned as a mechanism-based adjunct aimed at the immune and stromal terrain surrounding the tumor, rather than as a direct cytotoxic agent. Standard clinical doses range from 5 to 15 g daily of validated, low-molecular-weight, galactan-rich formulations. The intervention has a favorable safety profile, modest cost, and biologically plausible mechanism, but lacks the randomized phase 3 evidence that would move it into Part II of this chapter. Patients pursuing MCP should do so with full disclosure of evidence status and coordination with their oncology team.

15. Medicinal Mushrooms in Gastrointestinal and Other Cancers

Evidence tier: Mature Japanese and Chinese randomized trial literature for PSK; mixed Cochrane review confidence; substantial mechanistic literature; quality control issues in commercial supply.

15.1 Historical and Mechanistic Foundations

Medicinal mushrooms have been used in East Asian medical traditions for over two millennia. Modern oncologic adoption began in the 1970s and 1980s with the approval of polysaccharide-K (PSK; krestin) from Trametes versicolor and lentinan from Lentinula edodes in Japan as adjuncts to conventional cancer therapy.

The bioactivity of medicinal mushrooms derives from three principal compound classes: high-molecular-weight β-glucans and protein-bound polysaccharides; triterpenoids (most abundant in reishi); and a smaller contribution from peptides and nucleosides. β-(1→3)/(1→6)-glucans engage pattern-recognition receptors—Dectin-1, complement receptor 3, and Toll-like receptors 2 and 4—on innate immune cells, initiating macrophage activation, dendritic cell maturation, NK-cell cytotoxicity, and Th1-polarized adaptive immunity (Panda et al., 2022; Blagodatski et al., 2018).

15.2 Turkey Tail (Trametes versicolor)

PSK has the strongest oncology evidence base of any medicinal mushroom. A 2006 individual-patient-data meta-analysis of three randomized controlled trials including 1,094 patients with curatively resected colorectal cancer demonstrated that adjuvant PSK at 3 g daily added to standard chemotherapy improved both overall survival and disease-free survival, with approximately a 9% absolute reduction in 5-year mortality (Sakamoto et al., 2006). A parallel analysis in 8,009 patients with resected gastric cancer reported similar benefit (Oba et al., 2007). A 2017 network meta-analysis of 23 trials in 10,684 gastrointestinal cancer patients confirmed survival benefit of PSK plus chemotherapy over chemotherapy alone (Sun et al., 2017).

A 2022 Cochrane review of Coriolus versicolor in colorectal cancer adopted a more cautious tone, judging certainty of evidence as low to very low for individual symptom outcomes while acknowledging directional benefit and excellent safety (Roberts et al., 2022). The discrepancy reflects evolving methodological standards rather than refutation of effect.

15.3 Reishi (Ganoderma lucidum)

Reishi combines β-glucan immunomodulation with a uniquely rich triterpenoid fraction (ganoderic acids, lucidenic acids) that confers direct apoptotic and hepatoprotective effects (Ahmad et al., 2021; Sohretoglu & Huang, 2018). The Cochrane review of reishi in cancer concluded that G. lucidum could be administered as an adjunct to conventional therapy with potential to enhance tumor response and quality of life, though without sufficient evidence to support it as a first-line agent (Jin et al., 2016). A 2023 narrative review summarized consistent signals across colorectal, gastric, hepatocellular, and pancreatic cancers (Ren et al., 2023).

15.4 AHCC (Active Hexose Correlated Compound)

AHCC, a fermented mycelial extract derived primarily from shiitake, has demonstrated synergy with gemcitabine through downregulation of HSP27 in preclinical models—a mechanism directly relevant to pancreatic and biliary tract cancer chemoresistance (Suenaga et al., 2014). In a randomized clinical trial of 75 patients with pancreatic adenocarcinoma on gemcitabine-based chemotherapy, AHCC at 6 g daily produced a significant reduction in grade 3 adverse events (17% vs. 53%, p = .0005) and in chemotherapy-induced taste disorders (Yanagimoto et al., 2016). Matsui et al. (2002) documented improved postoperative outcomes in hepatocellular carcinoma. AHCC induces CYP2D6 and aromatase in preclinical models, with theoretical implications for doxorubicin, ondansetron, tamoxifen, and aromatase inhibitor pharmacology (Memorial Sloan Kettering Cancer Center, 2024).

15.5 Other Mushroom Species

Lentinan, a purified β-(1→3)-glucan from shiitake administered parenterally, has been used as an adjunct in advanced gastric cancer in Japan since 1985, with multiple trials suggesting improvements in survival and chemotherapy tolerability when combined with fluoropyrimidine-based regimens (Zhang et al., 2019). Maitake (Grifola frondosa) D-fraction has been studied for hematologic support and innate immune activation in myelodysplastic syndromes (Wesa et al., 2015). Cordyceps species are most often used for fatigue, exercise tolerance, and renal-protective effects during cisplatin chemotherapy. Lion's mane (Hericium erinaceus) shows promise for chemotherapy-induced peripheral neuropathy and cognitive impairment via hericenones and erinacines that stimulate nerve growth factor production.

15.6 Quality Control: A Practical Imperative

Many over-the-counter mushroom products are mycelium grown on grain substrate, dominated by indigestible α-glucan starch rather than the bioactive β-glucans found in fruiting bodies or hot-water extracts. Patients and clinicians should select products that disclose β-glucan content, document hot-water or dual-extraction preparation, and provide third-party testing for heavy metals and contaminants. The cost differential between adulterated and authentic preparations is substantial; the clinical difference is meaningful.

16. Drug Repurposing and the Berkson Protocol

Evidence tier: Mechanistic and preclinical evidence for ivermectin and mebendazole; case-series evidence only for the Berkson alpha-lipoic acid/low-dose naltrexone protocol; metformin alone has mature observational data and active prospective trials.

16.1 The Repurposing Imperative

Drug repurposing—the application of agents originally developed for other indications to oncology—offers compressed development timelines, established safety profiles, and dramatically reduced costs relative to novel drug development. The Repurposing Drugs in Oncology (ReDO) project has formalized this approach (Pantziarka et al., 2014). The clinical reality is that repurposed agents occupy a wide spectrum from well-established (metformin) to controversial and risky (ivermectin at oncology doses).

16.2 Metformin

Metformin is the most defensible repurposed oncology agent. Observational and meta-analytic data support reduced cancer incidence and improved outcomes across multiple malignancies, particularly in patients with type 2 diabetes or metabolic syndrome (Pascale et al., 2021). Mechanistically, metformin activates AMP-activated protein kinase, inhibits mTORC1, reduces hepatic gluconeogenesis, and lowers circulating insulin and IGF-1—all relevant to tumor metabolism. It is widely used as an integrative adjunct in obesity-related and metabolically driven malignancies, with active randomized trials in breast, prostate, endometrial, and colorectal cancer.

16.3 Ivermectin

Few repurposed agents have generated more public interest—and more clinical conflict—than ivermectin. Patient demand has, in the words of oncologists interviewed in 2025, "spread like wildfire," driven by social media, podcast endorsements, and pandemic-era stockpiling that produced a 2- to 10-fold increase in outpatient prescriptions and nearly 3 million COVID-related prescriptions between 2020 and 2023. An estimated 20–25% of oncology patients may be taking ivermectin without disclosing it to their treating clinicians (Oncology News Central, 2025). This pattern creates a distinctive clinical situation in which the gap between the strength of preclinical evidence, the weakness of clinical evidence, and the intensity of patient interest must be navigated with both intellectual rigor and clinical humility.

Preclinical Mechanism

Ivermectin's anticancer preclinical literature is extensive (Tang et al., 2021; Liu et al., 2020). Reported mechanisms include WNT-TCF pathway inhibition (Melotti et al., 2014, EMBO Molecular Medicine—the foundational WNT-TCF mechanistic work that motivated subsequent clinical investigation); PAK1 kinase inhibition with downstream MEK/ERK effects (Dou et al., 2016; Hashimoto et al., 2009); HSP27 phospho-activation inhibition with synergistic effects on AR and EGFR pathway inhibitors (Nappi et al., 2020, Journal of Clinical Investigation); PI3K/AKT modulation; reversal of multidrug resistance through EGFR/ERK/Akt/NF-κB signaling and P-glycoprotein inhibition (Jiang et al., 2019); resensitization of endocrine-resistant breast cancer (Lv et al., 2022, Cell Death and Disease, demonstrating FOXA1 and Ku70/Ku80 as direct targets in prostate cancer); and immune-modulatory conversion of "cold" to "hot" tumors with checkpoint inhibitor synergy (Draganov et al., 2021, NPJ Breast Cancer, the City of Hope mouse work that motivated the current Cedars-Sinai trial).

The Translational Gap

The critical limitation in the ivermectin literature is the translational gap between preclinical and clinical evidence. The intracellular concentrations effective in cell-line and mouse models would typically require human doses substantially exceeding standard antiparasitic dosing, and the safety profile of such doses in humans is incompletely characterized. As MD Anderson and other major cancer centers have emphasized, the doses effective in mice would likely be toxic in humans (Oncology News Central, 2025). This is not a peripheral observation; it is the central reason that decades of compelling preclinical data have not translated into demonstrated clinical efficacy.

MD Anderson's Research History

MD Anderson has been involved in two notable ivermectin oncology investigations, neither of which produced efficacy data supporting clinical adoption. First, the IVINCA trial (2014–2016), led by Dr. Jordi Rodon Ahnert in the Department of Investigational Cancer Therapeutics and funded by Gateway for Cancer Research, evaluated ivermectin as a WNT-TCF response inhibitor in early-phase investigational oncology. The trial did not produce results that supported ivermectin approval for cancer treatment. Second, a 2020 letter in Leukemia and Lymphoma by de Castro, Gregianin, and Burger of MD Anderson's Department of Leukemia reported that continuous high-dose ivermectin appeared safe in a small group of patients with acute myelogenous leukemia, with the explicit goal of informing potential repurposing for COVID-19 (de Castro et al., 2020). This was a safety observation, not an efficacy study; it documented that ivermectin could be administered at higher-than-standard doses without immediate prohibitive toxicity in this small cohort, not that it treated leukemia.

MD Anderson's institutional position—reflected in patient-facing materials and physician commentary—is that there is no conclusive clinical evidence supporting ivermectin for cancer prevention or treatment, and that the agent should not be used outside of clinical trial protocols (MD Anderson Cancer Center, n.d.).

Current Clinical Evidence: Cedars-Sinai NCT05318469

The only active U.S. oncology trial with reported preliminary efficacy data is the phase I/II investigator-initiated study at Cedars-Sinai Medical Center (NCT05318469), led by Dr. Yuan Yuan in collaboration with Dr. Peter P. Lee at City of Hope. The trial evaluates ivermectin combined with the anti-PD-1 antibodies balstilimab or pembrolizumab in metastatic triple-negative breast cancer patients who have progressed on prior chemotherapy. Patients receive balstilimab or pembrolizumab intravenously every 21 days, with oral ivermectin on Days 1–3, 8–10, and 15–17 of each cycle (Yuan et al., 2024 AACR abstract; Yuan et al., 2025 ASCO abstract).

Preliminary phase I data presented at ASCO 2025 reported on 9 patients in the dose-escalation phase, of whom 8 were evaluable. Results were modest: 1 partial response, 1 stable disease, 6 progressive disease, with median progression-free survival of 2.5 months and a 4-month clinical benefit rate of 37.5%. The investigators concluded that the combination was safe and well tolerated with "encouraging" clinical benefit that warranted continued investigation, but the response rate was comparable to immunotherapy alone in this heavily pretreated population. The trial continues to accrue, with the phase 2 expansion contingent on observation of additional responders. As of mid-2026, ivermectin has not been demonstrated to produce clinically meaningful effectiveness in any cancer population in any randomized or prospectively designed clinical trial.

Safety Profile and Clinical Risk

The safety profile of ivermectin warrants substantially more clinical attention than its preclinical literature typically receives. At standard antiparasitic doses, common adverse effects include skin irritation, rash, pruritus, nausea, diarrhea, and abdominal pain. At higher doses—the doses sometimes pursued for cancer indications by patients self-medicating—the agent can produce significant neurological toxicity, including confusion, disorientation, ataxia, generalized muscle weakness, and, in severe cases, coma. This neurological toxicity is the most consequential safety concern in cancer-related off-label ivermectin use (Oncology News Central, 2025).

Drug-drug interactions represent a parallel concern specific to the oncology population. Ivermectin is metabolized by CYP450 enzymes—particularly CYP3A4—and inhibits P-glycoprotein, placing it on a potential interaction pathway with many cancer-relevant agents including chemotherapy, kinase inhibitors, antiemetics, and certain antimicrobials. Cancer patients typically take multiple concurrent medications; the addition of unreported ivermectin can complicate the interpretation of treatment-related toxicity, alter the pharmacokinetics of evidence-based therapies, and produce difficult-to-attribute adverse events that delay appropriate intervention.

Compounding these risks is the increasing over-the-counter availability of ivermectin in several U.S. states (Arkansas, Idaho, and Tennessee as of 2025, with similar legislation pending in 13 additional states), the proliferation of non-pharmaceutical sources with uncertain quality control and potential for inaccurate dosing or contamination, and the documented pattern of patients delaying or forgoing evidence-based therapy in favor of unproven ivermectin protocols (Johnson et al., 2018; Oncology News Central, 2025). The Johnson et al. (2018) substitution-harm data discussed in Section 47—patients with curable cancers who chose complementary medicine over conventional treatment had a 2.5-fold increased mortality risk—is directly applicable to the ivermectin context.

Clinical Communication: A Nonjudgmental, Evidence-Anchored Framework

The combination of intense patient interest and limited clinical evidence creates a distinctive communication challenge. A nonjudgmental but evidence-anchored approach is more effective than dismissal. Patients who feel judged for asking about ivermectin become less likely to disclose its use, increasing the risk of unmonitored drug interactions and missed toxicity. The following clinical framework, adapted from contemporary oncology practice (Oncology News Central, 2025), provides a defensible approach:

• Acknowledge the patient's concern without minimizing or dismissing it. The question of whether ivermectin might help is legitimate; the answer—based on current evidence—is that it has not been demonstrated to do so.
• Provide clear information about the absence of human efficacy evidence, the translational gap between preclinical and clinical data, the meaningful safety risks at higher doses, and the specific drug-interaction concerns relevant to that patient's regimen.
• Explicitly request honest disclosure of any ivermectin use the patient is currently engaged in or considering, framing the request in terms of clinical safety rather than judgment. A useful framing: "I don't think ivermectin will work for cancer. But if you are going to take it, I would prefer you be honest with me about it, so I can be the most effective physician possible."
• Where appropriate, direct interested patients toward enrolled clinical trials (such as NCT05318469) rather than off-label use, both to support trial completion and to ensure structured monitoring.
• If a patient continues to use ivermectin despite medical advice, document the use, monitor for neurological symptoms (confusion, disorientation, muscle weakness), review the medication list for interactions, assess liver and kidney function if high-dose or prolonged use is suspected, and continue to engage rather than disengage.

This approach preserves clinical integrity, supports patient autonomy, maintains the therapeutic relationship, and minimizes the documented harms of unmonitored off-label use. It is also generalizable: the same framework applies to many other agents discussed in this chapter where patient interest substantially exceeds clinical evidence.

Position Within Integrative Oncology

Ivermectin in 2026 occupies the most epistemically uncomfortable position in this chapter. Its preclinical mechanistic literature is genuinely interesting and motivated investigation by serious academic groups including MD Anderson, City of Hope, and Cedars-Sinai. Its human clinical effectiveness data are essentially absent: the only prospective trial reporting efficacy outcomes—the Cedars-Sinai phase I/II—has shown response rates comparable to immunotherapy alone in early dose-escalation data. The safety profile at high doses is real and not adequately appreciated in patient-facing online discourse. The substitution-harm risk is substantial. And patient demand is intense.

The defensible integrative oncology position is that ivermectin should not be recommended for cancer treatment outside of clinical trial protocols; that patients pursuing it independently should be supported with nonjudgmental engagement, safety monitoring, and ongoing access to evidence-based therapy; that clinicians should be familiar with the actual evidence base rather than the social-media-mediated version of it; and that the agent represents a paradigmatic example of how integrative oncology must distinguish between mechanistic plausibility, preclinical efficacy, clinical efficacy, and the social dynamics of patient demand. Each of those is a distinct epistemic category, and they must not be conflated.

16.4 Mebendazole

Mebendazole has a stronger pharmacologic rationale than ivermectin for repurposing. As a benzimidazole anti-tubulin agent, it inhibits tubulin polymerization via the colchicine-binding domain—placing it mechanistically alongside vincristine and paclitaxel (Pantziarka et al., 2014; Guerini et al., 2019). Preclinical data demonstrate G2/M cell cycle arrest, double-strand DNA breaks, apoptosis across lung, breast, ovarian, colon, prostate, and osteosarcoma cell lines, anti-angiogenic effects through VEGFR2 inhibition, and cancer stem cell depletion (Bai et al., 2015).

Phase 1 trials in newly diagnosed and recurrent high-grade glioma have established safety with reversible grade 3 transaminitis at higher doses (Gallia et al., 2021; Patil et al., 2020). Polymorph C of mebendazole has superior blood–brain barrier penetration than polymorph A and is being developed for CNS indications. Oncology-level dosing carries documented hepatotoxicity and hematologic toxicity, and the combination of mebendazole with metronidazole has been associated with Stevens–Johnson syndrome and toxic epidermal necrolysis in an outbreak among Filipino laborers in Taiwan (Chen et al., 2003).

16.5 Combination Use

Published data on deliberate ivermectin-plus-mebendazole combination regimens for cancer are extremely sparse. No major guideline endorses a specific protocol for either agent—singly or combined—as cancer treatment. Patients pursuing these agents should do so under medical supervision, with appropriate hepatic, hematologic, and renal monitoring, and ideally within a clinical trial. The current evidence base does not support promoting these agents as a routine integrative oncology intervention outside of trial protocols.

16.6 The Berkson ALA/LDN Protocol

Burton Berkson developed an investigational protocol combining intravenous alpha-lipoic acid (ALA, 300–600 mg twice weekly) with oral low-dose naltrexone (LDN, 4.5 mg nightly), based initially on extensive clinical experience with ALA in hepatic disease. The first published case described a patient with metastatic pancreatic adenocarcinoma to the liver who survived years beyond predicted prognosis (Berkson et al., 2006). A subsequent series reported on three additional pancreatic cancer patients with prolonged survival and metabolic responses on positron emission tomography (Berkson et al., 2009). A detailed case in Clinics in Oncology in 2020 reported complete resolution of hepatocellular carcinoma in a 71-year-old woman after 27 months on the protocol.

Proposed Mechanisms

Alpha-lipoic acid is a redox-active cofactor in mitochondrial dehydrogenase complexes. Preclinical data support selective pro-apoptotic effects in tumor cells, modulation of pyruvate dehydrogenase kinase with implications for the Warburg effect, and epigenetic effects on histone deacetylase activity (Feuerecker et al., 2012; Tibullo et al., 2017). Low-dose naltrexone (1.5–4.5 mg nightly) transiently blocks opioid growth factor (OGF/met-enkephalin) receptors, producing rebound upregulation of OGF-OGF receptor signaling with antiproliferative and immunomodulatory effects (Liu et al., 2016; Zagon & McLaughlin, 2018). LDN has also been shown to modulate Toll-like receptor 4 signaling and to dampen pro-inflammatory cytokine cascades (Younger et al., 2014).

Evidence Quality and Clinical Integration

All human data for the Berkson protocol in oncology consist of case reports and small uncontrolled series. There are no randomized controlled trials. Berkson himself has framed the protocol as producing tumor reduction or dormancy rather than cure, with disease progression sometimes resuming when therapy is discontinued. Within an integrative oncology framework, the protocol may be considered for patients with advanced or treatment-resistant disease who can commit to sustained treatment and who understand the experimental nature of the approach. It should never be offered as a substitute for evidence-based first-line therapy.

16.7 Aspirin: A Repurposed Agent with Phase 3 Evidence

Aspirin is the repurposed agent in oncology with the strongest randomized evidence and is included in this section despite its conventional pharmacologic status because its cancer-prevention role illustrates the highest-tier example of drug repurposing. The CAPP2 trial (Burn et al., Lancet 2020) randomized 861 individuals with Lynch syndrome to aspirin 600 mg daily versus placebo for 25 months. At a mean of 10 years of follow-up, the aspirin arm showed significantly reduced colorectal cancer incidence (hazard ratio 0.65, 95% CI 0.43–0.97, p = .035), with per-protocol analyses among those completing at least 2 years of intervention showing further benefit (HR 0.56, p = .019). The 20-year registry-based follow-up confirmed sustained benefit.

Mechanistically, aspirin's anti-cancer activity operates through COX-2 inhibition, reduced prostaglandin E2 signaling, modulation of platelet-tumor cell interactions in the metastatic niche, and direct effects on Wnt/β-catenin and PI3K signaling. The 2010 Rothwell et al. Lancet analyses of long-term aspirin in cardiovascular prevention trials demonstrated reductions in cancer incidence and mortality across multiple sites, with the strongest effects in colorectal cancer.

The US Preventive Services Task Force's 2022 update softened its prior recommendation for low-dose aspirin in primary cardiovascular prevention pending more definitive data on bleeding risk, and explicitly did not endorse aspirin for primary cancer prevention in average-risk adults. Lynch syndrome remains a clinically distinct setting where the CAPP2 evidence supports chemoprevention discussion with affected individuals. The CAPP3 trial is evaluating optimal aspirin dosing in Lynch syndrome (100 mg vs. 300 mg vs. 600 mg daily).

Clinical integration: aspirin chemoprevention is appropriate for discussion with confirmed Lynch syndrome carriers, balancing cardiovascular comorbidity, bleeding risk, and patient preference. Average-risk primary cancer prevention with aspirin is not currently endorsed by major guidelines but may be discussed individually with patients who have cardiovascular indications and acceptable bleeding risk. Aspirin sits in this section as the credentialed example of pharmacologic chemoprevention—an integrative cancer prevention intervention with phase 3 randomized evidence that compares favorably to the supplement and botanical interventions discussed elsewhere in this chapter.

Part IV

Cross-Cutting Considerations

Microbiome, chronotherapy, disease-specific summaries,

special populations, end-of-life care, disparities,

and clinical implementation.

17. The Gut Microbiome and Immunotherapy Response

Evidence tier: Mature foundational literature; emerging clinical implementation data; rapid evolution of evidence.

17.1 Microbiome as Immunotherapy Modulator

The gut microbiome is now recognized as a major modulator of response to immune checkpoint inhibitors (ICIs) and an emerging therapeutic target (Gazzaniga & Kasper, 2025; Jani et al., 2025). Foundational work demonstrated that specific commensal bacteria—notably Akkermansia muciniphila and Bifidobacterium spp.—promote antitumor immunity and facilitate anti-PD-L1 efficacy (Sivan et al., 2015; Vétizou et al., 2015). The mechanisms include modulation of dendritic cell function, enhanced T-cell priming, and direct effects on tumor-infiltrating lymphocyte populations.

17.2 Fecal Microbiota Transplantation

Two seminal 2021 trials demonstrated that fecal microbiota transplantation from ICI responders can overcome anti-PD-1 resistance in melanoma patients (Baruch et al., 2021; Davar et al., 2021). Subsequent work has expanded to non-small-cell lung cancer, renal cell carcinoma, and gastrointestinal malignancies. FMT remains investigational in oncology and is delivered through clinical trials at specialized centers.

17.3 Probiotics: A Complicated Picture

Probiotic effects in clinical trials have been variable and sometimes contradictory. Clostridium butyricum improved outcomes in renal cell carcinoma patients receiving nivolumab plus ipilimumab and in those receiving cabozantinib plus nivolumab (Dizman et al., 2022). A 2024 Japanese cohort study found that probiotics improved the efficacy of ICIs in advanced NSCLC (Morita et al., 2024). However, a 2021 Science study (Spencer et al., 2021) found that off-the-shelf probiotics were associated with worse survival in melanoma patients on ICI therapy, and supplementing mice with a commercially available Bifidobacterium-based probiotic increased tumor sizes.

A 2025 quasi-experimental study in metastatic colorectal carcinoma (N = 96) reported that combining probiotics with ICIs or chemotherapy yielded superior survival at 6 months, 1 year, and 2 years, with higher levels of beneficial bacteria, improved gut barrier integrity markers, enhanced T-cell immunity, and reduced chemotherapy-induced gastrointestinal toxicity. The aggregate clinical implication is strain-specific and context-specific effects: a probiotic capsule is not a generic intervention but a microbiologically defined exposure whose effect depends on the specific organisms, the patient's baseline microbiome, and the concurrent therapy.

17.4 Dietary Fiber: A More Consistent Signal

Spencer and colleagues (2021), in Science, demonstrated that high dietary fiber intake was associated with significantly improved progression-free survival in melanoma patients on anti-PD-1 therapy, with each 5-gram daily fiber increase associated with a 30% reduction in progression risk. Strikingly, the protective effect was abrogated by concurrent probiotic supplementation, underscoring the complexity of the microbiome–immunotherapy axis and supporting the priority of food-based prebiotics over capsule-based interventions.

17.5 Clinical Translation

Current evidence supports food-based prebiotics—fermented vegetables, high-fiber whole foods, and a Mediterranean-style dietary pattern—as the most consistent recommendation for oncology patients on immunotherapy. Strain-specific probiotics with documented oncology-relevant data may be considered case-by-case, particularly in the setting of cytotoxic chemotherapy with significant gastrointestinal toxicity. High-dose or unregulated probiotic strains should be avoided in severely immunosuppressed patients and in those on immune checkpoint inhibitors without specific strain-level evidence supporting their use. Antibiotic stewardship in cancer patients (avoiding unnecessary broad-spectrum antibiotics, choosing narrower-spectrum agents when feasible) is an underappreciated dimension of microbiome optimization.

18. Chronotherapy and Circadian Alignment

Evidence tier: Strong preclinical literature; selected randomized trials with clinical signal; emerging field with significant translational implications.

The timing of drug or supplement administration relative to circadian rhythm—chrono-oncology—is an emerging field with significant translational implications. Circadian disruption (shift work, sleep deprivation, light exposure at night) is now recognized as a probable carcinogen by the International Agency for Research on Cancer (IARC) and accelerates tumor growth in preclinical models (Sulli et al., 2018). The molecular machinery of the circadian clock (BMAL1, CLOCK, PER, CRY) intersects with cell cycle regulation, DNA damage response, and metabolism in ways that have direct oncologic relevance.

18.1 Chronomodulated Chemotherapy

Chronomodulated chemotherapy delivery has been investigated extensively in colorectal and other cancers, with European trials led by Francis Lévi and colleagues suggesting that timing oxaliplatin, 5-fluorouracil, and irinotecan to the patient's circadian phase reduces toxicity and may improve efficacy in specific subgroups (Lévi et al., 2007; Innominato et al., 2022). The clinical translation has been limited by infrastructure requirements—programmable infusion pumps capable of delivering chronomodulated regimens—and by inconsistent results across heterogeneous patient populations. The principle, however, is biologically robust and is finding renewed attention in the era of precision oncology.

18.2 Melatonin in Oncology

Melatonin in oncology has been studied as both a circadian modulator and a direct anti-tumor agent. Seely and colleagues (2012) published a meta-analysis suggesting that adjunctive melatonin—typically dosed at 20 mg in the evening—reduced 1-year mortality risk and chemotherapy-related toxicity in advanced solid tumors. Methodological limitations of included trials warrant cautious interpretation, but the directional signal is consistent. Doses of 1–3 mg evening are commonly used for sleep and circadian alignment in oncology patients; doses of 10–20 mg evening are used in some integrative oncology protocols as a direct anti-tumor adjunct. Melatonin is generally well tolerated, with the principal cautions being daytime sedation, vivid dreams, and rare immunomodulatory effects requiring monitoring in autoimmune settings.

18.3 Exercise Timing and Other Circadian Interventions

Emerging data suggest that exercise performed in the late afternoon or early evening may produce greater metabolic and immune benefits than morning exercise in some cancer survivors, though confirmatory trials are pending. The CHALLENGE trial (Courneya et al., 2025) did not stratify by exercise timing. Other circadian interventions of clinical relevance include consistent sleep–wake schedules, morning bright-light exposure (and evening dim-light exposure) in disrupted sleep, restricting nocturnal light and screen exposure, and time-restricted eating windows aligned with the patient's individual chronotype.

19. Disease-Specific Integrative Oncology Summaries

Evidence tier: Synthesis of disease-specific evidence across the tiers established in this chapter.

The following disease-specific summaries integrate the evidence reviewed throughout this chapter, prioritizing modalities with the strongest evidence and noting key drug–nutrient interactions. They are intended as orientation, not as a substitute for individualized consultation.

19.1 Breast Cancer

Breast cancer is the most studied disease within integrative oncology. The SIO clinical practice guideline on integrative therapies during and after breast cancer treatment, endorsed by ASCO (Greenlee et al., 2017; Lyman et al., 2018), remains the most comprehensive disease-specific framework. Strongest recommendations include music therapy and meditation for mood disturbance; acupuncture for chemotherapy-induced nausea, joint pain, and hot flashes; yoga and tai chi for fatigue and quality of life; and exercise across the continuum of care.

Key emerging signals: fasting-mimicking diet during neoadjuvant chemotherapy (de Groot et al., 2020; Ligorio et al., 2024); mindfulness-based interventions with documented immune effects (Zhang et al., 2025); structured exercise for fatigue, mood, and quality of life. Caution: high-dose phytoestrogenic supplements in hormone receptor-positive disease; St. John's Wort with tamoxifen (CYP3A4 induction); AHCC's induction of aromatase in preclinical models (theoretical concern in aromatase inhibitor patients).

Critical context: The Ayoade et al. (2026) Yale analysis of more than two million breast cancer patients in the National Cancer Database documented a 3.7-fold higher 5-year mortality with CAM-alone substitution and a 40–45% higher mortality even with CAM combined with traditional therapy, attributable principally to skipped radiation and endocrine therapy. The clinical implication for integrative breast cancer care is unambiguous: integrative interventions must be positioned as adjunctive to, never as substitutes for, evidence-based locoregional and systemic therapy, with explicit attention to ensuring completion of radiation and endocrine therapy in eligible patients. See Section 47.3 for detailed discussion.

19.2 Colorectal Cancer

Practice-changing: structured exercise after adjuvant chemotherapy (CHALLENGE trial, Courneya et al., 2025) reduces recurrence by 28% and mortality by 37%. PSK (Trametes versicolor extract) at 3 g daily has individual-patient-data meta-analytic evidence for improved survival in resected colorectal cancer (Sakamoto et al., 2006). High dietary fiber intake is associated with improved outcomes on immunotherapy. Pharmacologic ascorbate has selective activity against KRAS-mutant disease (Yun et al., 2015), with phase 2 trials ongoing.

19.3 Pancreatic Cancer

The most aggressive solid malignancy and the disease in which integrative oncology has its most provocative emerging signals. Pharmacologic ascorbate added to gemcitabine/nab-paclitaxel doubled overall survival (16 vs. 8 months) in the University of Iowa phase 2 trial (Bodeker et al., 2024). AHCC at 6 g daily reduced chemotherapy toxicity in randomized comparison (Yanagimoto et al., 2016). The Italian modulated electro-hyperthermia cohorts suggest survival benefit but require randomized confirmation (Fiorentini et al., 2019, 2021, 2023). The Berkson ALA/LDN protocol has its strongest case-series experience in pancreatic cancer (Berkson et al., 2006, 2009). All integrative interventions should be anchored on evidence-based systemic therapy (FOLFIRINOX or gemcitabine/nab-paclitaxel).

19.4 Non-Small-Cell Lung Cancer

Mistletoe (Viscum album) added to PD-1/PD-L1 inhibitor therapy is associated with doubled median overall survival in registry data (Thronicke et al., 2024). Acupuncture has strong evidence for chemotherapy-induced symptoms and procedural anxiety. Probiotic effects on ICI response are particularly relevant given the prominence of immunotherapy in NSCLC, though strain-specific evidence is incomplete (Morita et al., 2024). Caution: high-dose antioxidants in patients on tyrosine kinase inhibitors and during active radiation therapy.

19.5 Prostate Cancer

Lifestyle intervention has among the strongest long-term outcome signals: Mediterranean-style dietary pattern, exercise, weight management, and stress reduction are associated with improved prostate cancer-specific outcomes in observational and small randomized studies. Lycopene-rich foods, modified citrus pectin, and pomegranate extract have mechanistic and small-trial data. Caution: zinc above 75 mg daily is associated with increased aggressive prostate cancer risk; selenium supplementation in well-replete men may increase risk in genetically susceptible subgroups; St. John's Wort interferes with abiraterone and enzalutamide.

19.6 Renal Cell Carcinoma

EGCG (green tea extract), curcumin, and quercetin have mechanistic and preclinical data; clinical translation is limited. Probiotics—specifically Clostridium butyricum—have improved outcomes on combination immunotherapy in randomized data (Dizman et al., 2022). Vitamin D should be replete; magnesium should be monitored on tyrosine kinase inhibitors. St. John's Wort is generally contraindicated. Detailed integrative protocol considerations were reviewed in Kim's 2025 publication.

19.7 Hematologic Malignancies

Pharmacologic ascorbate has specific mechanism in TET2-mutant AML and MDS, with case-level evidence of clinical remission (Das et al., 2019). Acupuncture has direct trial evidence for myeloprotection during cytotoxic chemotherapy in gynecologic malignancies (Lu et al., 2009), with mechanistic plausibility for other cytotoxic regimens. Caution: hematologic malignancies frequently involve cytopenias requiring acupuncture safety modifications (Lu, Doherty-Gilman, & Rosenthal, 2010); raw vegetables may need to be avoided during severe neutropenia.

19.8 Head and Neck Cancer

Acupuncture has direct trial evidence for chemoradiation-induced dysphagia (Lu et al., 2016) and xerostomia (Vehlow et al., 2025). Glutamine, honey, manuka topicals, and acupuncture have been investigated for mucositis. Calendula topicals are evidence-based for radiation dermatitis. Nutrition support is critical; gastrostomy tube placement should not be assumed to obviate the role of integrative supportive care.

19.9 Glioblastoma and CNS Malignancies

Pharmacologic ascorbate added to standard chemoradiation extended survival by approximately 5 months in the University of Iowa phase 2 trial (Allen et al., 2024). Ketogenic diet has biologically rational mechanism and small clinical series. Mebendazole crosses the blood–brain barrier (particularly polymorph C) and has phase 1 safety data in high-grade glioma (Gallia et al., 2021; Patil et al., 2020). Cognitive and mood support through mindfulness and CBT are essential. Caution: pseudoprogression management requires careful coordination with neuro-oncology.

20. Special Populations

Evidence tier: Population-specific evidence synthesis.

20.1 Adolescent and Young Adult Cancer Patients

A 2024 systematic review in Current Opinion in Oncology evaluated integrative oncology modalities specifically for adolescent and young adult (AYA) cancer patients. Among 19 RCTs included (74% addressing physical and psychological modalities, 26% psychological only), the most effective modalities were physical activity (most frequently assessed, 37% of studies), Mindfulness-Based Stress Reduction, massage, and light therapy. Notably, 58% of included studies had "some concerns" regarding risk of bias on the Cochrane RoB-2 tool, underscoring the need for more rigorous AYA-specific study designs. Dana-Farber's Young, Empowered & Strong (YES) mHealth application delivered tailored support based on patient-reported outcomes including anxiety, pain, menopausal symptoms, and financial concerns, demonstrating improved quality of life in AYA breast cancer survivors at the 2025 San Antonio Breast Cancer Symposium.

20.2 Older Adults

A 2025 JAMA Network Open meta-analysis demonstrated that exercise therapy reduced depression and anxiety severity and improved health-related quality of life in older adults with cancer (Liu et al., 2025). The CHALLENGE trial demonstrated that structured exercise was feasible and beneficial across age groups, including older adults (Courneya et al., 2025). Older adults benefit from acupuncture, mindfulness-based interventions, tai chi, and qigong with appropriate adaptation. Polypharmacy is a particular concern in this population; integrative supplements should be reviewed for interactions and consolidated where possible. Cognitive reserve, social engagement, and meaning-centered approaches are particularly valuable.

20.3 Pediatric Oncology

Pediatric integrative oncology has its own evidence base, with the strongest data for acupuncture (chemotherapy-induced nausea, pain), massage (anxiety, pain), music therapy, hypnosis (procedural pain and anxiety), and yoga (mood and quality of life). Parental involvement and child-centered programming are essential. The evidence base is smaller than in adults, and many integrative modalities require modification for pediatric anatomy and physiology. The Society for Integrative Oncology and the Children's Oncology Group provide guidance frameworks.

21. Integrative Approaches in Palliative and End-of-Life Care

Evidence tier: SIO-ASCO guideline support for palliative-care symptom management; growing evidence for psychedelic-assisted therapy in advanced cancer.

Integrative oncology has historically had its strongest foothold in palliative and end-of-life care, where symptom management, dignity preservation, and meaning-making intersect with conventional medicine's limits.

21.1 Symptom Management

The SIO-ASCO pain guideline (Mao et al., 2022) recommends massage during palliative care and acupuncture for general cancer pain. Hypnosis has evidence for procedural pain and breakthrough pain. Aromatherapy and music therapy have evidence for anxiety and agitation in advanced disease. Mind–body interventions reduce anxiety and depression symptoms in palliative populations (Carlson et al., 2023). Cannabis and cannabinoids have evidence for refractory chemotherapy-induced nausea and vomiting (Braun et al., 2024) and may have a role in cancer cachexia and refractory neuropathic pain in the palliative setting, though guideline support outside CINV is limited.

21.2 Existential and Spiritual Distress

Meaning-Centered Group Psychotherapy reduces depression, hopelessness, and existential distress in patients with advanced cancer (Breitbart et al., 2015). Logotherapy and meaning-centered interventions adapted for breast and gynecologic cancers show similar benefits. Psilocybin-assisted psychotherapy has the most rigorous evidence base for treating cancer-related existential distress, with rapid and sustained reductions in anxiety, depression, demoralization, and improved attitudes toward death (Griffiths et al., 2016; Ross et al., 2016). Phase 2b/3 confirmation is ongoing (NCT05398484).

21.3 Family and Caregiver Support

Integrative oncology in palliative care extends to the family and caregiver system. Mindfulness-based interventions for caregivers have evidence for reduced anxiety, depression, and caregiver burden. Bereavement support, anticipatory grief work, and ritual practices around death are part of comprehensive integrative care. The integrative oncology team's role at end of life often shifts from intervention to presence—an essential but undervalued contribution.

21.4 The Integrative Oncologist's Role in Hospice

Integrative oncology in hospice settings prioritizes comfort, dignity, and patient-defined goals. Many of the most evidenced integrative modalities—massage, acupuncture, music therapy, aromatherapy, meditation—are deliverable in the home setting with minimal equipment. The integrative oncologist's role may include coordinating these modalities, supporting the family, providing presence at end of life, and supporting bereavement. The literature on integrative care at end of life is smaller than that for active treatment, but the clinical and human importance is at least equally great.

22. Health Disparities, Demographics, and Equitable Access

Evidence tier: Empirical demographic and access data; emerging implementation science.

22.1 The Scale of the Problem

A defining problem of integrative oncology in 2026 is profound inequity in access and representation. While 60–80% of cancer patients use some form of complementary medicine in the general population, formal integrative oncology consultations and clinical trials systematically underrepresent racial, ethnic, sex, and linguistic minorities.

22.2 Clinical Trial Representation

In broad oncology trials, Black patients frequently comprise less than 5% of participants, and Hispanic patients less than 4%, despite representing approximately 13% and 19% of the U.S. population, respectively (Loree et al., 2019). In integrative oncology mind–body trials specifically, White women often constitute 80–90% of study cohorts. This systematic underrepresentation has practical clinical consequences: the evidence base on which the SIO-ASCO guidelines rest is generated predominantly in non-representative populations, raising questions about generalizability.

22.3 Access Barriers

A 2025 study in the Journal of Pain and Symptom Management analyzing 832 lung cancer patients found that only 14.4% attended an integrative oncology consultation despite free availability. Factors associated with significantly lower utilization included older age, male sex, non-dominant-language speakers, and absence of reported pain. The Lasheen et al. (2026) real-world cohort similarly documented systematic male underreferral. These patterns persist even in institutions where access is structurally available, suggesting that referral practices, cultural factors, and patient assumptions about "who integrative care is for" require active remediation.

22.4 The SIO-ASCO Pain Disparities Analysis

Liou and colleagues (2023), in JNCI Cancer Spectrum, examined the SIO-ASCO pain guideline through the lens of racial and ethnic disparities. They identified patient-, provider-, and system-level factors driving inequitable access: lower referral rates for racial and ethnic minorities; geographic concentration of integrative oncology programs in academic centers; limited Medicare and Medicaid coverage for acupuncture; cultural and linguistic mismatches between providers and patients; and the historical absence of community-engaged research in protocol development.

22.5 Structural Solutions

The two most promising structural solutions are (a) expanded insurance coverage, particularly for acupuncture and mind–body programming—Medicare's 2020 expansion of acupuncture coverage for chronic low back pain provides a partial model—and (b) digital delivery platforms such as IM@Home (Mao et al., 2025), which substantially reduce time, transportation, and proximity barriers. Community-based participatory research, culturally tailored programming, bilingual integrative oncology providers, and explicit outreach to historically excluded patient populations are additional priorities. The field cannot in good conscience continue to generate guidelines from non-representative samples and apply them universally; the work of inclusive evidence generation is overdue.

23. Clinical Implementation Framework

Evidence tier: Practical synthesis for the integrative oncology clinician.

23.1 Symptom-Domain Recommendations

The following table consolidates the strongest evidence across the tiers established in this chapter. Recommendations marked "strong" derive from SIO-ASCO joint guidelines and/or phase 3 randomized trials. Recommendations marked "conditional/emerging" derive from systematic reviews of mixed-quality evidence, phase 2 randomized data, or strong mechanistic plausibility.

23.2 Drug–Nutrient–Herb Interaction Cautions

Interactions between supplements, herbs, dietary components, and oncologic pharmacotherapy operate through three principal mechanisms that should be evaluated systematically rather than ad hoc. First, pharmacokinetic (PK) interactions affect drug absorption, distribution, metabolism, or excretion; the most clinically consequential mechanisms in oncology are CYP450 enzyme induction and inhibition (particularly CYP3A4, which metabolizes a substantial fraction of cancer therapies including most kinase inhibitors, tamoxifen, taxanes, vinca alkaloids, and cyclophosphamide), P-glycoprotein modulation affecting drug efflux, and UGT (glucuronidation) effects. Second, pharmacodynamic (PD) interactions occur when supplements act on the same biological pathways as cancer therapies, either antagonistically (the theoretical antioxidant interference with ROS-mediated cytotoxicity) or synergistically (additive hepatotoxicity, bleeding risk with antiplatelet effects). Third, formulation and quality interactions arise from contamination, mislabeling, or undisclosed pharmaceutical adulterants in supplement products.

The Cassileth, Yeung, and Gubili reference textbook "Herb-Drug Interactions in Oncology" (Memorial Sloan Kettering, multiple editions) and the MSK About Herbs database (mskcc.org/cancer-care/integrative-medicine/herbs) provide the clinical infrastructure for systematic interaction screening, and routine consultation of these resources is recommended before recommending or accepting any supplement in a patient on active systemic therapy. The chapter on CAM-chemotherapy interactions by Sparreboom and Baker in Abrams and Weil's Integrative Oncology (2014) remains a foundational synthesis. The clinically relevant interactions listed in the table below are illustrative rather than exhaustive; the operational principle is that any agent the patient is taking should be reviewed against the specific chemotherapy, targeted therapy, immunotherapy, or radiation regimen using current clinical resources, with particular attention to the patient's hepatic and renal function, comorbidities, and concurrent medications.

23.3 The Five-Part Clinical Framework

The synthesis of the foregoing chapter supports a five-part clinical framework for integrative oncology practice.

12. Anchor on evidence-based standard of care. Integrative therapies augment, not replace, surgery, radiation, cytotoxic chemotherapy, targeted therapy, and immunotherapy. Substitution is the highest-risk error in the discipline (Johnson et al., 2018), and the more recent Yale analysis of more than two million breast cancer patients demonstrated that even CAM use combined with traditional therapy was associated with 40–45% higher mortality when patients skipped radiation or endocrine therapy as part of their integrative regimen (Ayoade et al., 2026). Operationally: confirm and support completion of every component of evidence-based therapy.
13. Prioritize the SIO-ASCO guideline framework where available. For pain, anxiety, depression, fatigue, and breast cancer–specific symptom management, the published guidelines provide graded, evidence-based starting points.
14. Calibrate investigational interventions to the patient's clinical situation. Curative-intent regimens warrant more conservative integration than palliative-intent regimens. Tumors with established curative pathways differ from those with poor prognosis and few standard options. Patient-specific factors—G6PD status, renal function, CYP-metabolized regimens, performance status, and goals of care—shape the risk–benefit calculus.
15. Coordinate with the oncology team. Most cancer patients use complementary therapies; only a minority disclose this to their oncologist. The integrative physician's role includes facilitating that disclosure and ensuring drug–nutrient–herb interaction review against the specific regimen.
16. Practice intellectual honesty. The strongest integrative oncology practice neither dismisses emerging research nor accepts it uncritically. It distinguishes between the categories of evidence (mechanistic plausibility, in vitro, animal models, case reports, retrospective cohorts, randomized trials), tracks the data as they evolve, and communicates uncertainty to patients without abandoning the willingness to act.

23.4 Communication Frameworks: Operationalizing Patient-Clinician Dialogue

The substitution-harm literature (Section 47.3) and the documented patterns of non-disclosure of complementary therapy use (Davis et al., 2012 systematic review of CAM disclosure; Ayoade et al., 2026 Yale data) underscore that effective patient-clinician communication is not a soft skill peripheral to integrative oncology—it is core clinical infrastructure. The following structured communication frameworks, drawn from the broader medical communication literature and adapted for integrative oncology, provide operational scaffolding for the conversations that determine whether complementary therapies augment or undermine evidence-based care.

Routine Inquiry and Disclosure Facilitation

Every oncology and integrative oncology encounter should include explicit, normalized inquiry about supplement use, alternative therapy interest, and any treatments the patient is considering refusing or modifying. The framing matters substantially. "Are you taking any supplements?" is a closed-ended question often answered "no" by patients who do not consider their daily vitamin or herbal tea to be a supplement, or who fear judgment. "Many patients with cancer try other things in addition to standard treatment. What are you taking or considering—supplements, vitamins, herbs, teas, dietary approaches, anything?" normalizes use, opens the conversation, and produces substantially more accurate disclosure. The Wilson and Garroutte (NCCIH-funded) communication research demonstrates that patient disclosure correlates with clinician comfort, normalized inquiry, and demonstrated non-judgmental engagement; punitive or dismissive responses to initial disclosure produce non-disclosure in subsequent encounters.

Motivational Interviewing for Treatment Decisions

When patients are considering refusing a component of evidence-based therapy in favor of an integrative approach, motivational interviewing (MI), developed by Miller and Rollnick, provides a structured framework distinct from confrontation or persuasion. The four MI processes—engaging, focusing, evoking, and planning—operationalize a collaborative conversation that respects patient autonomy while preserving clinician honesty about evidence. Core MI techniques relevant to integrative oncology include open-ended questions ("Tell me what draws you to this approach"), reflective listening (paraphrasing the patient's stated concerns and values), affirmations (acknowledging the patient's agency in seeking information), and elicitation of "change talk" (the patient's own articulation of reasons to complete evidence-based treatment). MI does not require abandoning the clinician's evidence-based position; it requires presenting that position within a relationship that respects the patient's autonomy and emotional reality.

The PLISSIT Model for Sensitive Topics

The PLISSIT model (Annon, 1976)—Permission, Limited Information, Specific Suggestions, Intensive Therapy—was developed for clinical communication about sexual health but has broad applicability to other sensitive topics in oncology including complementary therapy use, end-of-life concerns, and existential distress. Permission involves explicitly inviting the patient to discuss the topic ("It's okay to talk about anything you're considering"). Limited Information provides initial evidence-based education matched to patient readiness. Specific Suggestions offer concrete behavioral recommendations. Intensive Therapy refers to referral for more specialized intervention. The model is particularly useful for clinicians who feel less comfortable with integrative oncology topics, as it permits stepwise engagement without requiring expertise in every modality.

Shared Decision-Making in High-Stakes Decisions

For decisions involving substantial trade-offs—accepting or refusing adjuvant chemotherapy, choosing between adjuvant therapy options with different toxicity profiles, deciding about prophylactic surgery in hereditary cancer syndromes, transition to hospice—formal shared decision-making frameworks (Elwyn et al., 2012) involve three steps: choice talk (presenting the existence of a decision), option talk (presenting the relevant options with their benefits and harms), and decision talk (eliciting patient preferences and supporting deliberation). Decision aids—structured information tools that present evidence in a balanced format—are validated tools available for many oncology decisions (Ottawa Decision Aids, Stanford Decision Aids, and others). The integrative oncology clinician's role in shared decision-making includes ensuring that integrative options where they exist (e.g., acupuncture for AI-related joint pain rather than continuing through pain) are presented alongside conventional options.

The Nonjudgmental Documentation Principle

If a patient continues to use a complementary therapy despite the clinician's evidence-based concerns, the appropriate clinical response is structured documentation rather than disengagement: document the discussion, the agent and dose, the patient's stated rationale, the specific concerns communicated by the clinician, the patient's informed decision, and the plan for ongoing monitoring (interaction screening, toxicity surveillance, continued offer of evidence-based therapy). This approach preserves the therapeutic relationship, supports patient autonomy, and produces the medico-legal record appropriate to the situation. Critically, it keeps the patient engaged with the medical system so that evidence-based care remains accessible if and when the patient is ready to accept it.

24. Case Vignettes: The Framework in Practice

The following three composite case vignettes illustrate the application of the clinical implementation framework to representative oncology scenarios. They are not specific patients; they are pedagogical constructs that draw on common presentations in integrative oncology practice.

Vignette 1: A 58-Year-Old Woman with Stage III Colon Cancer Post-Adjuvant Chemotherapy

A 58-year-old woman completes 6 months of FOLFOX for stage III colon cancer. She presents 4 months later for integrative oncology consultation reporting fatigue, mild residual peripheral neuropathy, and anxiety about recurrence. Performance status is excellent. She is interested in "anything that can lower my chance of recurrence."

Framework application: 

• Anchor on standard care. Confirm completion of adjuvant therapy and adherence to surveillance plan with her oncology team.
• Apply guideline-concordant interventions first. Recommend a structured exercise program targeting ≥10 MET-hours/week of moderate-intensity aerobic activity, per the CHALLENGE protocol—level 1 evidence for recurrence reduction.
• Calibrate further interventions. Mindfulness-based stress reduction or MBCR for anxiety (guideline strong); discuss PSK (Trametes versicolor extract) at 3 g daily as a low-risk adjunct with individual-patient-data meta-analytic survival signal; address residual neuropathy through acupuncture, B-complex, and exercise; consider increased dietary fiber intake.
• Coordinate. Communicate the plan to her medical oncologist and surveillance team.
• Honesty. CHALLENGE-tier evidence supports exercise; PSK has good but older Japanese data with low-certainty Cochrane review; mindfulness is well-evidenced for anxiety, not for recurrence per se. Frame each accordingly.

Vignette 2: A 65-Year-Old Man with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma

A 65-year-old man is diagnosed with metastatic pancreatic adenocarcinoma with multiple liver metastases. He has begun gemcitabine plus nab-paclitaxel and is tolerating it reasonably. He and his family are considering "everything possible" and have brought a long list of supplements and a question about hyperbaric oxygen, vitamin C infusions, and hyperthermia.

Framework application: 

• Anchor. Confirm anchor on optimal systemic therapy; ensure he is being treated at a center experienced in pancreatic cancer; consider second-opinion referral if not.
• Guidelines. Address fatigue, anxiety, depression, and pain per SIO-ASCO guidelines: exercise, mindfulness, acupuncture, music therapy. Cannabis/cannabinoids may be considered for refractory nausea if standard antiemetics fail.
• Phase 2 emerging. Discuss the Bodeker et al. (2024) phase 2 trial of pharmacologic ascorbate in metastatic pancreatic cancer (16 vs. 8 months median OS); G6PD screening, renal function assessment, Riordan protocol implementation at an experienced center. AHCC at 6 g daily has randomized data for reduced chemotherapy toxicity.
• Investigational. Hyperthermia: Italian retrospective signal is consistent but selection-biased; weigh costs, logistics, and probability of benefit. Berkson ALA/LDN protocol: case-series evidence only; appropriate disclosure required.
• Coordinate and remain honest. Each layer has different evidence weight; pancreatic cancer has poor prognosis but real signals exist for integrative interventions when carefully selected.

Vignette 3: A 42-Year-Old Woman with Stage II HER2-Negative Breast Cancer Beginning Neoadjuvant Chemotherapy

A 42-year-old woman is starting neoadjuvant AC-T chemotherapy for stage II hormone receptor-positive, HER2-negative breast cancer. She is highly motivated, exercises regularly, and is interested in maximizing pathological complete response. She asks about fasting-mimicking diet.

Framework application: 

• Anchor. Confirm staging, biomarkers, treatment plan with her medical oncologist.
• Guidelines. Continue exercise per ASCO/SIO recommendations; introduce MBIs for anticipatory anxiety; offer acupuncture for chemotherapy-induced nausea and—post-AC—for paclitaxel-related peripheral neuropathy.
• Phase 2 emerging. The DIRECT trial (de Groot et al., 2020) supports a 3-day fasting-mimicking diet around each chemotherapy cycle for HER2-negative breast cancer, with a higher rate of Miller-Payne 4/5 pathological response (OR 4.109, p = .016). Implementation requires dietitian supervision, exclusion of diabetes and significant cachexia, and oncologist coordination.
• Caution. Avoid high-dose antioxidant cocktails during cytotoxic therapy; avoid St. John's Wort (CYP3A4 interactions with tamoxifen); ensure vitamin D repletion; review all supplements against the chemotherapy regimen.
• Honesty. FMD evidence is phase 2 and biologically rational, not yet practice-changing; transparent communication that this is research-grade evidence is appropriate.

Part V

Survivorship and Treatment-Specific

Symptom Domains

Cognitive dysfunction, sexual health, cardio-oncology, bone health,

lymphedema, vasomotor symptoms, cachexia, and mucositis—

the survivorship and supportive-care domains that determine

quality of life across the cancer continuum.

25. Cancer-Related Cognitive Dysfunction

Evidence tier: Strong descriptive epidemiology; emerging randomized trial evidence for behavioral and exercise interventions; no FDA-approved pharmacologic agents.

25.1 The Scale of the Problem

Cancer-related cognitive impairment (CRCI)—commonly termed "chemo brain" or "chemo fog"—affects approximately 75% of patients during active chemotherapy and persists at clinically significant levels in roughly 35% of long-term survivors (Janelsins et al., 2014, 2017). The most affected domains are attention, working memory, processing speed, and executive function. Imaging studies document reductions in gray matter volume, altered functional connectivity in default mode and executive networks, and white matter integrity changes that correlate with symptom severity. Although the syndrome was historically attributed to systemic chemotherapy, contemporary evidence implicates surgery, radiation, hormonal therapy, immunotherapy, and the disease itself as additional contributors—cognitive changes are documented at baseline in many patients before cytotoxic treatment begins.

25.2 Mechanisms

Proposed mechanisms include direct chemotherapy-induced neurotoxicity, neuroinflammation mediated by elevated cytokines and microglial activation, oxidative stress with mitochondrial dysfunction, telomere shortening, hippocampal neurogenesis suppression, and indirect effects through fatigue, sleep disruption, depression, and chronic stress. The convergence of these mechanisms on the inflammatory and neurotrophic pathways suggests therapeutic targets accessible to integrative interventions.

25.3 Exercise

Aerobic exercise has the strongest emerging integrative evidence for CRCI. A 2026 randomized trial led by Michelle Janelsins at the University of Rochester randomized 86 cancer patients on chemotherapy to exercise plus ibuprofen, exercise plus placebo, ibuprofen alone, or double placebo, finding that the exercise arm significantly improved attention compared with placebo. The TACTIC trial and a series of subsequent investigations have consistently demonstrated improvements in self-reported cognitive function with structured aerobic exercise programs (Campbell et al., 2020). Mechanistically, exercise increases hippocampal volume, elevates BDNF, reduces systemic inflammation, and enhances cerebrovascular function—all relevant to CRCI.

25.4 Mindfulness-Based Interventions

Mindfulness-Based Stress Reduction has shown improvements in subjective cognitive function in breast cancer survivors, although objective neuropsychological testing has been less consistently affected. A randomized controlled trial by Duval and colleagues in Cancer (2022) demonstrated that MBSR reduced subjective memory-related impairments in breast cancer survivors post-chemotherapy. The intervention is most defensible for patients reporting cognitive distress impacting quality of life, with the candid acknowledgment that subjective and objective measures may diverge.

25.5 Cognitive Rehabilitation

Computerized cognitive training programs (BrainHQ, Lumosity-style protocols delivered with clinical structure) have demonstrated improvements in objective cognitive performance in breast cancer survivors in small randomized trials. Cognitive rehabilitation by occupational therapy or neuropsychology, combined with compensatory strategies (calendars, lists, single-tasking, environmental modification), forms the standard non-pharmacologic backbone of CRCI management.

25.6 Supplements and Pharmacologic Considerations

Omega-3 fatty acids have mechanistic and small-trial support for cognitive function in cancer survivors. Lion's mane (Hericium erinaceus) contains hericenones and erinacines that stimulate nerve growth factor production and has small-trial support in mild cognitive impairment outside oncology. Modafinil and methylphenidate have been studied for CRCI with mixed results and should not be prescribed outside clinical trials per current Cancer Network recommendations. Donepezil has not demonstrated benefit. The 2026 consensus is that pharmacologic agents for CRCI should not be prescribed outside of trial settings.

25.7 Clinical Integration

A reasonable CRCI care plan combines: cognitive screening with validated tools (MoCA, FACT-Cog); structured aerobic exercise; sleep optimization; MBSR or other formal mindfulness program; cognitive rehabilitation referral when functional impairment is present; treatment of comorbid depression, anxiety, and fatigue; correction of vitamin D, B12, and thyroid deficiencies; and frank discussion that the syndrome is real, biologically grounded, often improves with time, and is generally manageable with multimodal supportive care.

26. Sexual Health and Intimacy in Cancer Care

Evidence tier: Substantial descriptive literature; established multidisciplinary intervention frameworks; under-addressed across most oncology practice settings.

26.1 An Under-Addressed Survivorship Domain

Sexual dysfunction affects approximately 40–100% of cancer survivors depending on cancer type and treatment, yet is among the most consistently under-discussed survivorship issues in oncology clinics. Breast, gynecologic, prostate, colorectal, head-and-neck, hematologic, and bladder cancers all carry substantial sexual sequelae. Hormonal therapies, surgical interventions, radiation effects, neurotoxicities, and psychological dimensions (body image, fear of recurrence, partner dynamics) interact to produce a complex clinical picture. The Bober and Varela (2012) framework for sexual health in cancer survivors remains a foundational clinical reference.

26.2 Female Sexual Health

In female cancer survivors, common issues include vaginal atrophy and dryness (especially with aromatase inhibitors, ovarian suppression, and pelvic radiation), dyspareunia, decreased libido, anorgasmia, and altered body image. Evidence-based interventions include vaginal moisturizers and lubricants (water-, silicone-, and hyaluronic acid-based), local non-hormonal options, vaginal dilator therapy after pelvic radiation, pelvic floor physical therapy, mindfulness-based sex therapy (Brotto et al.'s body of work has demonstrated benefit in cancer survivors), and CBT for sexual concerns. Topical estrogen is debated in hormone-sensitive cancers; current consensus permits low-dose vaginal estrogen in selected breast cancer survivors after thorough discussion of risk.

26.3 Male Sexual Health

In male cancer survivors—particularly post-prostatectomy, post-pelvic radiation, and on androgen deprivation therapy—erectile dysfunction is the dominant symptom, with libido and orgasmic disturbances commonly accompanying. Phosphodiesterase-5 inhibitors remain first-line. Vacuum erection devices, intracavernosal injections, and penile prostheses follow. Pelvic floor physical therapy improves continence and erectile function post-prostatectomy. Acupuncture has emerging evidence for vasomotor symptoms and quality of life on androgen deprivation therapy.

26.4 Couples-Based and Psychosexual Approaches

Sexual health in cancer care is fundamentally relational. Couples-based interventions targeting communication, intimacy beyond intercourse, and shared adaptation have demonstrated benefit in randomized work by Manne, Badr, and others. Mindfulness-based sex therapy has emerging evidence for women across cancer types. Brief counseling models (PLISSIT, BETTER) provide a structured framework for oncology clinicians to address sexual health without specialist referral.

26.5 Clinical Implementation

The integrative oncology contribution to sexual health includes ensuring that the topic is named, normalized, and addressed in survivorship visits; that pelvic floor physical therapy referral is routine for relevant survivors; that mindfulness-based sex therapy is offered where available; that acupuncture is considered for vasomotor symptoms and pelvic pain; that complementary modalities (yoga for body image and sensate awareness, mind–body interventions for performance anxiety) are integrated; and that the partner is included in the conversation when appropriate. Sexual health is not optional supportive care—it is core to dignity and quality of life across the cancer continuum.

27. Cardio-Oncology and Integrative Cardiovascular Care

Evidence tier: ESC and ASCO cardio-oncology guidelines; phase 3 evidence for structured exercise in cardiotoxicity prevention; mechanistic rationale for several supplements.

27.1 The Scale of Cardiotoxicity

Cardiovascular disease is the leading cause of non-cancer death in long-term cancer survivors. Anthracyclines, trastuzumab and other HER2-directed therapies, fluoropyrimidines, taxanes, BRAF/MEK inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors (with their distinctive myocarditis profile), proteasome inhibitors, and mediastinal radiation each produce characteristic cardiac toxicities. The 2022 ESC Cardio-Oncology Guidelines and ASCO's 2017 guideline on prevention and monitoring of cardiac dysfunction provide the operational frameworks (Curigliano et al., 2020; Armenian et al., 2017).

27.2 Exercise

Structured aerobic exercise has the strongest cardioprotective evidence in oncology. Prospective trials by Scott, Jones, and others have demonstrated preserved or improved cardiopulmonary fitness, left ventricular ejection fraction stability, and reduced cardiotoxicity biomarkers (troponin, BNP) in patients receiving anthracycline-based chemotherapy who engaged in supervised exercise programs. The American Heart Association's 2019 scientific statement on exercise in cancer survivors codifies the evidence (Gilchrist et al., 2019). For survivors with established cardiotoxicity, cardiac rehabilitation programs adapted for oncology (cardio-oncology rehabilitation, or CORE) are increasingly available.

27.3 Pharmacologic and Supplement Considerations

Dexrazoxane has FDA approval for prevention of anthracycline cardiotoxicity in specific settings. Statins, angiotensin-converting enzyme inhibitors, and beta-blockers have evidence for both primary prevention (in high-risk patients) and treatment of established cardiotoxicity. Within integrative oncology, omega-3 fatty acids have mechanistic and small-trial support for cardioprotection during anthracycline therapy; CoQ10 has mechanistic plausibility (anthracyclines impair mitochondrial respiratory chain function at sites where CoQ10 acts) but inconsistent clinical evidence; vitamin D status optimization is reasonable; magnesium repletion is important given chemotherapy-related wasting.

27.4 Immune Checkpoint Inhibitor Myocarditis

ICI-associated myocarditis is rare but carries mortality of approximately 25–50% in the most severe cases. Early recognition and high-dose corticosteroids are the foundation of treatment. Integrative interventions have no role in active management of this oncologic emergency. The contribution of integrative care to ICI patients more broadly—through microbiome optimization, exercise, mind–body programming—is discussed in Section 17 and Section 36.

27.5 Clinical Integration

Cardio-oncology has matured into an institutional subspecialty at most major cancer centers. The integrative oncology clinician's role includes: ensuring that cardiac risk factor optimization (blood pressure, lipids, glycemic control, weight, smoking cessation) is addressed at survivorship visits; integrating exercise prescription with cardio-oncology guidance; reviewing supplements for cardiac interactions (particularly fish oil with anticoagulants, ephedra-containing weight-loss products, and stimulant herbs in patients on QT-prolonging cancer drugs); and supporting psychosocial adaptation to cardiac diagnoses superimposed on cancer survivorship.

28. Bone Health on Hormonal Therapy

Evidence tier: ASCO bone health guidelines; phase 3 evidence for bisphosphonates and denosumab; established role for weight-bearing and resistance exercise.

28.1 The Scale of Treatment-Induced Bone Loss

Aromatase inhibitors produce annual bone mineral density losses of approximately 2.5% in lumbar spine and 1.7% in hip in postmenopausal breast cancer patients—roughly twice the rate of natural postmenopausal bone loss. Androgen deprivation therapy in prostate cancer produces similar or greater losses, with fracture rates that double after several years of treatment. Cytotoxic chemotherapy, glucocorticoids, premature ovarian failure, and gastrointestinal cancers with malabsorption add to the burden. The ASCO clinical practice guideline on bone health in cancer survivors and the 2019 update provide operational guidance (Shapiro et al., 2019).

28.2 Exercise

Weight-bearing and resistance exercise is the foundation of integrative bone health management. Progressive resistance training preserves or improves bone mineral density in postmenopausal breast cancer survivors on aromatase inhibitors and in men on androgen deprivation therapy. The Schmitz Strength After Breast Cancer protocol and similar evidence-based programs combine resistance training with adaptive progression. High-impact training, jumping exercises, and tai chi for balance further reduce fracture risk by addressing the falls component of fracture epidemiology.

28.3 Vitamin D, Calcium, and Magnesium

Vitamin D deficiency is universal in oncology populations and should be corrected to a serum 25-hydroxyvitamin D of at least 30 ng/mL. Calcium intake of 1,000–1,200 mg daily, preferably from food sources, is standard. Magnesium is essential for vitamin D activation and is often deficient. Vitamin K2 (menaquinone-7) has mechanistic and emerging clinical support for directing calcium into bone rather than soft tissue, although the evidence base in oncology specifically is limited.

28.4 Pharmacologic Agents

Bisphosphonates (zoledronic acid, alendronate) and denosumab are evidence-based standards for both prevention and treatment of treatment-induced bone loss when DXA T-scores are below threshold or when fracture risk is elevated. Adjuvant zoledronic acid in postmenopausal breast cancer has demonstrated improvements in disease-free survival in addition to bone protection (EBCTCG meta-analysis). Osteonecrosis of the jaw requires dental clearance before initiation. The integrative oncology role is not to oppose these agents but to integrate them with comprehensive bone health support.

28.5 Bone Health in Older Adult Survivors

Older adult cancer survivors carry the highest absolute fracture risk and benefit most from integrated bone health programming combining DXA screening, vitamin D repletion, calcium-rich nutrition, weight-bearing and resistance exercise, fall prevention (tai chi, vestibular rehabilitation, home safety assessment), medication review for fall-promoting agents (sedatives, anticholinergics, orthostatic-hypotension-causing drugs), and pharmacologic therapy when indicated.

29. Lymphedema Management

Evidence tier: Mature evidence for complete decongestive therapy; landmark PAL trial reversing exercise restriction dogma; emerging surgical and integrative options.

29.1 Burden and Pathophysiology

Lymphedema affects approximately 20% of breast cancer survivors after axillary lymph node dissection, 5–10% after sentinel lymph node biopsy, and substantial proportions of pelvic, head and neck, and melanoma survivors. The condition is progressive without treatment and produces functional impairment, recurrent cellulitis, psychological distress, and quality-of-life decrement. Pathophysiology involves disrupted lymphatic drainage, protein-rich interstitial fluid accumulation, fibrosis, and adipose deposition.

29.2 Complete Decongestive Therapy

Complete decongestive therapy (CDT) remains the gold-standard intervention, comprising manual lymphatic drainage, multi-layer short-stretch compression bandaging, exercise, and skin care, followed by maintenance with compression garments. Certified lymphedema therapists (CLTs) are the appropriate clinical providers. CDT is most effective when initiated early; surveillance programs using bioimpedance or perometry have demonstrated improved outcomes when subclinical lymphedema is detected and treated.

29.3 Reversing the Old Exercise Dogma: The PAL Trial

For decades, breast cancer survivors with lymphedema were instructed to avoid exercise of the affected arm. The Physical Activity and Lymphedema (PAL) trial led by Schmitz and colleagues (2009, 2010, New England Journal of Medicine and JAMA) randomized breast cancer survivors with lymphedema to a progressive supervised resistance training program versus usual care, demonstrating that progressive resistance training did not exacerbate lymphedema, reduced exacerbation frequency, decreased symptoms, and improved strength. The trial fundamentally changed clinical practice and provides one of the cleanest examples of randomized evidence overturning entrenched clinical lore.

29.4 Integrative Adjuncts

Yoga has mechanistic rationale (gentle compression, breath-mediated thoracic duct drainage, lymphatic activation through movement) and emerging evidence for reducing lymphedema symptoms. Acupuncture has small-trial evidence for symptom reduction and is safely deliverable in the affected limb when standard precautions are observed (the historical injunction against any needling of the affected limb has been re-examined in light of low documented adverse-event rates in trained-acupuncturist practice; see Lu, Doherty-Gilman, & Rosenthal, 2010). Low-level laser therapy (photobiomodulation) has FDA clearance and emerging trial evidence for lymphedema. Pneumatic compression devices are useful adjuncts in selected patients.

29.5 Surgical and Procedural Advances

Lymphovenous bypass and vascularized lymph node transfer are increasingly available surgical interventions for selected patients with stable, manageable lymphedema. Liposuction for chronic lymphedema with adipose deposition has substantial evidence in the European literature (Brorson's work). These procedures sit outside integrative oncology per se but are part of the comprehensive lymphedema care framework into which integrative interventions integrate.

30. Vasomotor Symptoms and Hot Flashes

Evidence tier: Established randomized evidence for acupuncture, cognitive behavioral therapy, and selected pharmacologic agents; integrative options span SIO-ASCO guideline-concordant to investigational.

30.1 The Scope of the Problem

Hot flashes and other vasomotor symptoms affect approximately 70% of breast cancer survivors on tamoxifen or aromatase inhibitors and a similar proportion of prostate cancer patients on androgen deprivation therapy. Severity, frequency, and quality-of-life impact vary widely. Standard menopausal hormone therapy is contraindicated in hormone-sensitive cancers, leaving an unusually well-defined population for whom non-hormonal interventions are the entire treatment armamentarium.

30.2 Acupuncture

Acupuncture has accumulated some of the strongest randomized evidence in this domain. Multiple trials and meta-analyses demonstrate significant reductions in hot flash frequency and severity, with effects generally maintained for several weeks after course completion. The Lasheen et al. (2026) real-world cohort documented 66% of patients experiencing improvement in hot flashes by the second acupuncture session—the largest symptom-specific improvement in the cohort. Hot flashes are explicitly recognized in the SIO-ASCO 2022 pain guideline framework and in subsequent integrative oncology recommendations.

30.3 Mind-Body Interventions

Cognitive behavioral therapy specifically adapted for menopausal symptoms (Hunter's MENOS protocol) has demonstrated randomized-trial efficacy for hot flashes in breast cancer survivors. Mindfulness-based interventions reduce hot flash bother and improve sleep. Hypnosis has phase 3 evidence specifically for hot flashes (Elkins et al.) and is among the more underutilized effective interventions.

30.4 Supplements and Botanicals

Soy isoflavones are controversial in hormone-sensitive cancers. Black cohosh has mixed evidence and is not endorsed by current oncology guidelines. Flaxseed has weak evidence. Vitamin E at 800 IU daily has small-trial evidence for modest hot flash reduction. The general principle is that strongly phytoestrogenic supplements should be approached cautiously in hormone-sensitive disease, while nutritionally complete dietary sources of phytoestrogens (food-based soy in moderate amounts) appear safe in epidemiologic data.

30.5 Pharmacologic Options

SSRIs (paroxetine, venlafaxine, citalopram), gabapentin, oxybutynin, and clonidine have all demonstrated efficacy. The 2023 FDA approval of fezolinetant (a neurokinin-3 receptor antagonist) for moderate-to-severe vasomotor symptoms expands non-hormonal options, although its use in cancer survivors specifically remains under study. Integrative oncology pairs non-pharmacologic and pharmacologic approaches with attention to drug interactions (e.g., paroxetine reduces tamoxifen activation through CYP2D6 inhibition; venlafaxine or escitalopram is preferred in tamoxifen patients).

31. Cancer Cachexia and Nutritional Optimization

Evidence tier: ASCO and ESPEN guidelines; phase 3 evidence for several pharmacologic agents; emerging role for multimodal approaches integrating nutrition, exercise, and pharmacology.

31.1 The Burden of Cachexia

Cancer cachexia—a multifactorial syndrome of involuntary weight loss, muscle wasting, and systemic inflammation—is the proximate cause of death in approximately 20–30% of cancer patients. It is most prevalent in pancreatic, gastric, lung, esophageal, head-and-neck, and colorectal cancers. The Fearon international consensus framework (2011) defines pre-cachexia, cachexia, and refractory cachexia stages and underscores that early intervention in the reversible stages produces the greatest clinical benefit. The 2020 ASCO guideline on management of cancer cachexia provides operational recommendations (Roeland et al., 2020).

31.2 Nutrition Intervention

ESPEN clinical nutrition guidelines recommend energy intake of approximately 25–30 kcal/kg/day and protein intake of 1.2–1.5 g/kg/day in cancer patients with cachexia, with adjustments for renal function and disease setting. Oral nutritional supplements have mixed evidence; the strongest data exist for high-protein, energy-dense formulations consumed in addition to meals rather than as meal replacements. Eicosapentaenoic acid (EPA) from fish oil at approximately 2 g daily has mechanistic and selected trial support for preservation of lean body mass, although meta-analytic results are inconsistent.

31.3 Exercise

Resistance training is the most effective intervention for the muscle-wasting dimension of cachexia. Supervised programs combining resistance training with aerobic exercise have demonstrated preservation of lean body mass in pre-cachectic and early cachectic patients across multiple disease settings. Exercise also addresses the inflammatory and metabolic dimensions of cachexia.

31.4 Pharmacologic Agents

ASCO conditionally recommends progestins (megestrol acetate) and corticosteroids for short-term appetite stimulation in cachexia, with attention to thromboembolic and infectious risks respectively. Mirtazapine has small-trial evidence for appetite and mood. Olanzapine has emerging evidence for both appetite stimulation and nausea control. Anamorelin, an orally bioavailable ghrelin receptor agonist, was approved in Japan in 2021 for cachexia in non-small-cell lung, gastric, pancreatic, and colorectal cancer based on phase 3 data demonstrating lean body mass preservation (Wakabayashi et al., 2021); it was not approved in the European Union and is not FDA-approved in the United States. Cannabinoids have weak evidence for appetite in cancer cachexia outside the CINV setting.

31.5 Multimodal Approaches

The MENAC trial and similar studies are evaluating multimodal interventions combining nutrition counseling, omega-3 fatty acid supplementation, exercise, and pharmacologic appetite support, with the hypothesis that targeting the multiple mechanisms of cachexia simultaneously produces greater benefit than any single intervention. Integrative oncology supports this multimodal logic and adds attention to mind-body interventions for the appetite-suppressing effects of anxiety and depression, sleep optimization, and treatment of comorbid symptoms (taste changes, nausea, pain, mucositis) that limit oral intake.

32. Oral Mucositis and Photobiomodulation

Evidence tier: MASCC/ISOO guideline-level evidence for photobiomodulation in mucositis prevention; mature multi-modal supportive care framework.

32.1 The Burden of Mucositis

Oral mucositis affects approximately 40% of patients receiving standard-dose chemotherapy and nearly 100% of patients receiving head and neck radiotherapy or hematopoietic stem cell transplant conditioning regimens. Beyond the immediate symptom burden (pain, oral intake limitation, opioid requirement), severe mucositis frequently triggers chemotherapy dose reductions or treatment interruptions that compromise oncologic outcomes. Gastrointestinal mucositis adds diarrhea and malabsorption to the syndrome.

32.2 The MASCC/ISOO Guidelines

The Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Mucositis Guidelines, last updated in 2019–2020 (Elad et al., 2020), provide the evidence-based framework for prevention and management. Key recommendations include basic oral care protocols (oral hygiene, regular dental assessment, patient education), oral cryotherapy (ice chips) during 5-fluorouracil bolus and melphalan conditioning, intravenous palifermin in hematologic malignancies receiving stem cell transplant, benzydamine mouthwash for radiotherapy-induced mucositis prevention, and—most relevant to integrative oncology—photobiomodulation therapy.

32.3 Photobiomodulation Therapy

Photobiomodulation (PBM, formerly low-level laser therapy or LLLT) uses red and near-infrared light to modulate cellular function via cytochrome c oxidase and mitochondrial signaling, with downstream anti-inflammatory and tissue-regenerative effects. The MASCC/ISOO 2019 update by Zadik and colleagues formally recommends intra-oral PBM for the prevention of oral mucositis in adult patients undergoing hematopoietic stem cell transplant with high-dose chemotherapy conditioning (Level of Evidence I) and in patients undergoing head and neck radiotherapy (Level of Evidence I). The recommended protocols specify wavelengths (typically 633–685 nm or 780–830 nm), energy density, and treatment schedule.

This is among the most evidence-based light-therapy applications in oncology and represents an integrative oncology intervention that has crossed from "complementary" into formal supportive-care guideline endorsement. Hospital-based dental services, radiation oncology supportive care, and selected integrative oncology programs deliver PBM as standard care in qualifying patients. Implementation considerations include training of operators, device standardization, and integration into the radiation oncology or transplant workflow.

32.4 Additional Integrative Modalities

Honey (particularly Manuka honey) has multiple randomized trials and meta-analyses supporting its use in radiation-induced mucositis, with the strongest data in head and neck cancer. Glutamine has mixed evidence with some support for prevention of severe mucositis. Zinc supplementation has weak evidence. Chamomile mouthwash has traditional use and small-trial support. Aloe vera has mixed and largely negative evidence. Acupuncture has emerging evidence for xerostomia (the closely related radiation toxicity) and has been studied for mucositis pain. Each requires individualized integration into the broader MASCC/ISOO framework.

32.5 Clinical Integration

The integrative oncology contribution to mucositis care combines: ensuring guideline-concordant basic oral care; advocating for PBM availability in eligible patients; integrating honey, glutamine, and chamomile as patient-acceptable adjuncts where appropriate; addressing nutritional consequences of impaired oral intake; managing pain with multimodal approaches; and supporting psychological adaptation to a high-symptom-burden treatment phase. The progression of PBM from "alternative" to MASCC/ISOO-endorsed standard of care illustrates how integrative interventions evolve through the evidence hierarchy when rigorously studied.

Part VI

Pre-Treatment, Prevention,

and Adjunctive Procedures

Prehabilitation, hyperbaric oxygen, and the often-overlooked

centerpiece of population health: cancer prevention.

33. Prehabilitation

Evidence tier: Established evidence in surgical oncology; emerging trials in medical oncology; ERAS Society endorsement.

33.1 The Concept

Prehabilitation—optimizing fitness, nutrition, smoking cessation, alcohol reduction, and psychological readiness in the weeks before a major oncologic intervention—represents one of the highest-yield integrative oncology opportunities. The premise is that the few weeks between cancer diagnosis and definitive treatment provide a window in which targeted intervention measurably improves treatment tolerance, postoperative recovery, and possibly long-term outcomes. The Carli, Minnella, and ERAS Society body of work has provided the foundational evidence base in surgical oncology (Minnella et al., 2018; Carli et al., 2020).

33.2 Surgical Prehabilitation

Randomized trials in colorectal, esophageal, gastric, lung, and pancreatic cancer have demonstrated that 4–6 weeks of pre-operative trimodal prehabilitation (supervised aerobic and resistance exercise, nutritional optimization, psychological preparation) improves postoperative functional capacity, reduces postoperative complications in selected populations, shortens length of stay, and improves return-to-baseline-function timelines. The largest effects are observed in older, frailer, and more deconditioned patients—precisely the populations at highest risk of poor surgical outcomes.

33.3 Medical Oncology Prehabilitation

The application of prehabilitation principles to systemic therapy and radiotherapy is more recent but biologically rational. Trials in adjuvant chemotherapy contexts have demonstrated improved chemotherapy completion rates with pre-treatment exercise programs. The CHALLENGE trial findings (Courneya et al., 2025) demonstrating that exercise post-chemotherapy reduces recurrence by 28% in colon cancer raise the question whether pre-chemotherapy conditioning could compound the benefit—an active area of investigation.

33.4 Components

Effective prehabilitation programs share several components: structured progressive aerobic and resistance training (typically 3–5 sessions weekly with supervised initiation); nutritional optimization addressing protein adequacy (often 1.2–1.5 g/kg/day), micronutrient repletion, and calorie sufficiency; smoking cessation support (with explicit framing that even short-duration cessation pre-operatively reduces complications); alcohol reduction; sleep optimization; psychological preparation, often through mindfulness or CBT-based modules; and treatment of comorbidities (anemia, glycemic control, hypothyroidism, vitamin D deficiency).

33.5 Implementation

Prehabilitation programs are increasingly available at academic cancer centers, often delivered through cardiopulmonary rehabilitation infrastructure, physical therapy departments, integrative oncology programs, or dedicated prehabilitation clinics. The principal implementation barrier is the often-short interval between diagnosis and treatment in modern oncology. Even compressed 2-week prehabilitation programs have demonstrated benefit, suggesting that some prehabilitation is substantially better than none. Telehealth and digital delivery models extend prehabilitation reach to patients without in-person access.

34. Hyperbaric Oxygen Therapy in Cancer Care

Evidence tier: Established UHMS-approved indications in radiation-induced injury; emerging applications in radiation necrosis and selected wound healing.

34.1 Approved Indications

Hyperbaric oxygen therapy (HBOT) holds a distinctive position in integrative oncology: it is one of the few "integrative" modalities with established Centers for Medicare & Medicaid Services (CMS) reimbursement and Undersea and Hyperbaric Medical Society (UHMS) approved indications for cancer-related conditions. These include osteoradionecrosis of the mandible, radiation cystitis, radiation proctitis, soft-tissue radionecrosis, and delayed radiation injuries to other tissues. The mechanism combines tissue oxygenation in hypoxic radiation-injured tissue with stimulation of angiogenesis and fibroblast activity.

34.2 Radiation-Induced Injury

The strongest evidence base is for radiation-induced soft tissue and bone injury. Multiple randomized and observational studies support HBOT for osteoradionecrosis of the mandible (with surgical management coordination), hemorrhagic radiation cystitis, and radiation proctitis. Typical protocols involve 20–40 sessions at 2.0–2.5 atmospheres absolute, with each session lasting approximately 90–120 minutes. Implementation requires referral to a UHMS-accredited center.

34.3 Radiation Necrosis of the Brain

Cerebral radiation necrosis following stereotactic radiosurgery or fractionated radiotherapy has emerging evidence for HBOT, particularly in cases refractory to corticosteroids and bevacizumab. The evidence is observational and selection-biased; randomized trials are lacking but logistically difficult given the population. HBOT for this indication should be coordinated with neuro-oncology.

34.4 Controversies and Cautions

HBOT is contraindicated in untreated pneumothorax. Concurrent chemotherapy with specific agents (bleomycin in particular) requires caution. The use of HBOT for treatment of active cancer—as opposed to radiation injury—remains controversial. Theoretical concerns that elevated oxygen tension could promote tumor growth have not been clearly demonstrated in clinical studies, and emerging research explores whether HBOT may sensitize hypoxic tumors to radiation. This remains a research frontier and not a clinical indication.

34.5 Integration

The integrative oncology clinician's role with HBOT is primarily referral-based: recognition of qualifying radiation injury, identification of appropriate UHMS-accredited centers, coordination with the treating radiation oncology and surgical teams, and integration with other supportive interventions (nutrition, smoking cessation, dental care for osteoradionecrosis). HBOT represents an example of a once-marginal therapy that has earned a defined place in conventional supportive oncology when properly indicated.

35. Cancer Prevention and Risk Reduction

Evidence tier: Mature epidemiologic evidence; WCRF/AICR Continuous Update Project synthesis; selected pharmacologic chemoprevention with phase 3 evidence.

Prevention is the most consequential domain of integrative oncology and the most under-emphasized in clinical practice. Approximately 40% of cancer cases in the United States are attributable to modifiable risk factors. The economic, human, and clinical case for primary prevention is overwhelming. This section synthesizes the major modifiable risk factors and the integrative interventions that address them.

35.1 Tobacco

Tobacco remains the single largest preventable cause of cancer worldwide, responsible for approximately 30% of cancer deaths in high-income countries. Cessation reduces risk progressively over years and at any age. Integrative oncology's contribution to cessation includes mindfulness-based smoking cessation programs (Brewer et al.), acupuncture (mixed but generally positive evidence for cessation support), motivational interviewing, and integration with pharmacologic cessation aids (varenicline, bupropion, nicotine replacement therapy). Cessation should be addressed at every clinical encounter for current smokers, regardless of disease setting.

35.2 Alcohol

Alcohol is a Group 1 carcinogen (International Agency for Research on Cancer) with established causal relationships to oral, pharyngeal, laryngeal, esophageal, hepatocellular, colorectal, and female breast cancer. The 2018 World Cancer Research Fund / American Institute for Cancer Research Continuous Update Project explicitly recommends limiting alcohol consumption. There is no safe lower threshold for breast cancer risk; risk increases linearly from even low levels of consumption. The integrative oncology clinician should address alcohol use at survivorship visits and in primary prevention contexts, with attention to the cultural and social dimensions of alcohol consumption in which simplistic advice often fails.

35.3 Diet and Dietary Patterns

The WCRF/AICR recommendations synthesize the global evidence: predominantly plant-based eating with abundant vegetables, fruits, whole grains, and legumes; limited red meat (less than 500 g per week of cooked red meat); avoidance of processed meat; limited sugar-sweetened beverages; limited highly processed foods. The Mediterranean dietary pattern has the strongest observational and selected randomized-trial evidence across multiple cancers. The DASH pattern, plant-forward dietary patterns broadly defined, and traditional Asian dietary patterns share the principal protective features. Specific foods with the strongest cancer-protective signal include cruciferous vegetables (broccoli, kale, Brussels sprouts—source of sulforaphane), allium vegetables (garlic, onions), berries (anthocyanins), green tea (modest signal), and high-fiber foods broadly (with the microbiome interactions discussed in Section 17).

35.4 Physical Activity

Physical activity has dose-response cancer-protective effects for colon, breast, endometrial, kidney, bladder, esophageal, and gastric cancer. The 2018 Physical Activity Guidelines Advisory Committee Scientific Report cataloged this evidence in detail. Approximately 150 minutes weekly of moderate-intensity activity, or 75 minutes of vigorous activity, plus 2 weekly strength training sessions—identical to general health recommendations—is the operational starting point. Higher doses produce additional risk reduction. The integrative oncology emphasis is that physical activity is the closest thing to a polypill in cancer prevention.

35.5 Body Weight

Excess body weight is a Group 1 carcinogen for at least 13 cancers, including colorectal, postmenopausal breast, endometrial, esophageal adenocarcinoma, gastric cardia, hepatocellular, gallbladder, pancreatic, renal cell, multiple myeloma, meningioma, ovarian, and thyroid. Weight management through dietary pattern, physical activity, and behavioral intervention is foundational. The role of GLP-1 receptor agonists in cancer prevention is being studied, with preliminary data suggesting that the cancer-protective effect of weight loss may extend to pharmacologically induced weight loss. Bariatric surgery has documented cancer-protective effects in eligible patients.

35.6 Aspirin and Pharmacologic Chemoprevention

Aspirin sits at the intersection of pharmacology and integrative prevention with substantial randomized evidence. The CAPP2 trial (Burn et al., Lancet 2020) demonstrated that aspirin 600 mg daily for 25 months reduced colorectal cancer incidence in Lynch syndrome carriers by approximately 35% with effects persisting for over a decade. The 10-year follow-up and 20-year registry data support sustained benefit. Lower-dose aspirin (75–325 mg daily) has substantial observational evidence for colorectal cancer prevention in average-risk populations, although the US Preventive Services Task Force 2022 recommendation withdrew its prior endorsement for primary prevention pending updated data on bleeding risk. The CAPP3 trial is comparing aspirin doses in Lynch syndrome. The integrative oncology principle is that aspirin is a credentialed cancer chemoprevention agent for Lynch syndrome carriers and an emerging consideration for individualized risk-benefit discussions in average-risk patients with cardiovascular indications.

35.7 Vaccination

HPV vaccination is among the most effective cancer prevention interventions ever developed, with documented reductions in cervical cancer incidence in vaccinated cohorts entering adulthood. Hepatitis B vaccination prevents HBV-related hepatocellular carcinoma. Helicobacter pylori treatment in selected populations reduces gastric cancer risk. The integrative oncology clinician should be a consistent advocate for these vaccinations and infections-related preventions—an underappreciated dimension of the field.

35.8 Environmental and Occupational Exposures

Radon, ultraviolet radiation, ionizing radiation, asbestos, formaldehyde, benzene, and selected pesticides have established cancer-causing roles. Counseling on home radon testing, sun protection, sensible occupational exposure mitigation, and avoidance of high-risk environmental exposures is part of comprehensive prevention. Endocrine-disrupting chemicals (BPA, phthalates, certain perfluorinated compounds) have emerging but less definitively established cancer-promoting roles; reasonable risk reduction includes minimizing exposure to known endocrine disruptors without falling into the trap of unrealistic environmental avoidance.

35.9 Stress, Sleep, and Circadian Health

Chronic psychological stress, sleep deprivation, and circadian disruption have emerging evidence as cancer-promoting factors operating through neuroendocrine, immune, and inflammatory pathways (Sulli et al., 2018; IARC classification of shift work). Mindfulness-based stress reduction, sleep hygiene optimization, circadian regularity, and treatment of mood disorders constitute integrative prevention interventions with substantial face validity even where direct cancer-incidence evidence remains under development.

35.10 Personalized Risk Assessment and Inherited Susceptibility

Approximately 5–10% of cancers occur in individuals with identifiable hereditary cancer susceptibility syndromes (BRCA1/2, Lynch syndrome, Li-Fraumeni, hereditary diffuse gastric cancer, hereditary diffuse breast and ovarian cancer, MUTYH-associated polyposis, and others). Genetic counseling and testing for individuals with concerning family histories enables targeted screening, prophylactic surgery in selected cases, and—as in CAPP2—pharmacologic chemoprevention. Integrative oncology should routinely identify candidates for genetic counseling and facilitate referral.

35.11 Clinical Integration

Prevention belongs in every oncology and integrative medicine encounter, not as an afterthought but as a sustained therapeutic relationship. The patient with a cancer diagnosis often serves as a teachable moment for the family; the survivor in long-term follow-up is at elevated risk for second primaries; the well patient with hereditary risk requires structured surveillance. The asymmetry between the cost-effectiveness of prevention and the resources devoted to treatment is one of the most consequential structural problems in oncology. Integrative medicine—with its longer visits, emphasis on lifestyle, and orientation toward whole-person care—is uniquely positioned to address this gap.

Part VII

Special Settings and Populations

Immunotherapy adverse events, cellular therapy supportive care,

pediatric oncology, caregivers, and trauma-informed care—

populations and settings that require specific clinical attention.

36. Immunotherapy Adverse Event Management

Evidence tier: ASCO and NCCN guidelines for irAE management; emerging integrative role through microbiome optimization, exercise, and psychosocial support; no integrative substitutes for steroid management of high-grade irAEs.

36.1 The Landscape of Immune-Related Adverse Events

Immune checkpoint inhibitors—PD-1, PD-L1, CTLA-4, and emerging LAG-3 and TIGIT antagonists—have transformed cancer care across NSCLC, melanoma, renal cell, urothelial, hepatocellular, gastric, esophageal, head and neck, and many other malignancies. The trade-off is a distinctive toxicity profile of immune-related adverse events (irAEs) affecting essentially every organ system: colitis, pneumonitis, hepatitis, dermatitis, endocrinopathies (thyroiditis, hypophysitis, adrenal insufficiency, diabetes), nephritis, arthritis, myositis, myocarditis, and neurologic syndromes. ASCO and NCCN guidelines provide the operational framework for irAE management (Brahmer et al., 2021 ASCO update; Schneider et al., 2021 NCCN guidance).

36.2 The Foundational Principle

Grade 3 and 4 irAEs require immediate corticosteroid management, often with additional immunosuppressants, and integrative interventions have no role in displacing this foundational treatment. The integrative contribution operates in three distinct domains: (a) supporting irAE recovery and reducing symptom burden during corticosteroid management; (b) optimizing the host terrain for ICI response while minimizing irAE risk; and (c) supporting psychosocial adaptation to the unpredictability of ICI toxicities.

36.3 Microbiome Optimization

As discussed in Section 17, the gut microbiome is a major modulator of ICI response and toxicity. Dietary fiber supports beneficial commensals (Spencer et al., 2021 Science). Avoidance of unnecessary antibiotics, particularly in the weeks before ICI initiation, is increasingly recognized as important. Off-the-shelf probiotic capsules should generally be avoided given the Spencer data showing worse outcomes in melanoma patients on commercial probiotics. Mediterranean dietary patterns and fermented foods provide a defensible food-based approach to microbiome optimization without the strain-specific uncertainties of supplemental probiotics.

36.4 Exercise and Physical Activity

Pre-existing physical fitness predicts better ICI tolerance and possibly response. Maintenance of physical activity during ICI therapy supports cardiopulmonary fitness, mood, and immune function. The interaction between exercise and ICI response is an active research frontier (Wennerberg, Lundholm, and others).

36.5 Mind-Body and Psychosocial Support

The unpredictable timing and variable severity of irAEs creates a distinctive psychological burden. Patients may experience prolonged anticipatory anxiety, hypervigilance to bodily sensations, and existential uncertainty different from the rhythm of cytotoxic chemotherapy. Mindfulness-based interventions, CBT for health anxiety, and structured peer support are particularly relevant to this population.

36.6 During Corticosteroid Treatment

Patients on high-dose corticosteroids for irAE management often experience hyperglycemia, insomnia, anxiety, mood lability, fluid retention, and bone loss. Integrative interventions during this phase include sleep optimization, blood glucose monitoring and dietary support, mood-supportive mind-body practices, calcium and vitamin D repletion, weight-bearing exercise as tolerated, and gradual tapering coordination with the oncology team. Vitamin D supplementation during steroid courses is non-controversial and prudent.

36.7 Caveats and Cautions

High-dose antioxidants, immunomodulatory herbs (echinacea, astragalus, andrographis), and mushroom polysaccharides at immune-stimulating doses raise theoretical concerns during active ICI therapy—either of enhanced toxicity or of unpredictable immune modulation. The evidence base for these concerns is largely mechanistic; clinical data are limited. The defensible posture is conservative integration with strong oncology team coordination during active ICI treatment.

37. CAR-T and Hematopoietic Stem Cell Transplant Supportive Care

Evidence tier: Established supportive-care infrastructure in transplant medicine; emerging integrative integration; distinct toxicity profile requiring specific awareness.

37.1 The Cellular Therapy Era

Chimeric antigen receptor (CAR) T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) have transformed outcomes in B-cell malignancies, multiple myeloma, and selected other hematologic cancers. Both modalities produce distinctive toxicity profiles that require specialized supportive care: cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) with CAR-T; conditioning-related cytopenias, infections, and acute and chronic graft-versus-host disease (GVHD) with allogeneic transplant.

37.2 CAR-T-Specific Considerations

Cytokine release syndrome and ICANS require ICU-level management with tocilizumab, corticosteroids, and other targeted interventions. Integrative interventions have no role in active management. In the post-CAR-T recovery period, persistent cytopenias, B-cell aplasia with hypogammaglobulinemia, infection risk, and a distinctive fatigue and cognitive change pattern create supportive care needs. Acupuncture has been used cautiously in the post-CAR-T setting with attention to thrombocytopenia precautions (Lu, Doherty-Gilman, & Rosenthal, 2010); mindfulness-based interventions support the prolonged recovery period.

37.3 Hematopoietic Stem Cell Transplant

In the HSCT setting, photobiomodulation has Level I MASCC/ISOO evidence for oral mucositis prevention (Section 32). Acupuncture has emerging evidence for chemotherapy-induced nausea, pain, and anxiety in the transplant setting. Mind-body interventions support the prolonged hospitalization and isolation common in allogeneic transplant. Nutritional support is critical; raw food restrictions during severe neutropenia are standard. The dietary microbiome considerations relevant to GVHD prevention and treatment represent an active research frontier.

37.4 Chronic Graft-Versus-Host Disease

Chronic GVHD produces a multi-system inflammatory and fibrotic syndrome resembling autoimmune connective tissue disease, with oral, ocular, cutaneous, hepatic, pulmonary, gastrointestinal, and musculoskeletal manifestations. Standard treatment is immunosuppression with corticosteroids, calcineurin inhibitors, and—increasingly—ruxolitinib, ibrutinib, and belumosudil. Integrative supportive care addresses photoprotection for cutaneous GVHD, ocular surface support for ocular GVHD, dental care for oral GVHD, pulmonary rehabilitation for bronchiolitis obliterans, physical therapy for musculoskeletal GVHD, nutrition support for gastrointestinal involvement, and the mental health dimensions of a chronic immunosuppressed state.

37.5 Survivorship After Cellular Therapy

CAR-T and HSCT survivors carry long-term risks of secondary malignancy, cardiac dysfunction, endocrinopathies, infertility, neurocognitive change, and chronic GVHD (in HSCT). Survivorship clinics dedicated to long-term cellular therapy follow-up are increasingly available at major centers, and integrative oncology integration with these survivorship programs is a developing area.

38. Pediatric Integrative Oncology

Evidence tier: Children's Oncology Group and SIO frameworks; smaller evidence base than adult oncology; well-established role for selected mind-body interventions and acupuncture.

38.1 The Pediatric Context

Pediatric integrative oncology operates with a fundamentally different evidence base, regulatory environment, and family dynamic than adult practice. Childhood cancer survival has improved dramatically over decades, producing a substantial population of pediatric survivors who face decades of survivorship-related late effects. The Children's Oncology Group survivorship guidelines codify long-term follow-up frameworks. The Society for Integrative Oncology and the COG have collaborated on integrative oncology guidance for the pediatric population.

38.2 Evidence-Supported Modalities in Pediatric Oncology

Acupuncture and acupressure have evidence for chemotherapy-induced nausea and vomiting, post-operative pain, and procedural anxiety in children, with appropriate adaptations for age and anatomy. Massage therapy has evidence for pain, anxiety, and quality of life. Music therapy has substantial randomized-trial support for procedural anxiety and quality of life. Hypnosis has strong evidence for procedural pain and anticipatory nausea—pediatric patients often respond particularly well to hypnotic interventions. Yoga has emerging evidence for fatigue and mood. Mindfulness-based interventions adapted for children and adolescents support mood and quality of life.

38.3 Family-Centered Care

Pediatric integrative oncology is inherently family-centered. The patient is embedded in a family system whose stress, coping, communication patterns, and resources shape the child's experience. Family-based interventions, sibling support, parent stress reduction, and the integration of cultural and religious frameworks the family brings are central to pediatric integrative care.

38.4 Cautions in Pediatric Supplements and Herbs

Pediatric pharmacology differs from adult pharmacology in ways that matter for integrative interventions. Dose extrapolation from adult studies is unreliable for many botanical and supplement interventions. Safety data for most integrative interventions in pediatric oncology populations are limited. The conservative principle is to apply pediatric integrative interventions selectively, with documented safety in age-appropriate studies, and in close coordination with the pediatric oncology team.

38.5 Adolescent and Young Adult Patients

AYA cancer patients—roughly 15–39 years—occupy a distinctive position bridging pediatric and adult oncology. They face cancer at a developmentally critical period for education, career launch, relationship formation, family planning, and identity development. The 2024 systematic review by Lehmann and colleagues identified physical activity, MBSR, massage, and light therapy as the most evidence-supported modalities for AYA cancer patients (Lehmann et al., 2024). Dana-Farber's Young, Empowered & Strong mHealth platform represents a contemporary digital approach. Fertility preservation, body image, peer support, financial toxicity, and educational/vocational continuity require explicit attention in AYA integrative oncology programming.

39. Caregiver Wellness in Cancer Care

Evidence tier: Substantial descriptive literature on caregiver morbidity; emerging randomized evidence for caregiver-directed interventions; under-resourced in most oncology practice.

39.1 The Caregiver Burden

Cancer caregivers—usually spouses, adult children, and parents—provide an estimated 30–40 hours weekly of unpaid care during active treatment. The cumulative impact includes increased rates of depression, anxiety, sleep disturbance, immune dysregulation, fatigue, financial strain, and excess mortality (the "widowhood effect" extends to caregiving spouses well before bereavement). The 2016 Institute of Medicine report Families Caring for an Aging America documented the systemic under-recognition of caregiver morbidity in healthcare.

39.2 Caregiver-Directed Mind-Body Interventions

Mindfulness-based interventions for caregivers reduce caregiver depression, anxiety, and burden, with effects documented in multiple randomized trials. CBT for caregivers, psychoeducation programs, and structured peer support have demonstrated benefit. The Caregiver Outlook intervention developed by the Memorial Sloan Kettering psycho-oncology group provides an example of structured integration. Caregiver yoga and tai chi programs have emerging evidence.

39.3 Practical Caregiver Support

Beyond formal interventions, caregiver wellness requires practical scaffolding: respite resources, financial counseling, navigation assistance with medical complexity, sleep prioritization, and explicit normalization that caregiver self-care is not selfish but instrumentally necessary. The integrative oncology clinic visit, with its longer time horizon than typical oncology encounters, is well-positioned to include the caregiver in the conversation and to provide referrals to caregiver-specific resources.

39.4 Bereavement

Caregiver bereavement after a death from cancer carries elevated rates of complicated grief, persistent depression, and physical morbidity. Pre-bereavement intervention and post-bereavement support, often through hospice programs, social work, or pastoral care, are part of the comprehensive integrative care continuum. The integrative oncology relationship with the family can and should extend through bereavement when appropriate.

40. Trauma-Informed Cancer Care

Evidence tier: Established trauma-informed care frameworks from SAMHSA and primary care; emerging application to oncology settings; under-recognized in most clinical practice.

40.1 The Trauma Prevalence

A substantial proportion of cancer patients carry pre-existing trauma histories—childhood adverse experiences, intimate partner violence, sexual assault, combat exposure, refugee experiences, and the many forms of structural and racial trauma. Cancer diagnosis and treatment themselves can produce trauma symptoms: an estimated 20% of cancer patients meet criteria for cancer-related post-traumatic stress symptoms during or after treatment. The convergence of pre-existing and treatment-induced trauma shapes how patients engage with healthcare, tolerate procedures, communicate symptoms, and adhere to recommendations.

40.2 The Trauma-Informed Framework

Trauma-informed care, as developed by the Substance Abuse and Mental Health Services Administration (SAMHSA) and adapted for healthcare settings, rests on six principles: safety; trustworthiness and transparency; peer support; collaboration and mutuality; empowerment and choice; and cultural, historical, and gender sensitivity. Operationally, trauma-informed cancer care includes: routine universal screening for trauma history; choice and control offered to patients during procedures (e.g., chest port placement, pelvic exams, scans); explicit consent and step-by-step communication during physical examination; recognition that dissociation, hyperarousal, and avoidance during clinical encounters often reflect trauma rather than non-adherence; trauma-informed language; and clinician self-awareness about the potential to inadvertently re-traumatize.

40.3 Trauma-Specific Treatment

When trauma is identified as a clinically significant comorbidity, evidence-based trauma-specific treatments include cognitive processing therapy, prolonged exposure therapy, eye movement desensitization and reprocessing (EMDR), and emerging psychedelic-assisted therapies (MDMA for PTSD has phase 3 evidence outside of oncology; psilocybin has phase 2 evidence for cancer-related distress as discussed in Section 9). Integrative interventions with trauma-relevant evidence include somatic experiencing, body-oriented therapies, yoga adapted for trauma (Trauma-Sensitive Yoga developed by van der Kolk and colleagues), and mindfulness-based interventions modified for trauma populations.

40.4 Health Disparities and Structural Trauma

Trauma-informed cancer care intersects directly with health disparities. Black, Indigenous, Latino, LGBTQ+, refugee, and economically marginalized patients carry disproportionate trauma burdens, often with healthcare-specific trauma added to other dimensions. The Liou et al. (2023) JNCI analysis of SIO-ASCO pain guidelines through a disparities lens (Section 22) is one example of the kind of integration that trauma-informed care requires. Cultural humility, language access, and explicit attention to power dynamics in the clinical encounter are not optional features of integrative oncology but central elements of competent practice.

40.5 Clinician Trauma and Sustainability

Oncology clinicians—particularly those working in palliative and end-of-life settings—accumulate secondary traumatic stress and moral injury at high rates. Integrative oncology cannot sustainably ignore clinician wellness. Mindfulness-based interventions for clinicians, Schwartz Rounds, structured peer support, and institutional commitment to clinician mental health are part of the trauma-informed care framework as applied to the whole oncology system.

Part VIII

Practice Infrastructure, Context,

and Critical Engagement

History, workforce, health economics, quality measures,

nature-based interventions, global perspectives, and the

indispensable voices of the field's most thoughtful critics.

41. A Brief History of Integrative Oncology

Evidence tier: Historical and field-evolution synthesis.

41.1 Antecedents (Before 1990)

The strands now woven into integrative oncology pre-date the term itself by decades, even centuries. Traditional Chinese medicine, Ayurveda, indigenous healing traditions, and European herbal medicine each addressed cancer-related symptoms long before modern oncology existed. In the twentieth century, several individual movements established conceptual foundations: Linus Pauling's 1970s advocacy for high-dose vitamin C; Lawrence LeShan's psychosocial work on personality and cancer outcomes beginning in the 1950s; the development of meditation and biofeedback as clinical modalities through the 1960s and 1970s; Carl and Stephanie Simonton's controversial visualization work; Bernie Siegel's exceptional cancer patient framework (1986); and the introduction of MBSR by Jon Kabat-Zinn in 1979.

41.2 The Institutional Foundation (1990s)

In 1991, the U.S. Congress established the Office of Alternative Medicine (OAM) within the National Institutes of Health, the first federally funded research program dedicated to complementary therapies. The OAM was upgraded in 1998 to the National Center for Complementary and Alternative Medicine (NCCAM), and again in 2014 to the National Center for Complementary and Integrative Health (NCCIH). The terminological evolution—alternative to complementary and alternative to complementary and integrative—reflected substantive shifts: from a confrontational positioning against mainstream medicine, to an additive relationship, to the integrated model that now defines the field.

41.3 The Founding of SIO (2003)

The Society for Integrative Oncology was founded in 2003 by a group of academic oncologists, complementary medicine practitioners, and supportive care researchers seeking to create a rigorous, evidence-focused professional society. Founding figures included Barrie Cassileth (Memorial Sloan Kettering Cancer Center), Lorenzo Cohen (MD Anderson Cancer Center), Mary Hardy, David Rosenthal (Dana-Farber), and others. The Annual SIO conference, the launch of the Journal of the Society for Integrative Oncology (now integrated within JNCI Monographs), and the systematic development of practice guidelines collectively professionalized the field over the subsequent two decades.

41.4 The Survivorship Inflection (2006)

The Institute of Medicine's 2006 report From Cancer Patient to Cancer Survivor: Lost in Transition reframed cancer survivorship as a distinct clinical phase requiring dedicated infrastructure. The report's emphasis on coordinated survivorship care, treatment summaries, surveillance planning, and quality-of-life optimization created institutional space within which integrative oncology found a natural home. Survivorship clinics at major cancer centers became frequent locations for integrative oncology service delivery.

41.5 Guideline Maturation (2014–2024)

The decade between 2014 and 2024 saw integrative oncology mature from a clinical practice into a guideline-supported discipline. The 2014 SIO breast cancer guidelines (Greenlee et al., endorsed by ASCO in 2018) established the disease-specific framework. The 2017 Witt et al. definition of integrative oncology codified the field's self-understanding. The 2022 SIO-ASCO pain guideline, 2023 anxiety/depression guideline, 2024 fatigue update, and 2024 ASCO cannabis guideline established the cross-cutting operational infrastructure. The CHALLENGE trial publication in 2025 (Courneya et al.) marked the first phase 3 randomized survival evidence for an integrative oncology intervention.

41.6 The Present Moment

Integrative oncology in 2026 occupies a fundamentally different position than at SIO's founding two decades earlier. Major academic cancer centers—Memorial Sloan Kettering, MD Anderson, Dana-Farber, City of Hope, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Duke, and many others—maintain dedicated integrative oncology programs. NCCN survivorship guidelines incorporate integrative recommendations. Reimbursement remains uneven but expanding. The American Board of Integrative Medicine (ABOIM, established 2014) provides physician certification. The Fellowship of the American Board of Naturopathic Oncology (FABNO) certifies naturopathic oncologists. The trajectory from the 1991 OAM founding to the 2025 CHALLENGE NEJM publication is one of the most significant integrations of a once-marginal clinical movement into mainstream medicine in recent decades.

42. The Integrative Oncology Workforce

Evidence tier: Credentialing, training, and clinical workforce synthesis.

42.1 The Question of Who Provides This Care

A serious academic chapter on integrative oncology must address the operational question of who delivers it. The workforce is heterogeneous, multidisciplinary, and—across most regions—under-resourced relative to clinical demand. Effective integrative oncology programs require physicians with integrative medicine training, oncology acupuncturists, integrative nurses, naturopathic oncologists, dietitians with oncology expertise, exercise physiologists with oncology training, mind-body educators, psychologists, social workers, chaplains, and others. Each discipline carries its own training, credentialing, and scope-of-practice considerations.

42.2 Physician Training and Certification

The American Board of Integrative Medicine (ABOIM), founded in 2014 and administered by the American Board of Physician Specialties, provides physician certification in integrative medicine following completion of an accredited fellowship and successful examination. Fellowships are offered through the University of Arizona Andrew Weil Center for Integrative Medicine (the original two-year fellowship founded by Andrew Weil in 1997), Duke Integrative Medicine, the Osher Centers for Integrative Health at multiple institutions, and others. Oncology-specific physician training is offered through the SIO Fellowship Program and several institution-based pathways at Memorial Sloan Kettering, MD Anderson, Dana-Farber, and elsewhere.

42.3 Acupuncture and Oriental Medicine

Licensed acupuncturists in most U.S. states have completed Master's-level training (3,000+ hours) accredited by the Accreditation Commission for Acupuncture and Herbal Medicine (ACAHM) and have passed national certification through the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM). Oncology-specific acupuncture training—largely shaped by Dr. Weidong Lu's work at Dana-Farber (see Section 3)—is delivered through institutional fellowships, the Memorial Sloan Kettering oncology acupuncture program, and SIO-affiliated training. Physician medical acupuncturists complete training through the American Academy of Medical Acupuncture or similar programs.

42.4 Naturopathic Oncology

Naturopathic oncology, certified through the Fellowship of the American Board of Naturopathic Oncology (FABNO), represents one of the most clinically active integrative oncology disciplines in jurisdictions where naturopathic medicine is licensed. FABNO certification requires graduation from a CNME-accredited naturopathic medical school, a 2-year residency, and successful examination. The Oncology Association of Naturopathic Physicians (OncANP) provides professional infrastructure and continuing education. Scope of practice varies substantially by jurisdiction; integration with oncology teams varies accordingly.

42.5 Nursing, Dietetics, and Allied Health

Oncology nurses certified through the Oncology Nursing Certification Corporation (ONCC) often complete additional integrative nursing training. Registered Dietitian Nutritionists with oncology specialization (CSO credential) provide the nutrition backbone of most integrative oncology programs. Exercise physiologists certified through the American College of Sports Medicine, ideally with the Cancer Exercise Trainer specialty credential, deliver the increasingly evidence-based exercise oncology interventions. Mental health professionals (psychologists, social workers, psychiatrists), chaplains, music therapists, art therapists, and certified yoga and tai chi instructors complete the typical team.

42.6 Workforce Adequacy and Equity

The fundamental workforce challenge is that demand exceeds supply, particularly outside major academic centers. Rural, safety-net, and community oncology settings frequently lack any integrative oncology infrastructure. The training pipeline is small relative to need. Reimbursement mechanisms that don't support integrative oncology providers create financial barriers to expansion. Digital delivery platforms (Section 5, Section 22) partially address geographic equity but cannot fully substitute for in-person modalities such as acupuncture, manual therapy, and complete decongestive therapy. Sustainable workforce expansion requires policy, payer, and training-pipeline changes alongside the clinical advances documented throughout this chapter.

43. Health Economics and Value-Based Care

Evidence tier: Emerging health-economic evidence; substantive but incomplete reimbursement landscape.

43.1 The Economic Argument

Integrative oncology operates within an oncology economy dominated by extraordinarily expensive systemic therapies and procedural interventions. A single course of CAR-T therapy can exceed $400,000; novel targeted agents routinely cost $10,000–$20,000 monthly; ICU-level management of immune-related adverse events is similarly costly. Against this backdrop, integrative oncology interventions are inexpensive—acupuncture, exercise programming, mindfulness courses, and dietary counseling cost orders of magnitude less than the drugs and procedures with which they integrate. The economic argument for integrative oncology rests on this asymmetry: even modest reductions in symptom severity, treatment toxicity, emergency department utilization, and hospitalization can produce substantial cost offsets relative to the intervention cost.

43.2 The IM@Home Cost Signal

The IM@Home trial (Mao et al., 2025; Section 5) provides the most compelling recent economic signal in integrative oncology. The trial documented an emergency department visit rate ratio of 0.49, hospitalization rate of 4% versus 12.9% in control, and mean hospital length of stay of 4.25 versus 10 days in the intervention arm. At typical U.S. acute-care cost levels, these utilization reductions would substantially exceed the cost of delivering the digital integrative medicine program. Phase 3 multicenter confirmation is needed; if confirmed, the IM@Home findings provide a credible value-based-care argument for payer coverage.

43.3 Acupuncture Reimbursement

Medicare's 2020 decision to cover acupuncture for chronic low back pain (up to 12 visits initially, with additional visits available based on response) represented a partial precedent for oncology acupuncture coverage. Several state Medicaid programs cover acupuncture in selected contexts. Private insurance coverage remains highly variable. The SIO-ASCO pain guideline (Mao et al., 2022) and the strength of acupuncture evidence in cancer-related symptoms position the field for broader reimbursement advocacy, but uptake has been slower than the evidence base would support.

43.4 Bundled Payment Models

Value-based care frameworks—accountable care organizations, oncology medical homes, bundled payments around cancer episodes (such as the Oncology Care Model and its Oncology Care First successor)—create financial structures in which the cost-offset argument for integrative oncology becomes operationally tractable. When an oncology practice is responsible for the total cost of care during a treatment episode, interventions that reduce emergency department utilization and hospitalization produce direct financial value to the practice. Several large oncology practices have incorporated integrative oncology services within bundled-payment frameworks on this rationale.

43.5 The Equity Dimension of Economics

Economic structures shape who can access integrative oncology. Self-pay models—common for acupuncture, mind-body coaching, and many integrative consultations—systematically exclude lower-income patients. The disparities documented in Section 22 are not solely cultural or referral-pattern problems; they are economic problems requiring economic solutions. Equitable expansion of integrative oncology requires reimbursement mechanisms that don't depend on patient out-of-pocket payment, alongside the cultural and referral-pattern remediation discussed earlier.

43.6 The Cost-Effectiveness Research Agenda

Formal cost-effectiveness analyses of integrative oncology interventions remain limited. Cost-utility studies (cost per quality-adjusted life-year) of structured exercise programs, mindfulness-based interventions, acupuncture, and digital integrative medicine are needed to populate health technology assessment frameworks and support coverage decisions. The field's transition from evidence base to reimbursement infrastructure requires this analytic work as urgently as it requires additional efficacy trials.

44. Patient-Reported Outcomes and Quality Measures

Evidence tier: Established PRO instruments; emerging integration into clinical workflow and quality measurement.

44.1 The PRO Revolution in Oncology

Patient-reported outcomes (PROs)—standardized assessments of symptoms, function, and quality of life completed by patients themselves—have become an organizing infrastructure of contemporary oncology. The Basch et al. (2017) JAMA trial demonstrating that electronic PRO collection during chemotherapy improved overall survival in metastatic solid tumors fundamentally shifted the clinical role of PROs from research instrument to clinical intervention. Integrative oncology is particularly well-suited to PRO-driven care, given its focus on symptom and quality-of-life domains for which PROs are validated.

44.2 Major PRO Instruments

The PROMIS (Patient-Reported Outcomes Measurement Information System) suite, developed with NIH funding, provides domain-specific measures of pain, fatigue, anxiety, depression, sleep, physical function, and social function with rigorous psychometric validation across populations. The EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire) provides oncology-specific generic assessment with disease-specific modules. The FACT (Functional Assessment of Cancer Therapy) family of instruments provides parallel oncology-specific assessment, with the FACT-G and disease-specific FACT-B (breast), FACT-L (lung), FACT-C (colorectal), and others. NIH's PRO-CTCAE provides patient-reported counterparts to clinician-rated CTCAE toxicity grading.

44.3 Symptom-Specific Measures

Distress is captured by the NCCN Distress Thermometer with its problem list, providing a brief clinical screening tool. Pain is measured with the Brief Pain Inventory and PROMIS pain instruments. Fatigue is captured by the Brief Fatigue Inventory (used in the IM@Home trial) and PROMIS fatigue measures. Anxiety and depression are captured by the Hospital Anxiety and Depression Scale (HADS), PHQ-9, GAD-7, and PROMIS instruments. Cognitive function is measured by the FACT-Cog. Sexual function is captured by the Female Sexual Function Index (FSFI) and Sexual Health Inventory for Men (SHIM). For each PRO, integrative oncology integration requires routine collection, threshold-based clinical action, and longitudinal tracking.

44.4 Quality Measures and Accreditation

The Commission on Cancer (CoC) accreditation standards require psychosocial distress screening and survivorship care planning. The ASCO Quality Oncology Practice Initiative (QOPI) measures include selected symptom management indicators. NCCN guidelines incorporate PRO-driven symptom management thresholds. The integrative oncology contribution to quality measurement includes ensuring that symptom domains addressable by integrative interventions are systematically measured, that threshold-positive PROs trigger integrative referrals, and that integrative oncology outcomes are themselves tracked with validated measures.

44.5 Digital PRO Infrastructure

Electronic PRO collection through patient portals, mobile applications, and tablet-based clinic check-in tools has scaled the operational feasibility of routine PRO assessment. The IM@Home trial (Mao et al., 2025), the Dana-Farber Young, Empowered & Strong AYA application (Section 38), and similar digital integrative platforms illustrate the convergence of integrative oncology delivery and PRO infrastructure. The next generation of integrative oncology programming will increasingly be PRO-driven and digitally delivered.

45. Forest Bathing and Nature-Based Interventions

Evidence tier: Mature Japanese research literature on physiologic effects; emerging oncology-specific data; theoretical and field-experience foundation strong but small.

45.1 Shinrin-Yoku and the Japanese Research Tradition

Forest bathing—shinrin-yoku—is a Japanese practice of unhurried contemplative time in forest environments, formalized as a public health intervention by the Japanese Forestry Agency in the early 1980s and subsequently studied extensively in the academic literature by Qing Li and colleagues at Nippon Medical School. The intervention is distinct from hiking, exercise, or wilderness therapy: the emphasis is on slow, multisensory immersion in a forest environment with explicit attention to the smells, sounds, sights, and textures of the natural setting.

45.2 Physiologic Effects

The published literature documents reductions in salivary cortisol, sympathetic nervous system tone, and blood pressure; reductions in pro-inflammatory cytokines; improvements in mood and reductions in anxiety; and—most remarkably—increases in natural killer cell number and intracellular anti-cancer protein expression that persist for several days after the intervention (Li et al., 2007, 2008, and subsequent work). The proposed mechanisms include reduced HPA-axis activation, increased parasympathetic tone, and exposure to volatile organic compounds (phytoncides) released by coniferous trees with documented immunomodulatory effects in vitro.

45.3 Cancer-Specific Applications

Direct oncology randomized trials of forest bathing are sparse. The mechanistic literature on NK cell activation has motivated programmatic integration of nature-based interventions into selected cancer survivorship programs, with the explicit framing that the evidence is mechanistically suggestive rather than outcomes-validated in oncology populations specifically. Forest-based mindfulness retreats, structured nature exposure programs, and integration of horticultural therapy into outpatient cancer care represent the principal clinical applications.

45.4 Urban Nature, Blue Spaces, and Accessibility

The shinrin-yoku tradition is forest-based, but the broader environmental psychology literature on nature exposure—Ulrich's classic 1984 hospital window study, Kaplan's attention restoration theory, and the substantial subsequent literature—supports benefit from urban parks, garden environments, and even views of nature from windows. "Blue space" interventions involving water environments have a parallel emerging literature. From an equity standpoint, urban park and garden access is more universally available than wilderness immersion, and integrative oncology programming in urban settings increasingly leverages these resources.

45.5 Integration

The integrative oncology clinician's role with nature-based interventions includes recognizing the substantial mechanistic literature, recommending nature exposure as a low-risk wellness intervention, integrating with mindfulness-based programming where appropriate, and—importantly—not over-claiming oncology-specific outcome evidence that does not yet exist. Forest bathing represents a credible, low-risk, mechanism-informed integrative recommendation that does not require investigational caveats, while also not being a treatment-replacing intervention.

46. Global and Cultural Perspectives

Evidence tier: WHO Traditional Medicine Strategy framework; substantive global integrative medicine practice; under-represented in North American literature.

46.1 The Global Scale of Traditional Medicine Use

The World Health Organization Traditional Medicine Strategy (2014–2023, with extensions) recognizes that 80% of the global population uses traditional medicine for some aspect of primary healthcare. In oncology specifically, traditional medicine and complementary medicine integration varies enormously across regions: traditional Chinese medicine integrated into national oncology infrastructure in China; Ayurveda formally recognized through India's Ministry of AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy); traditional Korean medicine integrated into Korean oncology practice; traditional African medicine widely used but variably regulated across sub-Saharan Africa; Latin American curanderismo and other indigenous traditions persisting alongside Western medical oncology.

46.2 Traditional Chinese Medicine and Oncology

Traditional Chinese medicine (TCM) integration with Chinese oncology practice is substantially more extensive than acupuncture-focused Western integrative oncology. Chinese herbal formulas are routinely combined with cytotoxic chemotherapy in Chinese hospitals, with claimed benefits in toxicity reduction and treatment tolerance. The evidence base is large but methodologically variable; meta-analyses by Western methodological standards often classify the evidence as low-certainty due to study design limitations, despite substantial directional consistency. The integration of TCM into Chinese national oncology guidelines provides a parallel model to consider alongside the SIO-ASCO framework.

46.3 Ayurveda and Oncology

Ayurvedic integration with oncology has been formalized through India's Ministry of AYUSH and integrated practice at several Indian academic centers, including Tata Memorial Centre's integrative oncology program. Specific Ayurvedic interventions with emerging oncology data include curcumin (mechanistically validated, clinically variable), ashwagandha (Withania somnifera) for fatigue and quality of life, Triphala formulations for gastrointestinal toxicity, and Rasayana protocols for general supportive care. Western methodological appraisal of Ayurvedic interventions faces parallel challenges to those of TCM.

46.4 Traditional and Indigenous Healing

Indigenous and traditional healing practices—whether African, Latin American, Native American, Aboriginal Australian, or Maori—often coexist with Western medical oncology in patients of relevant cultural backgrounds. The clinically appropriate posture is cultural humility, explicit inquiry about traditional medicine use, integration where safe, frank discussion where interactions are concerning, and respect for the cultural meaning of traditional practices even when their clinical evidence base is limited. Bilingual and culturally matched integrative oncology providers are an under-developed but critically important workforce element.

46.5 The Asymmetric Evidence Base

This chapter is overwhelmingly anchored in English-language and Western European literature. The integrative oncology evidence base in Chinese, Korean, Japanese, Hindi, Arabic, Spanish, Portuguese, and other languages represents a substantial body of work that Western academic synthesis under-incorporates. The structural reasons—publication language bias, indexing in Western databases, methodological framing differences—are not easily addressed within a single chapter. The honest acknowledgment is that the field's evidence base is more global than Western-published syntheses typically reflect, and that genuine global integrative oncology requires ongoing translational and methodological work to bridge these traditions.

47. Skeptical Voices and Critical Engagement

Evidence tier: Critical and methodological literature engaging with integrative oncology evidence.

A serious academic chapter on integrative oncology must engage directly with the field's most thoughtful critics rather than dismiss them. The credibility of integrative oncology depends on its willingness to hold its own claims to the same evidentiary standards it asks of conventional oncology, and to acknowledge where critical voices have correctly identified weaknesses.

47.1 The Ernst Critique

Edzard Ernst, emeritus professor of complementary medicine at the University of Exeter, has produced the most sustained body of skeptical scholarship on complementary and alternative medicine over the past three decades. His systematic reviews have repeatedly identified methodological weaknesses, publication bias, and overstatement in the CAM literature broadly, and in selected integrative oncology areas specifically. His work on homeopathy, on chiropractic safety, and on the systematic overclaiming common in complementary medicine marketing represents an indispensable corrective. The defensible response within integrative oncology is to acknowledge where Ernst's critiques land correctly—and many do—while distinguishing them from blanket dismissal of areas with genuine evidence (acupuncture for selected indications, mindfulness-based interventions, structured exercise, several supplements with documented mechanism and trial support).

47.2 The Methodological Critique

Cochrane reviews of complementary and integrative interventions frequently classify evidence certainty as low or very low, even when directional signals are consistent. The Roberts et al. (2022) Cochrane review of Coriolus versicolor in colorectal cancer (Section 15) exemplifies the pattern: directionally supportive findings paired with low-certainty grading reflecting study design limitations. Rather than dismiss the methodological framework, integrative oncology should embrace it as the discipline that distinguishes evidence-based practice from advocacy. The implication is that the field's research priorities should explicitly target the methodological weaknesses Cochrane reviews identify: blinding (where feasible), adequate sample size, registered protocols, standardized outcome measures, and prospective rather than retrospective design.

47.3 The Substitution-Harm and Combination-Skip Literature

Two large analyses from Yale—a 2018 JAMA Oncology study by Johnson, Park, Gross, and Yu, and a 2026 JAMA Network Open study by Ayoade, Caturegli, Canavan, Resio, Berger, and Boffa—provide the most consequential evidence-based critiques of how complementary medicine can be misused in oncology. Together they constitute the most rigorous empirical foundation for the chapter's foundational principle that complementary therapies augment rather than replace standard care.

Johnson et al. (2018) analyzed National Cancer Database records of patients with non-metastatic breast, prostate, lung, and colorectal cancer and demonstrated that patients with curable cancers who chose complementary medicine in lieu of conventional treatment had significantly worse survival—a 2.5-fold increased risk of death. The finding established that substitution of complementary for conventional therapy in curable disease is itself a clinically harmful behavior, independent of whether the complementary therapies are intrinsically dangerous.

The Ayoade et al. (2026) Yale analysis substantially extended this work and produced a finding that should be considered required reading for every integrative oncology clinician. Using the National Cancer Database—approximately 70% of all newly diagnosed cancers in the United States—the team analyzed more than two million female breast cancer patients diagnosed between 2011 and 2021. Three comparisons were made: traditional therapies alone, complementary and alternative medicine (CAM) alone, and CAM combined with traditional therapy.

The headline findings were stark. Patients using CAM alone—as a substitute for conventional therapy—experienced an approximately 3.7-fold higher 5-year mortality risk than patients receiving traditional therapy alone, with outcomes essentially similar to receiving no treatment at all. More troubling for the integrative oncology field, patients using CAM in combination with traditional therapy still experienced approximately 40–45% higher overall mortality than patients receiving traditional therapy alone. This combination-harm signal was the unexpected finding.

On deeper analysis, the mechanism became clear: patients who used CAM in combination with traditional therapy were systematically skipping key components of conventional care, particularly radiation therapy and endocrine therapy. As senior author Dr. Daniel Boffa explained, "It seemed from the data that the patients who used CAM in combination were skipping some of the traditional treatments, particularly radiation and endocrine therapies, which likely contributed to the lower survival." The skipped therapies are precisely those most consequential for local recurrence (radiation) and systemic recurrence in hormone receptor-positive disease (tamoxifen, aromatase inhibitors).

The Ayoade et al. (2026) study also documented that many patients did not disclose their CAM use to their treating clinicians. The undisclosed nature of much CAM use means that even the substantial signal in the National Cancer Database likely undercounts actual exposure. As Boffa noted, "If patients didn't tell their clinicians about plans to use alternative treatments, their use wasn't reflected in our research."

The implications for integrative oncology are direct and uncomfortable. The Yale 2026 data do not show that complementary therapies are intrinsically harmful—they show that the way CAM is currently being used in U.S. breast cancer care is associated with substantial mortality. Some plausible mechanisms beyond explicit substitution include: patient preference for CAM contributing to the decision to skip radiation or endocrine therapy; loss of follow-up adherence in patients pursuing parallel CAM regimens; treatment-team disengagement when CAM is used covertly; and selection effects in which patients drawn to CAM may have unmeasured prognostic factors. The defensible integrative oncology response is not defensiveness but operational change: explicit attention at every visit to ensuring completion of all conventional therapy components, particularly radiation and endocrine therapy; structured screening for which conventional treatments a patient is considering refusing; nonjudgmental but persistent advocacy for completion of evidence-based regimens; and transparent acknowledgment that integrative oncology has not yet succeeded in operationalizing the "augment, not replace" principle as cleanly as the field's rhetoric suggests.

Dr. Boffa's summary articulates the appropriate clinical posture: "The best way to give patients the best care is to discuss the full range of factors influencing their treatment decisions, including their interest in alternative treatment." The chapter's foundational principle—that complementary therapies augment rather than replace evidence-based cancer care, and that anchoring on conventional standard of care is non-negotiable—is not abstract conservatism. It is the operational requirement that follows directly from these data.

47.4 Alternative Therapies Proposed as Primary Cancer Treatment: A Historical Critique

A category of agents distinct from the integrative supportive interventions discussed throughout this chapter consists of products historically marketed as primary cancer treatments in lieu of conventional therapy. Their critical engagement is essential to the integrity of the integrative oncology field, both for historical perspective and for the contemporary clinical task of responding to patients who encounter these products through online communities and alternative cancer clinics.

Laetrile (amygdalin), promoted from the 1950s through the 1980s as a non-toxic cancer cure, became the focus of one of the most consequential evaluations in oncology history. The 1982 NCI-sponsored clinical trial led by Charles Moertel at the Mayo Clinic and reported in the New England Journal of Medicine, paired with the seminal accompanying editorial by Barrie Cassileth ("After Laetrile, What?", NEJM 1982), demonstrated no evidence of efficacy and documented serious cyanide-related toxicities. The Milazzo et al. 2011 Cochrane review reaffirmed the absence of clinical benefit and recommended against further laetrile research, citing both inefficacy and serious adverse effects including cyanide poisoning (Kalyanaraman et al., 1983 described laetrile-induced neuromyopathy from cyanide intoxication). The Cassileth editorial title remains the operative question: after definitive evaluation of a substance shows no benefit and real harm, what should the field do with the patients who continue to seek it? The same question applies, with adjustments for evidence base, to each subsequent generation of alternative cancer products.

The Gerson protocol—a regimen of intensive raw fruit and vegetable juicing, coffee enemas, supplements, and other components developed by Max Gerson in the early twentieth century—has been evaluated repeatedly without demonstration of cancer-treating efficacy. The American Cancer Society, the FDA, the National Cancer Institute, and Cancer Research UK have all reviewed Gerson therapy and found no credible evidence that it treats cancer; documented adverse events include serious electrolyte abnormalities, coffee enema-related infections and electrolyte disturbances, and the well-documented opportunity cost of forgoing evidence-based therapy. Patient interest persists despite the absence of clinical evidence, often promoted through documentary films and online communities that selectively present testimonial accounts.

Antineoplastons, developed by Stanislaw Burzynski beginning in the 1970s, have been the focus of decades of regulatory action, FDA-imposed clinical hold modifications, and unresolved efficacy questions. The agents continue to be administered at the Burzynski Clinic in Houston under research protocols, but no phase 3 randomized evidence has emerged to support efficacy claims for the cancers targeted. The Burzynski enterprise has been the subject of substantive investigative journalism documenting concerns about marketing, patient charges for experimental therapy, and clinical practice patterns. Within integrative oncology, antineoplastons should be viewed as an investigational product without confirmed efficacy, with the additional concerns specific to long-running for-profit clinics operating under indefinitely extended research protocols.

Other historically prominent products in this category include hydrazine sulfate (evaluated in multiple NCI-sponsored trials without demonstrated efficacy), shark cartilage (Lane's Sharks Don't Get Cancer concept refuted by both biological data—sharks do develop cancer—and clinical trial failure), Essiac and related herbal cancer cures (insufficient clinical evidence despite long history of promotion), and high-dose intravenous chelation therapy as cancer treatment (no clinical evidence of efficacy, with known cardiac and renal toxicity risks). Each carries the same general pattern: testimonial-driven public interest, mechanistic claims unsupported or refuted by laboratory data, absence of randomized clinical evidence of cancer effect, real adverse event profiles, and—most consequentially—documented opportunity costs when patients pursue these products in lieu of evidence-based treatment for curable disease.

The clinical responsibility of the integrative oncology clinician toward these products is specific: not to dismiss the patients who ask about them, but to discuss the evidence honestly, document discussions about treatment substitution, emphasize the Johnson 2018 and Ayoade 2026 substitution-harm findings (Section 47.3) where curable disease is at stake, recognize the legitimate emotional and existential needs driving interest in alternative cures, and provide ongoing engagement and supportive integrative care so that patients who decline evidence-based treatment despite advice are not abandoned by the medical system. The position of this category of agents within the chapter is intentionally separate from the supportive and adjunctive interventions discussed throughout: they represent a distinct clinical and ethical situation requiring its own framework.

47.5 The Industry and Marketing Critique

Significant portions of the public-facing complementary medicine industry operate without regulatory oversight, with weak quality control, with extensive direct-to-consumer marketing that overstates evidence, and with financial relationships between supplement manufacturers and clinical advocates that parallel (and sometimes exceed) the pharmaceutical industry conflicts of interest critiqued in conventional medicine. The integrative oncology field's credibility requires explicit attention to these conflicts: disclosure of supplement industry relationships in published work, advocacy for FDA reform of supplement regulation, support for third-party testing infrastructure, and intellectual honesty about quality-control problems in commonly recommended products.

47.6 The Cultural and Epistemological Critique

A more philosophical critique—articulated by writers including Paul Offit, Steven Salzberg, and others—argues that integrative medicine represents an epistemological retreat from evidence-based standards, conflating modalities of widely varying evidence quality under a single "integrative" banner that lends scientific credibility to weakly supported practices. The defensible response within integrative oncology is to acknowledge the partial validity of this concern and to insist on the explicit evidence-tier framework adopted in this chapter (Parts I–IV): not to abolish the distinction between robust and speculative evidence but to make it explicit, and to communicate it transparently to patients.

47.7 The Position of This Chapter

The structure of this chapter—four explicit evidence tiers (Parts I–IV) plus survivorship, prevention, special-population, and critical-engagement sections—is itself a response to the substitution and methodological critiques. The intellectual honesty principle articulated in Section 23.3 (point 5) reflects the position that integrative oncology should neither dismiss its critics nor capitulate to them, but engage with their arguments seriously while continuing to advance rigorous evidence-based practice. The discipline's future credibility depends on this engagement.

48. Research Gaps and Future Directions

Despite substantial progress, several critical research gaps persist in integrative oncology and define the priorities for the next decade.

17. Implementation specificity. Current guidelines recommend broad categories—"yoga," "acupuncture," "mindfulness"—without specifying dose, duration, frequency, technique, or provider training. Translation to consistent clinical practice requires explicit implementation specifications.
18. Diversity in study samples. Most published RCTs over-represent White, female, younger breast cancer patients. Concrete remediation through community-engaged research and intentional diverse enrollment is overdue.
19. Biomarker integration. While biological plausibility exists for most integrative oncology modalities, biomarker-integrated trials linking interventions to immune, metabolic, microbiome, and circadian markers remain limited.
20. Survival outcomes. The CHALLENGE trial (exercise in CRC), the University of Iowa pancreatic ascorbate trial, the DIRECT and NCT03340935 fasting-mimicking diet trials in breast cancer, and the Network Oncology mistletoe registries provide the most credible survival-level signals; phase 3 confirmation is needed across most modalities.
21. Digital scalability and reimbursement. Phase 3 confirmation of IM@Home findings is needed for widespread payer coverage, and parallel implementation in safety-net systems is critical for equitable access.
22. Microbiome and metabolic intervention timing. Optimal timing of probiotics, prebiotics, fasting-mimicking diet, and exercise relative to specific chemotherapy and immunotherapy regimens remains poorly characterized.
23. Precision integrative oncology. Identifying which patient subgroups benefit most from specific modalities—reflected in moderator analyses of MATCH (Carlson et al., 2025)—is essential for personalization.
24. Psychedelic-assisted therapy expansion. Pending NCT05398484 phase 2b/3 results and broader trials in depression, end-of-life care, caregiver distress, and chronic pain.
25. Integrative interventions during immunotherapy. Mistletoe, probiotics, dietary fiber, exercise, and microbiome interventions during ICI therapy represent one of the most promising and rapidly evolving research frontiers.
26. Prevention research. Most integrative oncology research focuses on treatment-phase support; less work has examined the role of integrative interventions in primary and secondary prevention, despite the substantial opportunity. The CAPP2 trial (Burn et al., 2020) provides one model; expansion to other inherited cancer syndromes and average-risk populations is warranted.
27. Survivorship-symptom evidence base. Cognitive dysfunction, sexual health, and cardio-oncology each have smaller evidence bases than they should, given prevalence and quality-of-life impact. Dedicated funding for integrative interventions in these survivorship domains is overdue.
28. Methodological rigor. Cochrane-level critiques of integrative oncology trial methodology (Section 47) identify a recurring need for adequately blinded, registered, prospectively designed trials with validated outcome measures.

49. Clinical Pearls

The following summary of clinical pearls is intended for rapid reference at the point of care.

• Exercise is medicine. Structured aerobic exercise at ≥10 MET-hours per week reduces colon cancer recurrence by 28% and mortality by 37% (CHALLENGE trial). This is level 1 evidence.
• Mindfulness for anxiety and depression. MBIs receive the strongest SIO-ASCO recommendations for both anxiety and depression in oncology. MBCR and tai chi/qigong are comparably effective (MATCH trial).
• Acupuncture for multiple symptoms. Strong evidence for pain (especially aromatase-inhibitor joint pain), CINV, post-treatment anxiety, hot flashes, fatigue, and radiation-induced xerostomia/dysphagia.
• Pharmacologic ascorbate doubles OS in metastatic pancreatic cancer. Phase 2 evidence (Bodeker et al., 2024); requires G6PD screening, renal function, Riordan protocol implementation.
• Fasting-mimicking diet around chemotherapy. Phase 2 evidence for higher pathological response in HER2-negative breast cancer (DIRECT trial); requires dietitian supervision.
• Mistletoe doubled OS in NSCLC + ICI (registry data). Thronicke et al. (2024); phase 3 confirmation pending; available investigationally in US.
• Dietary fiber, not probiotic capsules, during ICI therapy. Spencer et al. (2021) Science data: each 5-g daily fiber increment associated with 30% reduction in progression risk; off-the-shelf probiotics may be harmful in melanoma ICI.
• AHCC reduces gemcitabine toxicity. Randomized data in pancreatic cancer (Yanagimoto et al., 2016): grade 3 AEs 17% vs. 53%.
• Avoid St. John's Wort universally on systemic cancer therapy. Potent CYP3A4 inducer; reduces TKI, tamoxifen, and chemotherapy levels.
• Avoid high-dose antioxidant cocktails during cytotoxic therapy. Theoretical interference with ROS-mediated cytotoxicity; NAC has accelerated lung cancer progression in murine models.
• Quality matters in mushroom supplements. Specify hot-water or dual extraction, disclosed β-glucan content, and third-party testing.
• Psilocybin-assisted therapy for existential distress. Two foundational 2016 trials (Griffiths, Ross); phase 2b/3 confirmation ongoing.
• G6PD screen before IV-C; magnesium monitoring on TKIs. Two foundational safety checks.
• Meaning-centered psychotherapy for advanced cancer. Reduces existential distress and hopelessness (Breitbart).
• Radical Remission factors are Bayesian-informative, not RCT-validated. Turner's ten themes (dietary reset, agency, intuition, supplements, emotional release, positive emotions, social support, spiritual deepening, strong reasons for living, exercise) are not proven causal mechanisms, but they represent the largest systematic qualitative dataset on patients with exceptional survival in advanced cancer. The appropriate posture is Bayesian: low-prior-probability events warrant attention to consistently observed accompanying features, integrated as supportive adjuncts to (never substitutes for) evidence-based oncologic care.
• Aspirin 600 mg daily in Lynch syndrome. CAPP2 (Burn et al., 2020): ~35% reduction in colorectal cancer with persistent effect; integrative chemoprevention with phase 3 evidence.
• Resistance training does not worsen lymphedema. PAL trial (Schmitz et al., 2009/2010) overturned old exercise restriction dogma; progressive resistance training is now standard.
• Photobiomodulation prevents oral mucositis. MASCC/ISOO Level I recommendation for HSCT conditioning and head/neck radiotherapy mucositis prevention (Zadik et al., 2019).
• Exercise during chemotherapy improves attention. Janelsins 2026 RCT: 6-week exercise program improved attention versus placebo in cognitive symptoms during chemo.
• Don't substitute integrative therapies for evidence-based treatment. Johnson et al. (2018): patients with curable cancers who chose CAM over conventional treatment had 2.5-fold mortality risk. Ayoade et al. (2026 JAMA Network Open Yale study of >2 million breast cancer patients): CAM alone produced 3.7-fold higher 5-year mortality; CAM combined with traditional therapy still produced 40–45% higher mortality, principally through skipping radiation or endocrine therapy. Operational implication: ensure completion of every conventional therapy component.
• Prevention is integrative oncology's biggest underutilized lever. WCRF/AICR framework: dietary pattern, weight, physical activity, alcohol, tobacco, HPV vaccination, sun protection.

50. Self-Assessment Questions

The following self-assessment questions test the major concepts in this chapter. Answers and rationale follow.

1. 

Which of the following integrative oncology interventions has phase 3 randomized evidence for reducing disease recurrence in stage II–III colon cancer?

• A. Pharmacologic ascorbate
• B. Structured aerobic exercise
• C. Mistletoe (Viscum album)
• D. Modified citrus pectin

2. 

The Mayo Clinic trials of oral vitamin C in cancer (Creagan 1979; Moertel 1985) found no benefit. The principal reason this does not invalidate the case for pharmacologic intravenous ascorbate is:

• A. The trials were too small to detect benefit
• B. Maximally tolerated oral doses produce plasma ascorbate of ~220 µmol/L, whereas IV doses can reach ~13,400 µmol/L—a 60-fold difference
• C. The trials were not blinded
• D. Vitamin C is no longer considered an antioxidant

3. 

In a patient on PD-1 inhibitor therapy for melanoma, which of the following dietary recommendations has the strongest evidence?

• A. High-dose Lactobacillus probiotic capsules
• B. Dietary fiber from whole foods (e.g., legumes, vegetables)
• C. Ketogenic diet
• D. Intravenous glutathione weekly

4. 

Which of the following is the principal absolute contraindication to pharmacologic intravenous ascorbate?

• A. Type 2 diabetes mellitus
• B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency
• C. History of nephrolithiasis
• D. Concurrent use of tamoxifen

5. 

The Mindfulness and Tai Chi for Cancer Health (MATCH) trial demonstrated which of the following?

• A. Mindfulness-based cancer recovery is significantly superior to tai chi/qigong for mood
• B. Tai chi/qigong is significantly superior to mindfulness-based cancer recovery for mood
• C. Both interventions improved mood, with no difference based on whether participants chose or were randomized
• D. Neither intervention outperformed waitlist control

6. 

Dr. Weidong Lu's pilot randomized sham-controlled trial of acupuncture in gynecologic malignancies (2009) found:

• A. No difference between active and sham acupuncture
• B. Reduced grade 2–4 leukopenia in the active acupuncture arm (30% vs. 90%)
• C. Improved overall survival in the active acupuncture arm
• D. Worse outcomes with active acupuncture due to interference with chemotherapy

7. 

The therapeutic effect of psilocybin in cancer-related existential distress is best predicted by:

• A. The total milligram dose administered
• B. The intensity of the mystical-type experience during the session
• C. The duration of preparatory psychotherapy
• D. The patient's baseline mood score

8. 

Which of the following is generally contraindicated in patients on systemic cancer therapy?

• A. Vitamin D
• B. Omega-3 fatty acids
• C. St. John's Wort
• D. American ginseng

9. 

The CAPP2 trial (Burn et al., Lancet 2020) demonstrated which of the following?

• A. Aspirin 600 mg daily for 25 months reduced colorectal cancer incidence in Lynch syndrome carriers, with effects persisting for over a decade
• B. Aspirin reduced overall cancer incidence in average-risk women
• C. Aspirin reduced breast cancer recurrence in BRCA1/2 carriers
• D. Aspirin had no benefit in any cancer population

10. 

The Physical Activity and Lymphedema (PAL) trial led by Schmitz et al. (NEJM 2009; JAMA 2010) established which of the following?

• A. Resistance training exacerbates lymphedema and should be avoided
• B. Progressive resistance training does not exacerbate lymphedema and reduces exacerbations
• C. Lymphatic massage is contraindicated in breast cancer survivors
• D. Compression garments are unnecessary in established lymphedema

11. 

Photobiomodulation for the prevention of oral mucositis has which level of evidence per MASCC/ISOO guidelines (Zadik et al., 2019)?

• A. Insufficient evidence to recommend
• B. Level III evidence; conditional recommendation
• C. Level I evidence; recommendation for HSCT and head/neck radiotherapy populations
• D. Recommended against

12. 

Anamorelin for cancer cachexia is best characterized as:

• A. FDA-approved for cachexia in NSCLC, gastric, pancreatic, and colorectal cancer
• B. Approved in Japan only (2021); not FDA-approved or EMA-approved
• C. Cannabinoid-based appetite stimulant
• D. Withdrawn from all markets due to safety concerns

13. 

The Ayoade et al. (2026) Yale JAMA Network Open analysis of more than two million breast cancer patients in the National Cancer Database found that:

• A. CAM-alone use was associated with mortality comparable to traditional therapy
• B. CAM combined with traditional therapy improved survival over traditional therapy alone
• C. CAM-alone use was associated with ~3.7-fold higher mortality; CAM combined with traditional therapy was still associated with ~40–45% higher mortality, principally attributable to skipping radiation and endocrine therapy
• D. CAM use had no measurable association with survival in any direction

Answer Key

1. B — The CHALLENGE trial (Courneya et al., 2025) demonstrated a 28% reduction in recurrence and 37% reduction in mortality with structured exercise in high-risk stage II/III colon cancer.

2. B — The 2004 pharmacokinetic study by Padayatty et al. demonstrated the 60-fold differential. The Mayo Clinic trials were testing a pharmacologically different intervention than Cameron and Pauling.

3. B — Spencer et al. (2021) Science: each 5-g daily fiber increase was associated with a 30% reduction in PD-1 progression risk; off-the-shelf probiotics were associated with worse survival.

4. B — G6PD deficiency can produce severe or fatal oxidative hemolysis with pharmacologic ascorbate (Marik, 2019).

5. C — Both MBCR and TCQ significantly improved mood; choice versus random assignment did not modify outcomes (Carlson et al., 2025).

6. B — Lu, Matulonis, et al. (2009) found significantly lower grade 2–4 leukopenia in the active acupuncture arm.

7. B — Mediation analyses across both 2016 trials demonstrated that mystical-type experience intensity predicted enduring therapeutic outcome, independent of overall drug effect intensity (Griffiths et al., 2016; Ross et al., 2016).

8. C — St. John's Wort is a potent CYP3A4 inducer that reduces plasma levels of many chemotherapies, TKIs, and tamoxifen.

9. A — CAPP2 (Burn et al., Lancet 2020): aspirin 600 mg daily reduced colorectal cancer incidence in Lynch syndrome, with persistent benefit at 10 and 20-year follow-up.

10. B — The PAL trial overturned the prior "avoid resistance training" dogma in lymphedema, demonstrating that progressive resistance training does not exacerbate and may reduce lymphedema (Schmitz et al., 2009, 2010).

11. C — MASCC/ISOO 2019 update (Zadik et al.) assigns Level I evidence for intra-oral PBM for mucositis prevention in adults undergoing HSCT conditioning chemotherapy and head/neck radiotherapy.

12. B — Anamorelin received approval in Japan in 2021 (Wakabayashi et al., 2021) for cachexia in four cancer types. The European Medicines Agency did not approve it. It is not FDA-approved in the United States.

13. C — Ayoade et al. (2026): CAM alone was associated with ~3.7-fold higher 5-year mortality versus traditional therapy alone; CAM combined with traditional therapy was still associated with ~40–45% higher mortality, attributable principally to skipped radiation and endocrine therapy. The operational implication is that integrative oncology must explicitly ensure completion of every component of evidence-based therapy.

51. Conclusion

Integrative oncology in 2026 occupies a fundamentally different position than it did even five years ago. The discipline has acquired authoritative practice guidelines (SIO-ASCO across pain, anxiety/depression, fatigue, and cannabis), phase 3 randomized survival evidence (CHALLENGE in colon cancer), phase 2 randomized evidence in selected disease settings (Iowa pancreatic ascorbate, DIRECT fasting-mimicking diet in breast cancer, the foundational 2016 psilocybin trials), substantive comparative effectiveness evidence (MATCH trial), and a credible infrastructure within institutional cancer care. Real-world evidence cohorts—Lasheen's 2,239 acupuncture patients, the Italian hyperthermia series, the Network Oncology mistletoe registry—document that the operational delivery of integrative oncology is achievable and beneficial outside the constrained world of randomized trials.

This chapter has extended that synthesis across the full continuum of cancer care: from primary and secondary prevention through prehabilitation, from treatment-phase symptom support through the survivorship-specific domains of cognitive dysfunction, sexual health, cardio-oncology, bone health, lymphedema, vasomotor symptoms, cachexia, and mucositis; from the special settings of immunotherapy adverse events and cellular therapy supportive care to the special populations of pediatric, adolescent and young adult, geriatric, and caregiver constituencies; and from the practice-infrastructure questions of workforce, health economics, and quality measurement to the indispensable critical engagement with the field's most thoughtful skeptics. The discipline cannot stand on its evidence base alone; it must also stand on its honesty about that evidence, its responsiveness to its critics, its accountability for equitable access, and its insistence that complementary interventions augment rather than substitute for evidence-based cancer care.

What remains unchanged is the central commitment of integrative oncology: to care for the whole person living with cancer—body, metabolism, immune terrain, mind, relationships, meaning, family, community, and culture—while respecting the rigor of conventional oncologic evidence and the seriousness of the disease. The discipline is neither alternative medicine in disguise nor an unconditional embrace of the conventional. It is, when practiced well, a sustained effort to bring the best of both traditions to the bedside of patients who deserve nothing less.

The challenges ahead—equitable access, diverse representation in clinical trials, phase 3 confirmation of phase 2 signals, integration of microbiome and circadian frameworks, expansion of psychedelic-assisted therapy, scalable digital delivery, sustainable workforce development, value-based reimbursement, prevention-focused investment, and global integration that honors the asymmetric evidence base—are substantial but tractable. The patients who will benefit from solving them are not abstract; they are present in every oncology waiting room, every infusion center, every survivorship clinic, every hospice bedside, and every family kitchen where a person living with cancer is trying to figure out what comes next. The work continues.

Appendix: Resources for Clinicians, Patients, and Caregivers

The following curated resources represent the principal organizations, databases, and patient-facing services in integrative oncology and supportive cancer care as of 2026. URLs are subject to change; the institutional names and core functions are the more durable references.

Professional Societies and Guideline Bodies

• Society for Integrative Oncology (SIO). integrativeonc.org. Founded in 2003; the principal professional society of the discipline. Publishes joint guidelines with ASCO, organizes the annual SIO international conference, maintains the SIO Fellowship and certification framework, and serves as the field's principal clinical and research home.
• American Society of Clinical Oncology (ASCO). asco.org. Joint partner with SIO in pain (Mao et al., 2022), anxiety/depression (Carlson et al., 2023), and fatigue (Bower et al., 2024) guidelines; independent publisher of the cannabis guideline (Braun et al., 2024). The ASCO Annual Meeting is the principal venue for new oncology trial presentations including integrative oncology data.
• Multinational Association of Supportive Care in Cancer (MASCC). mascc.org. Publishes the MASCC/ISOO Mucositis Guidelines (Elad et al., 2020), the antiemetic guideline framework, and other operational supportive-care standards relevant to integrative oncology.
• National Comprehensive Cancer Network (NCCN). nccn.org. The NCCN Survivorship Guidelines incorporate integrative recommendations on fatigue, anxiety/depression, sexual function, exercise, nutrition, and other domains.
• Oncology Association of Naturopathic Physicians (OncANP). oncanp.org. Professional infrastructure and continuing education for naturopathic oncologists; manages the Fellowship of the American Board of Naturopathic Oncology (FABNO) credential.
• American Board of Integrative Medicine (ABOIM). abpsus.org/integrative-medicine. Physician board certification in integrative medicine, established in 2014.

Clinician-Facing Databases and Decision Support

• About Herbs (Memorial Sloan Kettering Cancer Center). mskcc.org/cancer-care/integrative-medicine/herbs. The most clinically useful free integrative oncology database for clinicians and patients. Maintained by MSK's Integrative Medicine Service under the direction of Jun Mao and colleagues, the database provides evidence-graded monographs on hundreds of herbs, supplements, and complementary therapies including mechanisms, clinical evidence, drug-herb interactions, contraindications, and dosing. Recommended as a routine consultation tool for any clinician evaluating supplement use in cancer patients.
• Natural Medicines Comprehensive Database. naturalmedicines.therapeuticresearch.com. Subscription-based clinical reference with comprehensive evidence ratings, interaction checkers, and condition-specific monographs.
• NCCIH (National Center for Complementary and Integrative Health). nccih.nih.gov. The NIH center for complementary and integrative health research; publishes evidence-based fact sheets, funds research, and maintains clinical practice resources.
• Cochrane Complementary Medicine. cam.cochrane.org. Cochrane reviews specific to complementary and integrative interventions, with rigorous methodological appraisal.
• PubMed (NLM/NIH). pubmed.ncbi.nlm.nih.gov. Indexed access to the peer-reviewed literature; foundational for evidence-based integrative oncology practice.
• ClinicalTrials.gov. clinicaltrials.gov. Registry of active clinical trials including integrative oncology investigations; useful for both clinician referral and patient self-search.

Major Academic Integrative Oncology Programs

The following academic centers maintain robust integrative oncology programs offering clinical services, research, and educational resources. Most have patient-facing websites with practical information about services, referral processes, and (in many cases) free educational content.

• Memorial Sloan Kettering Cancer Center, Integrative Medicine Service. mskcc.org/cancer-care/integrative-medicine. Founded by Barrie Cassileth; current leadership Jun Mao.
• MD Anderson Cancer Center, Integrative Medicine Center. mdanderson.org/integrative-medicine. Led by Lorenzo Cohen.
• Dana-Farber Cancer Institute, Leonard P. Zakim Center for Integrative Therapies. dana-farber.org/integrative-therapies. Site of Dr. Weidong Lu's oncology acupuncture research program.
• City of Hope, Center for Integrative Medicine. cityofhope.org. Active integrative oncology research and clinical care.
• Cleveland Clinic Center for Functional Medicine and Integrative Health. clevelandclinic.org/integrative-health. Integrates functional medicine principles with oncology care.
• Mayo Clinic, Integrative Medicine and Health. mayoclinic.org. Multi-site integrative oncology services with substantial research output.
• Johns Hopkins Center for Psychedelic and Consciousness Research. hopkinspsychedelic.org. Principal site of cancer-related psilocybin research (Griffiths et al.).
• University of Arizona Andrew Weil Center for Integrative Medicine. integrativemedicine.arizona.edu. The original integrative medicine fellowship; foundational training program.
• Duke Integrative Medicine. dukeintegrativemedicine.org. Substantial integrative oncology clinical and educational programming.

Patient-Facing Support Organizations

• Cancer Support Community / Gilda's Club. cancersupportcommunity.org. Helpline: 1-888-793-9355. Formed in 2009 through the merger of The Wellness Community (founded 1982 by Harold and Harriet Benjamin in Santa Monica) and Gilda's Club Worldwide (founded 1991 in honor of comedian Gilda Radner). With over 200 locations across 50 markets globally, CSC and Gilda's Club locations provide free professional support groups, individual counseling, educational programs, exercise and mind-body classes, child and teen programming, and caregiver services. The CancerSupportSource distress screening tool is used in healthcare settings nationwide. Frankly Speaking About Cancer educational materials and the Cancer Experience Registry provide accessible patient resources and research infrastructure.
• American Cancer Society (ACS). cancer.org. Helpline: 1-800-227-2345. Patient navigation services, transportation assistance (Road to Recovery), free lodging (Hope Lodge), and comprehensive educational resources.
• CancerCare. cancercare.org. Helpline: 1-800-813-4673. Free professional counseling, support groups, educational workshops, and financial assistance.
• Cancer Hope Network. cancerhopenetwork.org. One-on-one peer support matching cancer survivors with patients in active treatment, by cancer type and treatment experience.
• LIVESTRONG Foundation. livestrong.org. Survivorship-focused programming, the LIVESTRONG at the YMCA exercise program, and navigation services.
• National Coalition for Cancer Survivorship (NCCS). canceradvocacy.org. Survivor-led advocacy organization with educational resources on survivorship planning and quality cancer care.
• Cancer Research Institute. cancerresearch.org. Patient-facing immunotherapy education and clinical trial finder.

Disease-Specific Patient Organizations

• Susan G. Komen / Komen Care. komen.org. Breast cancer patient navigation, support, and treatment assistance.
• Living Beyond Breast Cancer. lbbc.org. Survivorship-focused breast cancer programming.
• Prostate Cancer Foundation. pcf.org. Patient resources and research advocacy.
• Pancreatic Cancer Action Network (PanCAN). pancan.org. Patient services, clinical trial navigation, and research advocacy.
• Colorectal Cancer Alliance. ccalliance.org. Helpline, peer support, and survivorship programming.
• Lung Cancer Research Foundation / GO2 for Lung Cancer. lungcancerresearchfoundation.org; go2.org. Patient support and advocacy.
• Leukemia & Lymphoma Society. lls.org. Patient services, financial assistance, and disease-specific resources.
• Ovarian Cancer Research Alliance. ocrahope.org. Patient support and research advocacy.
• Multiple Myeloma Research Foundation. themmrf.org. Patient services and clinical trial finder.

Caregiver-Specific Resources

• Family Caregiver Alliance. caregiver.org. Comprehensive caregiver support, education, respite resource location, and policy advocacy.
• National Alliance for Caregiving. caregiving.org. Research, advocacy, and resource development for family caregivers.
• Caregiver Action Network. caregiveraction.org. Free caregiver resources and support across all caregiving contexts.
• Well Spouse Association. wellspouse.org. Peer support for spousal caregivers.

Mental Health and Existential Distress

• American Psychosocial Oncology Society (APOS). apos-society.org. Provider locator for trained psycho-oncology clinicians.
• National Suicide Prevention Lifeline / 988. 988lifeline.org. Crisis support; dial or text 988.
• Meaning-Centered Psychotherapy (Breitbart and colleagues). Available through Memorial Sloan Kettering training programs and licensed practitioners; published manualized framework.

Financial Toxicity and Practical Support

• Patient Advocate Foundation. patientadvocate.org. Case management, co-pay relief, and financial navigation.
• HealthWell Foundation. healthwellfoundation.org. Co-pay assistance for insured patients.
• CancerCare Co-Payment Assistance Foundation. cancercarecopay.org. Financial support for treatment-related costs.
• Triage Cancer. triagecancer.org. Legal and financial education for cancer patients and survivors.

Nutrition and Lifestyle

• American Institute for Cancer Research (AICR) / World Cancer Research Fund (WCRF). aicr.org; wcrf.org. The WCRF/AICR Continuous Update Project synthesizes the global evidence on diet, nutrition, physical activity, and cancer (see Section 35).
• Academy of Nutrition and Dietetics – Oncology Nutrition. oncologynutrition.org. Locator for Board-Certified Specialists in Oncology Nutrition (CSO credential).
• Cooking for Your Life. cookingforyourlife.com. Free recipes and nutrition education developed specifically for cancer patients and survivors.

Exercise Oncology

• American College of Sports Medicine (ACSM) – Moving Through Cancer / Exercise is Medicine. exerciseismedicine.org; movingthroughcancer.com. Patient and clinician resources for exercise during and after cancer treatment, including Cancer Exercise Trainer certification.
• LIVESTRONG at the YMCA. livestrong.org/what-we-do/program/livestrong-at-the-ymca. Free 12-week structured exercise program for cancer survivors at participating YMCAs.

Survivorship Care Planning

• Journey Forward. journeyforward.org. Survivorship care plan templates and tools.
• OncoLink Cancer Care Plan Tool. oncolink.org/oncolife. Free patient-completed survivorship care plan generator developed at the University of Pennsylvania.
• Children's Oncology Group Long-Term Follow-Up Guidelines. survivorshipguidelines.org. Survivorship care framework for childhood, adolescent, and young adult cancer survivors.

End-of-Life and Hospice Resources

• National Hospice and Palliative Care Organization (NHPCO) / CaringInfo. nhpco.org; caringinfo.org. Hospice locator, advance care planning resources, and family caregiver education.
• Get Palliative Care. getpalliativecare.org. Palliative care education and provider locator developed by the Center to Advance Palliative Care.
• Compassion & Choices. compassionandchoices.org. End-of-life option education and advocacy.

Clinical Trials and Research Participation

• ClinicalTrials.gov. clinicaltrials.gov. Federal registry of clinical trials.
• National Cancer Institute Clinical Trials Search. cancer.gov/about-cancer/treatment/clinical-trials/search. NCI-curated trial search with patient-friendly interface.
• Cancer Support Community Clinical Trial Resource. cancersupportcommunity.org/clinical-trials-and-clinical-research. Patient-facing trial education and matching resources.

Practical Note on Resource Use

The resources listed above are representative rather than exhaustive. Clinicians integrating these into practice should: verify current URLs and contact information before referral; recognize that regional and local programs often complement these national resources; respect patient preferences and cultural fit when recommending support organizations; remain alert to the dynamic nature of the resource landscape, as organizations merge, rebrand, or restructure (the 2009 Wellness Community–Gilda's Club merger to form Cancer Support Community is a recent example); and contribute referral patterns back into the integrative oncology team's institutional knowledge so that resource referrals can be tracked, evaluated, and refined.

Acknowledgments

The author thanks the patients, colleagues, and teachers whose questions, clinical experience, and rigor have shaped this work over more than two decades of integrative medicine practice. Particular acknowledgment is owed to the foundational scientists, clinicians, and trialists whose work is synthesized here—including the SIO-ASCO guideline panels, the CHALLENGE and MATCH trial investigators, the University of Iowa pharmacologic ascorbate group, the DIRECT trial collaborators, Dr. Weidong Lu and the Dana-Farber oncology acupuncture program, the Johns Hopkins and NYU psilocybin teams, the Network Oncology mistletoe registry investigators, the CAPP2 trial team, the Schmitz PAL trial collaborators, the MASCC/ISOO Mucositis Study Group, the Janelsins exercise-and-cognition research program, and the many others whose published work makes a chapter like this possible. Errors and inadequacies are the author's alone.

The author also acknowledges patients with cancer who have made the courageous decision to enroll in clinical trials of integrative interventions, often during the most vulnerable periods of their lives. Their participation is the foundation on which the evidence base rests. Finally, the author thanks the family caregivers—often invisible in the literature—whose sustained labor of love makes integrative oncology and oncology more broadly possible.

References

References are formatted in APA 7th edition style. Where DOIs are available, they are included. Citations are alphabetized by first author surname.

Agathocleous, M., Meacham, C. E., Burgess, R. J., Piskounova, E., Zhao, Z., Crane, G. M., Cowin, B. L., Bruner, E., Murphy, M. M., Chen, W., Spangrude, G. J., Hu, Z., DeBerardinis, R. J., & Morrison, S. J. (2017). Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature, 549(7673), 476–481. https://doi.org/10.1038/nature23876

Ahmad, R., Riaz, M., Khan, A., Aljamea, A., Algheryafi, M., Sewaket, D., & Alqathama, A. (2021). Ganoderma lucidum (Reishi) an edible mushroom: A comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. Phytotherapy Research, 35(11), 6030–6062. https://doi.org/10.1002/ptr.7215

Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014). Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews, 2014(3), CD005228. https://doi.org/10.1002/14651858.CD005228.pub4

Allen, B. G., Bodeker, K. L., Smith, M. C., Monga, V., Sandhu, S., Hohl, R., Carlisle, T., Brown, H., Hollenbeck, N., Vollstedt, S., Greenlee, J. D., Howard, M. A., Mapuskar, K. A., Seyedin, S. N., Caster, J. M., Jensen, R. L., Buatti, J. M., Spitz, D. R., & Cullen, J. J. (2024). First-in-human phase II trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. Clinical Cancer Research, 30(2), 271–281.

Baghli, I., Makis, W., Marik, P. E., Gonzalez, M. J., Grant, W. B., Hunninghake, R., Levy, T. E., Lim, H., Cheng, R. Z., Bondarenko, I., Bousquet, P., Ortiz, R., Mary, M., D'Agostino, D. P., & Martinez, P. (2024). Targeting the mitochondrial–stem cell connection in cancer treatment: A hybrid orthomolecular protocol. Journal of Orthomolecular Medicine, 39(3).

Bahrami, A., Haghighi, S., Malekzadeh Moghani, M., Khodakarim, N., & Hejazi, E. (2024). Fasting mimicking diet during neo-adjuvant chemotherapy in breast cancer patients: A randomized controlled trial study. Frontiers in Nutrition, 11, 1483707. https://doi.org/10.3389/fnut.2024.1483707

Bai, R. Y., Staedtke, V., Rudin, C. M., Bunz, F., & Riggins, G. J. (2015). Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology, 17(4), 545–554. https://doi.org/10.1093/neuonc/nou234

Barnett, J. B., Wang, G. C., Zeng, W., Ramos, C., Beadle, B. M., & Turner, K. A. (2024). Effect of the Radical Remission Multimodal Intervention on quality of life of people with cancer. Integrative Cancer Therapies, 23, 15347354241293197.

Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., … Boursi, B. (2021). Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 371(6529), 602–609. https://doi.org/10.1126/science.abb5920

Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23(10), 1124–1134. https://doi.org/10.1038/nm.4409

Berkson, B. M., Rubin, D. M., & Berkson, A. J. (2006). The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integrative Cancer Therapies, 5(1), 83–89.

Berkson, B. M., Rubin, D. M., & Berkson, A. J. (2009). Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: A report of 3 new cases. Integrative Cancer Therapies, 8(4), 416–422.

Blagodatski, A., Yatsunskaya, M., Mikhailova, V., Tiasto, V., Kagansky, A., & Katanaev, V. L. (2018). Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. Oncotarget, 9(49), 29259–29274.

Blaschke, K., Ebata, K. T., Karimi, M. M., Zepeda-Martínez, J. A., Goyal, P., Mahapatra, S., Tam, A., Laird, D. J., Hirst, M., Rao, A., Lorincz, M. C., & Ramalho-Santos, M. (2013). Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature, 500(7461), 222–226. https://doi.org/10.1038/nature12362

Bodeker, K. L., Smith, B. J., Berg, D. J., Chandrasekharan, C., Sharif, S., Fei, N., Vollstedt, S., Brown, H., Chandler, M., Olalde, A., Mapuskar, K. A., Steffen, B. T., Wagner, B. A., Allen, B. G., Buatti, J. M., Spitz, D. R., & Cullen, J. J. (2024). A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biology, 77, 103375. https://doi.org/10.1016/j.redox.2024.103375

Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.

Bouffette, S., Botez, I., & De Ceuninck, F. (2023). Targeting galectin-3 in inflammatory and fibrotic diseases. Trends in Pharmacological Sciences, 44(8), 519–531.

Bower, J. E., Lacchetti, C., Alici, Y., Barton, D. L., Bruner, D., Canin, B. E., Escalante, C. P., Ganz, P. A., Garland, S. N., Gupta, S., Jim, H., Ligibel, J. A., Loh, K. P., Peppone, L., Tripathy, D., Yennu, S., Zick, S., & Mustian, K. (2024). Management of fatigue in adult survivors of cancer: ASCO–Society for Integrative Oncology guideline update. Journal of Clinical Oncology, 42(20), 2456–2487. https://doi.org/10.1200/JCO.24.00541

Braun, I. M., Bohlke, K., Abrams, D. I., Anderson, H., Balneaves, L. G., Bar-Sela, G., Bowles, D. W., Chai, P. R., Damani, A., Gupta, A., Hallmeyer, S., Subbiah, I. M., Twelves, C., Wallace, M. S., & Roeland, E. J. (2024). Cannabis and cannabinoids in adults with cancer: ASCO guideline. Journal of Clinical Oncology, 42(13), 1575–1593. https://doi.org/10.1200/JCO.23.02596

Breitbart, W., Rosenfeld, B., Pessin, H., Applebaum, A., Kulikowski, J., & Lichtenthal, W. G. (2015). Meaning-centered group psychotherapy: An effective intervention for improving psychological well-being in patients with advanced cancer. Journal of Clinical Oncology, 33(7), 749–754.

Brown, J. C., Sturgeon, K., Sarwer, D. B., Troxel, A. B., DeMichele, A. M., Denlinger, C. S., & Schmitz, K. H. (2024). The dose-response effect of aerobic exercise on inflammation in colon cancer survivors. Frontiers in Oncology, 13, 1256762.

Caffa, I., Spagnolo, V., Vernieri, C., Valdemarin, F., Becherini, P., Wei, M., Brandhorst, S., Zucal, C., Driehuis, E., Ferrando, L., Piacente, F., Tagliafico, A., Cilli, M., Mastracci, L., Vellone, V. G., Piazza, S., Cremonini, A. L., Gradaschi, R., Mantero, C., … Longo, V. D. (2020). Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature, 583(7817), 620–624.

Cameron, E., & Pauling, L. (1976). Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences, 73(10), 3685–3689.

Cameron, E., & Pauling, L. (1978). Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences, 75(9), 4538–4542.

Carlson, L. E., Ismaila, N., Addington, E. L., Asher, G. N., Atreya, C., Balneaves, L. G., Bradt, J., Fuller-Shavel, N., Goodman, J., Hoffman, C. J., Huston, A., Mehta, A., Paller, C. J., Richardson, K., Seely, D., Siwik, C. J., Temel, J. S., Rowland, J. H., Lopez, A. M., … Mehta, K. (2023). Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology–ASCO guideline. Journal of Clinical Oncology, 41(28), 4562–4591.

Carlson, L. E., Jones, J. M., Oberoi, D., Piedalue, K.-A., Wayne, P. M., Santa Mina, D., Lawal, O. A., & Speca, M. (2025). Mindfulness and Tai Chi for Cancer Health (MATCH) study: Primary outcomes of a preference-based multisite randomized comparative effectiveness trial. Journal of Clinical Oncology, 43(21), 2372–2386. https://doi.org/10.1200/JCO-24-02540

Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer. Journal of Clinical Oncology, 20(16), 3478–3483.

Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M., & Catalano, G. (1995). Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer. Journal of Clinical Oncology, 13(1), 26–32.

Chen, K. T., Twu, S. J., Chang, H. J., & Lin, R. S. (2003). Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. American Journal of Public Health, 93(3), 489–492.

Chen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005). Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proceedings of the National Academy of Sciences, 102(38), 13604–13609.

Chen, Q., Espey, M. G., Sun, A. Y., Lee, J. H., Krishna, M. C., Shacter, E., Choyke, P. L., Pooput, C., Kirk, K. L., Buettner, G. R., & Levine, M. (2007). Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proceedings of the National Academy of Sciences, 104(21), 8749–8754.

Chen, Q., Espey, M. G., Sun, A. Y., Pooput, C., Kirk, K. L., Krishna, M. C., Khosh, D. B., Drisko, J., & Levine, M. (2008). Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proceedings of the National Academy of Sciences, 105(32), 11105–11109.

Chen, S. J., Yao, X. D., Peng, B. O., Xu, Y. F., Wang, G. C., Huang, J., Liu, M., & Zheng, J. H. (2016). Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells. Experimental and Therapeutic Medicine, 11(4), 1025–1032.

Cimmino, L., Dolgalev, I., Wang, Y., Yoshimi, A., Martin, G. H., Wang, J., Ng, V., Xia, B., Witkowski, M. T., Mitchell-Flack, M., Grillo, I., Bakogianni, S., Ndiaye-Lobry, D., Martín, M. T., Guillamot, M., Banh, R. S., Xu, M., Figueroa, M. E., Dickins, R. A., … Aifantis, I. (2017). Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell, 170(6), 1079–1095.

Courneya, K. S., Vardy, J. L., O'Callaghan, C. J., Friedenreich, C. M., Campbell, K. L., Prapavessis, H., Crawford, J. J., O'Brien, P., Dhillon, H. M., Jonker, D. J., Chua, N. S., Lupichuk, S., Sanatani, M. S., Karapetis, C. S., Kim, J., Underhill, C., Ginnerup-Pedersen, B., Stricker, T., Auer, R., … Booth, C. M. (2025). Structured exercise after adjuvant chemotherapy for colon cancer. New England Journal of Medicine, 393(1), 13–25. https://doi.org/10.1056/NEJMoa2502760

Creagan, E. T., Moertel, C. G., O'Fallon, J. R., Schutt, A. J., O'Connell, M. J., Rubin, J., & Frytak, S. (1979). Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. New England Journal of Medicine, 301(13), 687–690.

Dang, C. V. (2012). Links between metabolism and cancer. Genes & Development, 26(9), 877–890.

Das, A. B., Kakadia, P. M., Wojcik, D., Pemberton, L., Browett, P. J., Bohlander, S. K., & Vissers, M. C. M. (2019). Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1. Blood Cancer Journal, 9(10), 82.

Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J. M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., … Zarour, H. M. (2021). Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science, 371(6529), 595–602.

de Groot, S., Lugtenberg, R. T., Cohen, D., Welters, M. J. P., Ehsan, I., Vreeswijk, M. P. G., Smit, V. T. H. B. M., de Graaf, H., Heijns, J. B., Portielje, J. E. A., van de Wouw, A. J., Imholz, A. L. T., Kessels, L. W., Vrijaldenhoven, S., Baars, A., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van der Hoeven, J. J. M., … Kroep, J. R. (2020). Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications, 11(1), 3083. https://doi.org/10.1038/s41467-020-16138-3

Di Tano, M., Raucci, F., Vernieri, C., Caffa, I., Buono, R., Fanti, M., Brandhorst, S., Curigliano, G., Nencioni, A., de Braud, F., & Longo, V. D. (2020). Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. Nature Communications, 11(1), 2332.

Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., Hsu, J., Zengin, Z., Salgia, S., Salgia, N., Malhotra, J., Chawla, N., Chehrazi-Raffle, A., Muddasani, R., Gillece, J., … Pal, S. K. (2022). Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial. Nature Medicine, 28(4), 704–712.

Dong, R., Zhang, M., Hu, Q., Zheng, S., Soh, A., Zheng, Y., & Yuan, H. (2018). Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). International Journal of Molecular Medicine, 41(2), 599–614.

Dou, Q., Chen, H. N., Wang, K., Yuan, K., Lei, Y., Li, K., Lan, J., Chen, Y., Huang, Z., Xie, N., Zhang, L., Xiang, R., Nice, E. C., Wei, Y., & Huang, C. (2016). Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Research, 76(15), 4457–4469.

Draganov, D., Gopalakrishna-Pillai, S., Chen, Y. R., Zuckerman, N., Moeller, S., Wang, C., Ann, D., & Lee, P. P. (2021). Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer, 7, 22.

Eliaz, I., Hotchkiss, A. T., Fishman, M. L., & Rode, D. (2007). The effect of modified citrus pectin on urinary excretion of toxic elements. Phytotherapy Research, 21(7), 654–657.

Eliaz, I., & Raz, A. (2019). Pleiotropic effects of modified citrus pectin. Nutrients, 11(11), 2619.

Feuerecker, B., Pirsig, S., Seidl, C., Aichler, M., Feuchtinger, A., Bruchelt, G., & Senekowitsch-Schmidtke, R. (2012). Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biology & Therapy, 13(14), 1425–1435.

Fiorentini, G., Sarti, D., Casadei, V., Milandri, C., Dentico, P., Mambrini, A., Nani, R., Fiorentini, C., & Guadagni, S. (2019). Modulated electro-hyperthermia as palliative treatment for pancreatic cancer: A retrospective observational study on 106 patients. Integrative Cancer Therapies, 18, 1534735419878505.

Fiorentini, G., Sarti, D., Mambrini, A., Hammarberg Ferri, I., Bonucci, M., Sciacca, P. G., Ballerini, M., Bonanno, S., Milandri, C., Nani, R., Fiorentini, C., & Guadagni, S. (2023). Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer. World Journal of Clinical Oncology, 14(6), 215–226.

Fiorentini, G., Sarti, D., Ranieri, G., Gadaleta, C. D., Fiorentini, C., Milandri, C., Mambrini, A., & Guadagni, S. (2021). Modulated electro-hyperthermia in stage III and IV pancreatic cancer. World Journal of Clinical Oncology, 12(11), 1064–1071.

Frankl, V. E. (2006). Man's search for meaning. Beacon Press. (Original work published 1946)

Gallia, G. L., Holdhoff, M., Brem, H., Joshi, A. D., Hann, C. L., Bai, R. Y., Staedtke, V., Blakeley, J. O., Sengupta, S., Jarrell, T. C., Wollett, J., Szajna, K., Helie, N., Mattox, A. K., Ye, X., Rudin, C. M., Bettegowda, C., Riggins, G. J., & Grossman, S. A. (2021). Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas. Neuro-Oncology Advances, 3(1), vdaa154.

Gazzaniga, F. S., & Kasper, D. L. (2025). The gut microbiome and cancer response to immune checkpoint inhibitors. Journal of Clinical Investigation, 135(3), e184321. https://doi.org/10.1172/JCI184321

Glinsky, V. V., & Raz, A. (2009). Modified citrus pectin anti-metastatic properties: One bullet, multiple targets. Carbohydrate Research, 344(14), 1788–1791.

Goodwin, P. J., Leszcz, M., Ennis, M., Koopmans, J., Vincent, L., Guther, H., Drysdale, E., Hundleby, M., Chochinov, H. M., Navarro, M., Speca, M., & Hunter, J. (2001). The effect of group psychosocial support on survival in metastatic breast cancer. New England Journal of Medicine, 345(24), 1719–1726.

Greenlee, H., DuPont-Reyes, M. J., Balneaves, L. G., Carlson, L. E., Cohen, M. R., Deng, G., Johnson, J. A., Mumber, M., Seely, D., Zick, S. M., Boyce, L. M., & Tripathy, D. (2017). Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians, 67(3), 194–232.

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513

Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., Bresciani, R., Magrini, S. M., & Buglione, M. (2019). Mebendazole as a candidate for drug repurposing in oncology. Cancers, 11(9), 1284.

Guha, P., Kaptan, E., Bandyopadhyaya, G., Kaczanowska, S., Davila, E., Thompson, K., Martin, S. S., Kalvakolanu, D. V., Vasta, G. R., & Ahmed, H. (2013). Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proceedings of the National Academy of Sciences, 110(13), 5052–5057.

Hecht, F., Zocchi, M., Tuttle, E. T., Ward, N. P., Alimohammadi, F., Khan, A. A., Gomes, V. C., Smith, B., Twardowski, J. J., Mills, B. N., Welle, K. A., Ghaemmaghami, S., Zhou, Z., Gan, Y., Kang, Y. P., Cazarin, J., Soares, Z. G., Ozgurses, M. E., Zhao, H., … Harris, I. S. (2026). Catabolism of extracellular glutathione supplies cysteine to support tumours. Nature. Advance online publication. https://doi.org/10.1038/s41586-026-10268-2

Innominato, P. F., Karaboué, A., Focan, C., Chollet, P., Giacchetti, S., Bouchahda, M., Ulusakarya, A., Torsello, A., Lévi, F., & Garufi, C. (2022). Chronomodulated chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer, 126(5), 717–724.

Irwin, M. L. (2025). Extending cancer survival with exercise—time for oncology to act. New England Journal of Medicine, 393(1), 82–84. https://doi.org/10.1056/NEJMe2506363

Israeli, A., Bar-Sela, G., Schiff, E., & Ben-Arye, E. (2025). Access to integrative oncology among diverse patient populations: A retrospective analysis of 832 lung cancer patients. Journal of Pain and Symptom Management, 69(2), 145–153.

Jani, C. T., Salazar, A. S., & Watson, D. C. (2025). Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy. Frontiers in Immunology, 16, 1713382.

Jiang, L., Wang, P., Sun, Y. J., & Wu, Y. J. (2019). Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. Journal of Experimental & Clinical Cancer Research, 38(1), 265.

Jin, X., Ruiz Beguerie, J., Sze, D. M., & Chan, G. C. (2016). Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews, 4(4), CD007731.

Johnson, S. B., Park, H. S., Gross, C. P., & Yu, J. B. (2018). Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncology, 4(10), 1375–1381.

Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020). Role of glutathione in cancer: From mechanisms to therapies. Biomolecules, 10(10), 1429.

Lamb, R., Ozsvari, B., Lisanti, C. L., Tanowitz, H. B., Howell, A., Martinez-Outschoorn, U. E., Sotgia, F., & Lisanti, M. P. (2015). Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types. Oncotarget, 6(7), 4569–4584.

Lasheen, W., Walsh, D., Polsky, J., Yaguda, S. I., & York, B. (2026). Acupuncture for cancer symptoms: Clinical application and longitudinal impact—a retrospective observational real-world data study. Supportive Care in Cancer, 34(2), 145. https://doi.org/10.1007/s00520-026-10372-z

Leal, A. D., Qin, R., Atherton, P. J., Haluska, P., Behrens, R. J., Tiber, C. H., Watanaboonyakhet, P., Weiss, M., Adams, P. T., Dockter, T. J., & Loprinzi, C. L. (2014). North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy. Cancer, 120(12), 1890–1897.

Lehmann, V., Hagedoorn, M., Tuinman, M. A., & Geerse, O. P. (2024). Integrative oncology in adolescent and young adult cancer patients: A systematic review. Current Opinion in Oncology, 36(4), 285–293.

Lévi, F., Focan, C., Karaboué, A., de la Valette, V., Focan-Henrard, D., Baron, B., Kreutz, F., & Giacchetti, S. (2007). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery Reviews, 59(9–10), 1015–1035.

Ligibel, J. A., Bohlke, K., May, A. M., Clinton, S. K., Demark-Wahnefried, W., Gilchrist, S. C., Irwin, M. L., Late, M., Mansfield, S., Marshall, T. F., Meyerhardt, J. A., Thomson, C. A., Wood, W. A., & Alfano, C. M. (2022). Exercise, diet, and weight management during cancer treatment: ASCO guideline. Journal of Clinical Oncology, 40(22), 2491–2507.

Ligorio, F., Lobefaro, R., Fucà, G., Provenzano, L., Zanenga, L., Nasca, V., Sposetti, C., Salvadori, G., Ficchì, A., Franza, A., Martinetti, A., Sottotetti, E., Formisano, B., Depretto, C., Scaperrotta, G., Bianchi, G. V., Capri, G., Longo, V. D., de Braud, F., & Vernieri, C. (2024). Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial. International Journal of Cancer, 154(1), 114–123. https://doi.org/10.1002/ijc.34701

Liou, K. T., Ashare, R., Worster, B., Jones, K. F., Yeager, K. A., Acevedo, A. M., Ferrer, R., & Meghani, S. H. (2023). SIO-ASCO guideline on integrative medicine for cancer pain management: Implications for racial and ethnic pain disparities. JNCI Cancer Spectrum, 7(4), pkad042.

Liu, F. T., & Stowell, S. R. (2023). The role of galectins in immunity and infection. Nature Reviews Immunology, 23(8), 479–494.

Liu, J., Zhang, K., Cheng, L., Zhu, H., & Xu, T. (2020). Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin. Drug Design, Development and Therapy, 14, 285–296.

Liu, L., Yu, J., Tian, Z., Wang, Y., Wang, M., Wang, X., & Lv, H. (2025). Exercise therapy and depression, anxiety, and quality of life in older adults with cancer: A meta-analysis. JAMA Network Open, 8(3), e2510234.

Liu, W. M., Scott, K. A., Dennis, J. L., Kaminska, E., Levett, A. J., & Dalgleish, A. G. (2016). Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy. International Journal of Oncology, 49(2), 793–802.

Longo, V. D., & Mattson, M. P. (2014). Fasting: Molecular mechanisms and clinical applications. Cell Metabolism, 19(2), 181–192.

Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Lavoie Smith, E. M., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. Journal of Clinical Oncology, 38(28), 3325–3348.

Loree, J. M., Anand, S., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., Overman, M. J., & Raghav, K. (2019). Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncology, 5(10), e191870.

Lu, W., Doherty-Gilman, A. M., & Rosenthal, D. S. (2010). Recent advances in oncology acupuncture and safety considerations in practice. Current Treatment Options in Oncology, 11(3–4), 141–146.

Lu, W., Hu, D., Dean-Clower, E., Doherty-Gilman, A., Legedza, A. T., Lee, H., Matulonis, U., & Rosenthal, D. S. (2007). Acupuncture for chemotherapy-induced leukopenia: Exploratory meta-analysis of randomized controlled trials. Journal of the Society for Integrative Oncology, 5(1), 1–10.

Lu, W., Matulonis, U. A., Doherty-Gilman, A., Lee, H., Dean-Clower, E., Rosulek, A., Gibson, C., Goodman, A., Davis, R. B., Buring, J. E., Wayne, P. M., Rosenthal, D. S., & Penson, R. T. (2009). Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: A pilot randomized, sham-controlled clinical trial. Journal of Alternative and Complementary Medicine, 15(7), 745–753. https://doi.org/10.1089/acm.2008.0589

Lu, W., Matulonis, U. A., Dunn, J. E., Lee, H., Doherty-Gilman, A., Dean-Clower, E., Goodman, A., Davis, R. B., Buring, J., Wayne, P., Rosenthal, D. S., & Penson, R. T. (2012). The feasibility and effects of acupuncture on quality of life scores during chemotherapy in ovarian cancer. Medical Acupuncture, 24(4), 233–240. https://doi.org/10.1089/acu.2012.0904

Lu, W., Posner, M. R., Wayne, P., Rosenthal, D. S., & Haddad, R. I. (2010). Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: A case series report. Integrative Cancer Therapies, 9(3), 284–290. https://doi.org/10.1177/1534735410378856

Lu, W., Wayne, P. M., Davis, R. B., Buring, J. E., Li, H., Macklin, E. A., Lorch, J. H., Burke, E., Haddad, T. C., Goguen, L. A., Rosenthal, D. S., Tishler, R. B., Posner, M. R., & Haddad, R. I. (2016). Acupuncture for chemoradiation therapy-related dysphagia in head and neck cancer: A pilot randomized sham-controlled trial. The Oncologist, 21(12), 1522–1529. https://doi.org/10.1634/theoncologist.2015-0538

Lugtenberg, R. T., de Groot, S., Kaptein, A. A., Fischer, M. J., Kranenbarg, E. M. K., Carpentier, M. D., Cohen, D., de Graaf, H., Heijns, J. B., Portielje, J. E. A., van de Wouw, A. J., Imholz, A. L. T., Kessels, L. W., Vrijaldenhoven, S., Baars, A., Fiocco, M., van der Hoeven, J. J. M., Gelderblom, H., Longo, V. D., … Kroep, J. R. (2021). Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT trial. Breast Cancer Research and Treatment, 185(3), 741–758.

Lyman, G. H., Greenlee, H., Bohlke, K., Bao, T., DeMichele, A. M., Deng, G. E., Fouladbakhsh, J. M., Gil, B., Hershman, D. L., Mansfield, S., Mussallem, D. M., Mustian, K. M., Price, E., Rafte, S., & Cohen, L. (2018). Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. Journal of Clinical Oncology, 36(25), 2647–2655.

Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S. K., Owens, L. T., Bossis, A. P., Belser, A. B., Agin-Liebes, G., Bogenschutz, M. P., & Ross, S. (2018). Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Frontiers in Pharmacology, 9, 256.

Mao, J. J., Bryl, K., Gillespie, E. F., Green, A., Hung, T. K. W., Baser, R., Panageas, K., Postow, M. A., & Daly, B. (2025). Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment. npj Digital Medicine, 8(1), 29. https://doi.org/10.1038/s41746-024-01387-z

Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., Greenlee, H., Leblanc, T., Lee, R. T., Lopez, A. M., Loprinzi, C., Lyman, G. H., MacLeod, J., Master, V. A., Ramchandran, K., Wagner, L. I., Walker, E. M., Watkins Bruner, D., Witt, C. M., & Bruera, E. (2022). Integrative medicine for pain management in oncology: SIO–ASCO guideline. Journal of Clinical Oncology, 40(34), 3998–4024.

Marik, P. E. (2019). Is intravenous vitamin C contraindicated in patients with G6PD deficiency? Critical Care, 23(1), 109.

Marini, H. R., Facchini, B. A., di Francia, R., Freni, J., Puzzolo, D., Montella, L., Facchini, G., Ottaiano, A., Berretta, M., & Minutoli, L. (2023). Glutathione: Lights and shadows in cancer patients. Biomedicines, 11(8), 2226.

Matsui, Y., Uhara, J., Satoi, S., Kaibori, M., Yamada, H., Kitade, H., Imamura, A., Takai, S., Kawaguchi, Y., Kwon, A. H., & Kamiyama, Y. (2002). Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: A prospective cohort study. Journal of Hepatology, 37(1), 78–86.

McLelland, J. (2018). How to starve cancer without starving yourself (2nd ed.). Agenor Publishing.

Memorial Sloan Kettering Cancer Center. (2024). About herbs: AHCC. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/ahcc

MD Anderson Cancer Center. (n.d.). Does ivermectin prevent or cure COVID-19? https://www.mdanderson.org/cancerwise/does-ivermectin-prevent-or-cure-covid-19.h00-159464001.html

Melotti, A., Mas, C., Kuciak, M., Lorente-Trigos, A., Borges, I., & Ruiz i Altaba, A. (2014). The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Molecular Medicine, 6(10), 1263–1278. https://doi.org/10.15252/emmm.201404084

de Castro, C. G., Jr., Gregianin, L. J., & Burger, J. A. (2020). Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leukemia & Lymphoma, 61(10), 2536–2537. https://doi.org/10.1080/10428194.2020.1786559

Lv, S., Wu, Z., Luo, M., Zhang, Y., Zhang, J., Pascal, L. E., Wang, Z., & Wei, Q. (2022). Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell Death & Disease, 13(8), 754. https://doi.org/10.1038/s41419-022-05182-0

Nappi, L., Aguda, A. H., Nakouzi, N. A., Lelj-Garolla, B., Beraldi, E., Lallous, N., Thi, M., Moore, S., Fazli, L., Battsogt, D., Stief, S., Ban, F., Nguyen, H. H., Anderson, S., Wyatt, A. W., Zoubeidi, A., Hassona, M., Williams, D. E., Talman, L., … Cherkasov, A. (2020). Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. Journal of Clinical Investigation, 130(2), 699–714.

Oncology News Central. (2025). Interest in ivermectin for cancer has spread "like wildfire," oncologists say. https://www.oncologynewscentral.com/oncology/interest-in-ivermectin-for-cancer-has-spread-like-wildfire-oncologists-say

Yuan, Y., Shiao, S., Tighiouart, M., Mita, M., Bitar, J.-S., McAndrew, P., Dorothy, P., El-Masry, M., Frankel, P., & Lee, P. (2024). Abstract PO1-19-07: A phase I study accessing immunotherapy combination of balstilimab and ivermectin in patients with metastatic triple negative breast cancer. Cancer Research, 84(9 Supplement), PO1-19-07. https://doi.org/10.1158/1538-7445.SABCS23-PO1-19-07

Yuan, Y., Shiao, S., Tighiouart, M., Mita, M., Bitar, J.-S., McAndrew, P., Dorothy, P., El-Masry, M., Frankel, P., & Lee, P. (2025). A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer. Journal of Clinical Oncology, 43(16 Supplement), e13146. https://doi.org/10.1200/JCO.2025.43.16_suppl.e13146

Mikirova, N. A., Casciari, J. J., Riordan, N. H., & Hunninghake, R. E. (2013). Clinical experience with intravenous administration of ascorbic acid. Journal of Translational Medicine, 11, 191.

Mikirova, N., Ichim, T., & Riordan, N. (2008). Anti-angiogenic effect of high doses of ascorbic acid. Journal of Translational Medicine, 6, 50.

Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., & Ames, M. M. (1985). High-dose vitamin C versus placebo in the treatment of patients with advanced cancer. New England Journal of Medicine, 312(3), 137–141.

Morita, A., Ichihara, E., Inoue, K., Fujiwara, K., Yokoyama, T., Harada, D., et al. (2024). Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer. International Journal of Cancer, 154(9), 1607–1615.

Mustian, K., Lacchetti, C., Zick, S., & Bower, J. E. (2024). Management of fatigue in adult survivors of cancer: ASCO–SIO guideline update clinical insights. JCO Oncology Practice, 20, 1575–1579.

Nakajima, K., Kho, D. H., Yanagawa, T., Zimel, M., Heath, E., Hogan, V., & Raz, A. (2021). Galectin-3: An immune checkpoint target for musculoskeletal tumor patients. Cancer Metastasis Reviews, 40(1), 297–302.

Nangia-Makker, P., Hogan, V., Honjo, Y., Baccarini, S., Tait, L., Bresalier, R., & Raz, A. (2002). Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. Journal of the National Cancer Institute, 94(24), 1854–1862.

National Cancer Institute. (n.d.). Hyperthermia to treat cancer. https://www.cancer.gov/about-cancer/treatment/types/hyperthermia

Nierengarten, M. B. (2024). ASCO guideline on cannabis use in adults with cancer. Cancer, 130(17), 2982–2983.

Oba, K., Teramukai, S., Kobayashi, M., Matsui, T., Kodera, Y., & Sakamoto, J. (2007). Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunology, Immunotherapy, 56(6), 905–911.

Padayatty, S. J., Sun, A. Y., Chen, Q., Espey, M. G., Drisko, J., & Levine, M. (2010). Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects. PLOS ONE, 5(7), e11414.

Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004). Vitamin C pharmacokinetics: Implications for oral and intravenous use. Annals of Internal Medicine, 140(7), 533–537.

Paller, C. H., Wang, L., Brawley, O. W., et al. (2023). A first-in-human phase I study of intravenous mistletoe (Viscum album L.) in patients with advanced cancer. Cancer Research Communications, 3(8), 1499–1508.

Panda, S. K., Sahoo, G., Swain, S. S., & Luyten, W. (2022). Anticancer activities of mushrooms: A neglected source for drug discovery. Pharmaceuticals, 15(2), 176.

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing drugs in oncology (ReDO)—mebendazole as an anti-cancer agent. Ecancermedicalscience, 8, 443.

Park, Y., & Jeong, E. M. (2024). Glutathione dynamics in the tumor microenvironment. International Journal of Stem Cells, 17(3), 270–283.

Pascale, R. M., Calvisi, D. F., Simile, M. M., Feo, C. F., & Feo, F. (2021). Metformin and cancer: Is the evidence strong enough? European Journal of Cancer, 145, 198–208.

Patil, V. M., Bhelekar, A., Menon, N., Bhattacharjee, A., Simha, V., Abhinav, R., et al. (2020). Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma. Cancer Medicine, 9(13), 4676–4685.

Piskounova, E., Agathocleous, M., Murphy, M. M., Hu, Z., Huddlestun, S. E., Zhao, Z., Leitch, A. M., Johnson, T. M., DeBerardinis, R. J., & Morrison, S. J. (2015). Oxidative stress inhibits distant metastasis by human melanoma cells. Nature, 527(7577), 186–191.

Ramachandran, C., Wilk, B. J., Hotchkiss, A., Chau, H., Eliaz, I., & Melnick, S. J. (2011). Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complementary and Alternative Medicine, 11, 59.

Ren, A., Wang, H., Zhu, Z., & Ye, Y. (2023). A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer. Chinese Medicine, 18(1), 107.

Riordan, H. D., Casciari, J. J., Gonzalez, M. J., Riordan, N. H., Miranda-Massari, J. R., & Jackson, J. A. (2005). A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Puerto Rico Health Sciences Journal, 24(4), 269–276.

Roberts, H., Greenwood, R., Donovan, E. E., Jones, C., Hilliam, R., Brown, M., Patel, R., Whittam, R., & Cusack, J. (2022). Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database of Systematic Reviews, 2022(11), CD012053.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512

Sakamoto, J., Morita, S., Oba, K., Matsui, T., Kobayashi, M., Nakazato, H., & Ohashi, Y. (2006). Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer. Cancer Immunology, Immunotherapy, 55(4), 404–411.

Sayin, V. I., Ibrahim, M. X., Larsson, E., Nilsson, J. A., Lindahl, P., & Bergo, M. O. (2014). Antioxidants accelerate lung cancer progression in mice. Science Translational Medicine, 6(221), 221ra15.

Schmid, D., & Leitzmann, M. F. (2014). Association between physical activity and mortality among breast cancer and colorectal cancer survivors. Annals of Oncology, 25(7), 1293–1311.

Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G. P., Bellotti, C., Salehi, L. B., & Ricci, A. (2018). Galectin-3: One molecule for an alphabet of diseases, from A to Z. International Journal of Molecular Sciences, 19(2), 379.

Seely, D., Wu, P., Fritz, H., Kennedy, D. A., Tsui, T., Seely, A. J., & Mills, E. (2012). Melatonin as adjuvant cancer care with and without chemotherapy. Integrative Cancer Therapies, 11(4), 293–303.

Seyfried, T. N., & Shelton, L. M. (2010). Cancer as a metabolic disease. Nutrition & Metabolism, 7, 7.

Seyfried, T. N., Yu, G., Maroon, J. C., & D'Agostino, D. P. (2017). Press-pulse: A novel therapeutic strategy for the metabolic management of cancer. Nutrition & Metabolism, 14, 19.

Siegel, B. S. (1986). Love, medicine and miracles: Lessons learned about self-healing from a surgeon's experience with exceptional patients. Harper & Row.

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M. L., Chang, E. B., & Gajewski, T. F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 350(6264), 1084–1089.

Sohretoglu, D., & Huang, S. (2018). Ganoderma lucidum polysaccharides as an anti-cancer agent. Anti-Cancer Agents in Medicinal Chemistry, 18(5), 667–674.

Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., Wong, M. C., Morad, G., Rodgers, T., Badger, J. H., Helmink, B. A., Andrews, M. C., Rodrigues, R. R., Morgun, A., Kim, Y. S., … Wargo, J. A. (2021). Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 374(6575), 1632–1640.

Spiegel, D., Bloom, J. R., Kraemer, H. C., & Gottheil, E. (1989). Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet, 2(8668), 888–891.

Spiegel, D., Butler, L. D., Giese-Davis, J., Koopman, C., Miller, E., DiMiceli, S., Classen, C. C., Fobair, P., Carlson, R. W., & Kraemer, H. C. (2007). Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer. Cancer, 110(5), 1130–1138.

Suenaga, S., Kuramitsu, Y., Kaino, S., Maehara, S., Maehara, Y., Sakaida, I., & Nakamura, K. (2014). Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells. Anticancer Research, 34(1), 141–146.

Sulli, G., Manoogian, E. N. C., Taub, P. R., & Panda, S. (2018). Training the circadian clock, clocking the drugs, and drugging the clock to prevent, manage, and treat chronic diseases. Trends in Pharmacological Sciences, 39(9), 812–827.

Sun, Y., Hu, B., Sun, W. B., Pang, D. J., Wang, B., & Zhou, M. L. (2017). Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? Oncotarget, 8(51), 89108–89118.

Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207.

Thronicke, A., Steele, M. L., Grah, C., Matthes, B., & Schad, F. (2024). Immune checkpoint blockade combined with abnobaViscum® therapy is linked to improved survival in advanced or metastatic non-small-cell lung cancer patients. Pharmaceuticals, 17(12), 1713.

Tibullo, D., Volti, G. L., Giallongo, C., Grasso, S., Tomassoni, D., Anfuso, C. D., Lupo, G., Amenta, F., Avola, R., & Bramanti, V. (2017). Biochemical and clinical relevance of alpha lipoic acid. Inflammation Research, 66(11), 947–959.

Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013). Role of glutathione in cancer progression and chemoresistance. Oxidative Medicine and Cellular Longevity, 2013, 972913.

Turner, K. A. (2014). Radical remission: Surviving cancer against all odds. HarperOne.

Turner, K. A., & White, T. (2020). Radical hope: 10 key healing factors from exceptional survivors of cancer & other diseases. Hay House.

van der Horst, A., Versteijne, E., Besselink, M. G. H., Daams, J. G., Bulle, E. B., Bijlsma, M. F., Wilmink, J. W., van Delden, O. M., van Hooft, J. E., Franken, N. A. P., van Laarhoven, H. W. M., Crezee, J., & van Tienhoven, G. (2018). The clinical benefit of hyperthermia in pancreatic cancer. International Journal of Hyperthermia, 34(7), 969–979.

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect. Science, 324(5930), 1029–1033.

Vehlow, A., Cordes, N., Vázquez-Patiño, A., et al. (2025). Integrative interventions in radiation oncology: Evidence and clinical applications. Current Oncology Reports, 27(6), 542–558.

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P., Poirier-Colame, V., Roux, A., Becharef, S., Formenti, S., Golden, E., Cording, S., Eberl, G., Schlitzer, A., Ginhoux, F., … Zitvogel, L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350(6264), 1079–1084.

Vityala, Y. (2024). Enhancing the efficacy of radiation therapy and chemotherapy in cancer treatment with modified citrus pectin and metformin. Asian Journal of Pharmaceutics, 18(1).

Wagner, M., Müller, J., Schink, M., et al. (2025). Mistletoe in cancer cell biology: Recent advances. Current Issues in Molecular Biology, 47(8), 672.

Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.

Wesa, K. M., Cunningham-Rundles, S., Klimek, V. M., Vertosick, E., Coleton, M. I., Yeung, K. S., Lin, H., Nimer, S., & Cassileth, B. R. (2015). Maitake mushroom extract in myelodysplastic syndromes (MDS): A phase II study. Cancer Immunology, Immunotherapy, 64(2), 237–247.

Witt, C. M., Balneaves, L. G., Cardoso, M. J., Cohen, L., Greenlee, H., Johnstone, P., Kücük, Ö., Mailman, J., & Mao, J. J. (2017). A comprehensive definition for integrative oncology. JNCI Monographs, 2017(52), lgx012.

Yanagimoto, H., Satoi, S., Yamamoto, T., Hirooka, S., Yamaki, S., Kotsuka, M., Ryota, H., Ishida, Y., Matsui, Y., & Kon, M. (2016). Alleviating effect of active hexose correlated compound (AHCC) on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma. Nutrition and Cancer, 68(2), 234–240.

Yeh, H.-W., DelGaudio, N. L., Uygur, B., Millet, A., Khan, A., Unlu, G., Xiao, M., Timson, R. C., Li, C., Ozcan, K., Smith, K. W., Martins Nascentes Melo, L., Allies, G., Basturk, O., Sickmann, A., Bayraktar, E. C., Possemato, R., Tasdogan, A., & Birsoy, K. (2025). Mitochondrial glutathione import enables breast cancer metastasis via integrated stress response signaling. Cancer Discovery, 15(12), 2437–2449. https://doi.org/10.1158/2159-8290.CD-24-1556

Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459.

Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalukas, S. L., Nezami Ranjbar, M. R., Yang, X., Goncalves, M. D., Sennett, B. R., Pollak, M. N., Hatzivassiliou, G., Klimek, V., Birsoy, K., Mukherjee, P., Hibshoosh, H., Hardy, B., Liu, S. V., Chen, F., … Cantley, L. C. (2015). Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science, 350(6266), 1391–1396.

Zagon, I. S., & McLaughlin, P. J. (2018). Targeting the opioid growth factor:opioid growth factor receptor axis for treatment of human ovarian cancer. Experimental Biology and Medicine, 243(7), 583–592.

Annon, J. S. (1976). The PLISSIT model: A proposed conceptual scheme for the behavioral treatment of sexual problems. Journal of Sex Education and Therapy, 2(1), 1–15.

Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Ganz, P. A., Heckman-Stoddard, B. M., Khakoo, A. Y., Liu, J. E., Madhuri, V., Major-Pedersen, A., Marraffino, A., Mayer, E. L., Moseley, M., Patel, A. R., Schiff, R., Stelzer, R., … Lenihan, D. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO clinical practice guideline. Journal of Clinical Oncology, 35(8), 893–911.

Ayoade, O. F., Caturegli, G., Canavan, M. E., Resio, B. J., Berger, E. R., & Boffa, D. J. (2026). Use of complementary and alternative medicine in the management of breast cancer. JAMA Network Open, 9(3), e260337. https://doi.org/10.1001/jamanetworkopen.2026.0337

Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197–198.

Bober, S. L., & Varela, V. S. (2012). Sexuality in adult cancer survivors: Challenges and intervention. Journal of Clinical Oncology, 30(30), 3712–3719.

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., Lacouture, M. E., Masters, G. A., Naidoo, J., Nanni, M., Perales, M.-A., Puzanov, I., Santomasso, B. D., Shanbhag, S. P., Sharma, R., … Ernstoff, M. S. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer, 9(6), e002435.

Burn, J., Sheth, H., Elliott, F., Reed, L., Macrae, F., Mecklin, J.-P., Möslein, G., McRonald, F. E., Bertario, L., Evans, D. G., Gerdes, A.-M., Ho, J. W. C., Lindblom, A., Morrison, P. J., Rashbass, J., Ramesar, R., Seppälä, T., Thomas, H. J. W., Pylvänäinen, K., … CAPP2 Investigators. (2020). Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial. The Lancet, 395(10240), 1855–1863. https://doi.org/10.1016/S0140-6736(20)30366-4

Campbell, K. L., Zadravec, K., Bland, K. A., Chesley, E., Wolf, F., & Janelsins, M. C. (2020). The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: Systematic review of randomized controlled trials. Physical Therapy, 100(3), 523–542.

Cassileth, B. R. (1982). After Laetrile, what? New England Journal of Medicine, 306(24), 1482–1484.

Cassileth, B. R., & Vickers, A. J. (2004). Massage therapy for symptom control: Outcome study at a major cancer center. Journal of Pain and Symptom Management, 28(3), 244–249.

Cassileth, B. R., Vickers, A. J., & Magill, L. A. (2003). Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: A randomized controlled trial. Cancer, 98(12), 2723–2729.

Cassileth, B. R., Yeung, K. S., & Gubili, J. (2010). Herb-drug interactions in oncology (2nd ed.). People's Medical Publishing House.

Davis, E. L., Oh, B., Butow, P. N., Mullan, B. A., & Clarke, S. (2012). Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: A systematic review. The Oncologist, 17(11), 1475–1481.

Elwyn, G., Frosch, D., Thomson, R., Joseph-Williams, N., Lloyd, A., Kinnersley, P., Cording, E., Tomson, D., Dodd, C., Rollnick, S., Edwards, A., & Barry, M. (2012). Shared decision making: A model for clinical practice. Journal of General Internal Medicine, 27(10), 1361–1367.

Izgu, N., Metin, Z. G., Karadas, C., Ozdemir, L., Demirci, U., & Bostanci, M. (2019). Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: An assessor-blinded randomized controlled trial. European Journal of Oncology Nursing, 40, 36–43.

Kalyanaraman, U. P., Kalyanaraman, K., Cullinan, S. A., & McLean, J. M. (1983). Neuromyopathy of cyanide intoxication due to "laetrile" (amygdalin): A clinicopathologic study. Cancer, 51(12), 2126–2133.

Milazzo, S., Ernst, E., Lejeune, S., Boehm, K., & Horneber, M. (2011). Laetrile treatment for cancer. Cochrane Database of Systematic Reviews, (11), CD005476.

Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people change (3rd ed.). Guilford Press.

Puchalski, C. M., Vitillo, R., Hull, S. K., & Reller, N. (2014). Improving the spiritual dimension of whole person care: Reaching national and international consensus. Journal of Palliative Medicine, 17(6), 642–656.

Carli, F., Bousquet-Dion, G., Awasthi, R., Elsherbini, N., Liberman, S., Boutros, M., Stein, B., Charlebois, P., Ghitulescu, G., Morin, N., Jagoe, T., Scheede-Bergdahl, C., Minnella, E. M., & Fiore, J. F. Jr. (2020). Effect of multimodal prehabilitation vs postoperative rehabilitation on 30-day postoperative complications for frail patients undergoing resection of colorectal cancer: A randomized clinical trial. JAMA Surgery, 155(3), 233–242.

Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., … Cardinale, D. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 31(2), 171–190.

Duval, A., Davis, C. G., Khoo, E.-L., Romanow, H., Shergill, Y., Rice, D., Smith, A. M., Poulin, P. A., & Collins, B. (2022). Mindfulness-based stress reduction and cognitive function among breast cancer survivors: A randomized controlled trial. Cancer, 128(13), 2520–2528.

Egolf, B., Lasker, J., Wolf, S., & Potvin, L. (1992). The Roseto effect: A 50-year comparison of mortality rates. American Journal of Public Health, 82(8), 1089–1092. https://doi.org/10.2105/ajph.82.8.1089

Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., Ariyawardana, A., Correa, M. E., Ranna, V., Bossi, P., & Mucositis Guidelines Leadership Group of the MASCC/ISOO. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423–4431.

Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., & Baracos, V. E. (2011). Definition and classification of cancer cachexia: An international consensus. The Lancet Oncology, 12(5), 489–495.

Gilchrist, S. C., Barac, A., Ades, P. A., Alfano, C. M., Franklin, B. A., Jones, L. W., La Gerche, A., Ligibel, J. A., Lopez, G., Madan, K., Oeffinger, K. C., Salamone, J., Scott, J. M., Squires, R. W., Thomas, R. J., Treat-Jacobson, D. J., Wright, J. S., American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Peripheral Vascular Disease, & Council on Genomic and Precision Medicine. (2019). Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: A scientific statement from the American Heart Association. Circulation, 139(21), e997–e1012.

Institute of Medicine. (2006). From cancer patient to cancer survivor: Lost in transition. The National Academies Press.

Institute of Medicine. (2016). Families caring for an aging America. The National Academies Press.

Janelsins, M. C., Heckler, C. E., Peppone, L. J., Kamen, C., Mustian, K. M., Mohile, S. G., Magnuson, A., Kleckner, I. R., Guido, J. J., Young, K. L., Conlin, A. K., Weiselberg, L. R., Mitchell, J. W., Ambrosone, C. A., Ahles, T. A., & Morrow, G. R. (2017). Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: An analysis from a nationwide, multicenter, prospective longitudinal study. Journal of Clinical Oncology, 35(5), 506–514.

Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014). Prevalence, mechanisms, and management of cancer-related cognitive impairment. International Review of Psychiatry, 26(1), 102–113.

Li, Q., Morimoto, K., Nakadai, A., Inagaki, H., Katsumata, M., Shimizu, T., Hirata, Y., Hirata, K., Suzuki, H., Miyazaki, Y., Kagawa, T., Koyama, Y., Ohira, T., Takayama, N., Krensky, A. M., & Kawada, T. (2007). Forest bathing enhances human natural killer activity and expression of anti-cancer proteins. International Journal of Immunopathology and Pharmacology, 20(2 Suppl 2), 3–8.

Li, Q., Morimoto, K., Kobayashi, M., Inagaki, H., Katsumata, M., Hirata, Y., Hirata, K., Suzuki, H., Li, Y. J., Wakayama, Y., Kawada, T., Park, B. J., Ohira, T., Matsui, N., Kagawa, T., Miyazaki, Y., & Krensky, A. M. (2008). Visiting a forest, but not a city, increases human natural killer activity and expression of anti-cancer proteins. International Journal of Immunopathology and Pharmacology, 21(1), 117–127.

Minnella, E. M., Awasthi, R., Loiselle, S. E., Agnihotram, R. V., Ferri, L. E., & Carli, F. (2018). Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: A randomized clinical trial. JAMA Surgery, 153(12), 1081–1089.

Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., Rugo, H. S., Schnipper, H. H., Smith, T. J., Tan, W., & Loprinzi, C. L. (2020). Management of cancer cachexia: ASCO guideline. Journal of Clinical Oncology, 38(21), 2438–2453.

Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010). Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet, 376(9754), 1741–1750.

Schmitz, K. H., Ahmed, R. L., Troxel, A., Cheville, A., Smith, R., Lewis-Grant, L., Bryan, C. J., Williams-Smith, C. T., & Greene, Q. P. (2009). Weight lifting in women with breast-cancer–related lymphedema. New England Journal of Medicine, 361(7), 664–673.

Schmitz, K. H., Ahmed, R. L., Troxel, A. B., Cheville, A., Lewis-Grant, L., Smith, R., Bryan, C. J., Williams-Smith, C. T., & Chittams, J. (2010). Weight lifting for women at risk for breast cancer-related lymphedema: A randomized trial. JAMA, 304(24), 2699–2705.

Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Ghosh, M., Jaiyesimi, I., Mammen, J. S., Naing, A., Nastoupil, L. J., Phillips, T., … Bollin, K. (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology, 39(36), 4073–4126.

Shapiro, C. L., Van Poznak, C., Lacchetti, C., Kirshner, J., Eastell, R., Gagel, R., Smith, S., Edwards, B. J., Frank, E., Lyman, G. H., Smith, M. R., Mhaskar, R., Henderson, T., & Neuner, J. (2019). Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. Journal of Clinical Oncology, 37(31), 2916–2946.

Stout, C., Morrow, J., Brandt, E. N., Jr., & Wolf, S. (1964). Unusually low incidence of death from myocardial infarction: Study of an Italian American community in Pennsylvania. JAMA, 188(10), 845–849. https://doi.org/10.1001/jama.1964.03060360005001

Substance Abuse and Mental Health Services Administration. (2014). SAMHSA's concept of trauma and guidance for a trauma-informed approach (HHS Publication No. SMA 14-4884). U.S. Department of Health and Human Services.

U.S. Preventive Services Task Force. (2022). Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA, 327(16), 1577–1584.

Wakabayashi, H., Arai, H., & Inui, A. (2021). The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: Facts and numbers. Journal of Cachexia, Sarcopenia and Muscle, 12(1), 14–16.

World Cancer Research Fund / American Institute for Cancer Research. (2018). Diet, nutrition, physical activity and cancer: A global perspective. Continuous Update Project Expert Report 2018. WCRF International. https://www.wcrf.org/diet-and-cancer/

World Health Organization. (2013). WHO traditional medicine strategy: 2014–2023. World Health Organization.

Zadik, Y., Arany, P. R., Fregnani, E. R., Bossi, P., Antunes, H. S., Bensadoun, R.-J., Gueiros, L. A., Majorana, A., Nair, R. G., Ranna, V., Tissing, W. J. E., Vaddi, A., Lubart, R., Migliorati, C. A., Lalla, R. V., Cheng, K. K. F., Elad, S., & Mucositis Study Group of the MASCC/ISOO. (2019). Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 27(10), 3969–3983.

Zhang, M., Zhang, Y., Zhang, L., & Tian, Q. (2019). Mushroom polysaccharide lentinan for treating different types of cancers. Progress in Molecular Biology and Translational Science, 163, 297–328.

Zhang, Y., Cao, M., Huang, X., et al. (2025). Effect of mindfulness-based meditation on immune function in breast cancer patients: A three-level meta-analysis. PLOS ONE, 20(4), e0287654.